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Patients with chronic kidney disease experience a progressive loss of renal function 
over a period of months or years. The chronic decline in kidney function can progress 
to end-stage renal disease, a condition where the kidneys are no longer able to 
filter enough blood and the body retains fluids and harmful waste products 1;2. This 
complete or almost complete failure of kidney function is permanent and usually 
requires renal replacement therapy in the form of either dialysis or transplantation. 
The preferred treatment for patients suffering from end-stage renal disease is kidney 
transplantation.
The first successful kidney transplantation was performed in 1954 in Boston, when 
Joseph Murray, John Merrill and Hartwell Harrison transplanted a kidney from one 
identical twin to another 3. However, vigorous immune responses directed against the 
donor graft remained a major barrier for successful kidney transplantation between 
genetically non-identical humans, eventually leading to rejection of the allograft. This 
boosted the interest in research into organ transplantation, resulting in increased 
knowledge on transplantation related immunology. Since the 1960s, improvement 
in surgical techniques, tissue matching, and immunosuppressive medication has 
led to a significant reduction in the incidence of acute allograft rejection and to a 
substantial improvement in graft survival rates 4;5. Nowadays, kidney transplantation 
has become a routine procedure. However, renal allograft rejection remains an 
important problem that affects long-term graft outcome.
Immunity and allograft rejection
The first important studies for organ and tissue transplantation were performed in 
the early 1940s by Peter Medawar 6;7. His studies on the transplantation of skin grafts 
revealed that the immune system plays a major role in allograft rejection. The human 
immune system can be divided into the innate and the acquired immune system. 
The innate immune system is the first line of defense against infectious agents. It 
provides an immediate, but non-specific immune response to invading pathogens, 
but does not confer long lasting or protective immunity. The innate immune system 
acts via both the complement system and cellular responses. The complement 





































The innate immune cells include natural killer (NK) cells, which respond to cells 
missing ‘self’ markers, and phagocytic cells, such as macrophages and dendritic cells, 
which internalize and kill pathogens 9-11. Innate immune cells also play a role in the 
activation of the acquired immune system 12. Transplantation procedures can lead to 
activation of the innate immune system through heat and cold shock, and ischemia 
and reperfusion insult 8.
The acquired immune system is composed of a repertoire of antigen-specific cells 
that become activated upon an antigenic challenge, aimed at protecting the body 
against foreign pathogens. In contrast to non-specific immune cells of the innate 
immune system, cells of the acquired immune system express antigen-specific 
receptors on their cell surface and retain long-term immunological memory after the 
encounter of the antigen. Upon activation, naïve immune cells start to expand, and 
they differentiate into effector cells for the elimination of the pathogen. Part of the 
naïve cells differentiate into memory cells, which enables a rapid response in case 
of a second encounter of the body with the same pathogen 13. Acquired immune 
responses involve both cellular and humoral components. These include T cells 
involved in cellular immunity and B cells involved in humoral immunity. The renal 
allograft contains many foreign antigens that can activate the recipient’s acquired 
immune system.
Human leukocyte antigens
An important hallmark in the transplantation field was the discovery of the antigens 
of the major histocompatibility complex (MHC) 14-18. MHC antigens are cell surface 
molecules that present peptides to T cells, thereby initiating the acquired immune 
response. The glycoproteins encoded by the MHC are present on virtually all cells of 
vertebrates. In humans, the MHC molecules are known as human leukocyte antigens 
(HLA). The HLA system is the most polymorphic system in humans 19;20. This high 
degree of polymorphisms is an evolutionary feature providing the human population 
as a whole with optimal protection against the wide range of pathogens it can 
encounter.
Classes of HLA molecules
The HLA molecules are divided into two classes, based on their structure and 













































class I molecules (HLA-A, -B, and -C) are constitutively expressed on all nucleated 
cells and are involved in the protection against intracellular infections. They 
present endogenously generated peptides, such as self-peptides or virus-induced 
peptides 21;22. These peptides have a length of 8-13 amino acids 22-24. The HLA class II 
molecules (HLA-DR, -DQ, and -DP) are less widely expressed than class I molecules 
and present peptides derived from extracellular proteins. They are mainly expressed 
on professional antigen presenting cells (APCs), such as dendritic cells (DCs), 
macrophages (MФ), and B cells, but also on activated T cells. The peptides presented 
by HLA class II molecules are primarily of exogenous origin and have a typical length 
of 12-25 amino acids 21;22;25.
Figure 1. The structure of HLA class I and HLA class II molecules. HLA class I (left) consists of a 
heavy α-chain linked to a light chain β2-microglobulin (β2m). HLA class II (right) is a heterodimer 
consisting of an α-chain and a β-chain. ED, extracellular domain; TM, transmembrane region; 
CT, cytoplasmic tail.
HLA matching
Incompatibility of HLA molecules between the donor and the recipient may impede 
successful graft outcome after transplantation. T cells detect the presence of foreign 
antigens through their polymorphic T cell receptor (TCR), which can recognize foreign 
peptides bound by HLA molecules. All T cells are antigen specific and recognize an 
antigenic peptide presented only by one self-HLA molecule. This HLA restriction 
presents a big advantage for coping with pathogens, but represents a hurdle in 





































HLA molecules as well as peptides derived from donor antigens presented by self-
HLA on APCs. Both mechanisms may contribute to transplant rejection 26. Matching 
for HLA molecules between donor and recipient lowers the chance for a patient to 
develop acute rejection. A higher degree of HLA matching, especially at the HLA-DR 
locus, is associated with better graft outcome 27-31. The high degree of polymorphism 
in HLA makes it difficult to find a matched unrelated donor in most cases 19. 
Immunosuppression
Immunosuppression has become a cornerstone of the transplantation field for the 
prevention of allograft rejection. Investigation into the use of immunosuppression to 
prevent transplant rejection started in the early 1950s. Medawar’s demonstration that 
allograft rejection is an immunological process increased the interest into methods 
to suppress the recipient’s immune system and protect the allograft from rejection 
6;7. The first tested therapies were total body irradiation 32;33 and adrenal cortical 
steroids 34-36. Both therapies led to prolonged skin graft survival. These early findings 
set the stage for the development of the current immunosuppressive drug therapies. 
Nowadays, almost all transplant recipients are treated with immunosuppressive 
drugs to minimize the chance of acute rejection, which act by inhibiting the activation 
and/or effector functions of T cells.
Immunosuppression is used as induction, maintenance and anti-rejection therapy. 
Induction therapy is a conditioning treatment given at the time of transplantation, 
which leads to a short-term depletion of lymphocytes. This conditioning is achieved 
by administering depleting antibody treatment, such as the interleukin-2 receptor 
blocker Daclizumab or anti-thymocyte globulin (ATG) 37;38. The aim of induction 
therapy is to prevent acute rejection during the first weeks after transplantation. 
After transplantation, patients receive lifelong maintenance therapy. This therapy 
consists of a combination of corticosteroids and a calcineurin inhibitor, with or 
without the addition of a cytostatic drug.
Corticosteroids
Synthetic corticosteroids, such as prednisone and methylprednisolone, were first used 
as maintenance therapy in transplantation during the early 1960s 39;40. They modulate 
the gene transcription of immune cells, resulting in a strong anti-inflammatory effect 













































rejection therapy. More detailed information on corticosteroid treatment of allograft 
rejection can be found in the “treatment of acute rejection” section.
Calcineurin inhibitors
The calcineurin inhibitors Cyclosporine and Tacrolimus were introduced in the 
1980s and marked a great improvement in maintenance therapy for solid organ 
transplantation 42-44. Cyclosporine and Tacrolimus reduce the activation of T cells 
by inhibiting the protein phosphatase calcineurin. Activation of T cells via their 
TCR induces an increase in intracellular calcium. This increase in calcium activates 
calcineurin, which subsequently activates members of the nuclear factors of activated 
T cells (NFAT) family. The activated NFAT translocate to the nucleus and upregulate 
the expression of IL-2, which in turn stimulates the growth and differentiation of T 
cells 45;46.
Cytostatic drugs
The first proliferation inhibitors, 6-mercaptopurine and azathioprine, were introduced 
in the 1960s in an attempt to mimic the immunosuppressive effects of total body 
irradiation 33;47;48. This first generation of cytostatic drugs inhibited DNA synthesis, 
thereby preventing proliferation of lymphocytes. Currently, the commonly used 
cytostatic drug for maintenance therapy is Mycophenolate Mofetil (MMF). MMF 
is a reversible inhibitor of the enzyme inosine-5’-monophosphate dehydrogenase 
(IMPDH). This enzyme is involved in purine synthesis, which is an essential substrate 
for DNA and RNA synthesis in lymphocytes 49;50. By inhibiting IMPDH, MMF inhibits 
DNA synthesis of lymphocytes and prevents their proliferation.
Renal allograft rejection
Renal allograft rejection can be classified into three phases based on the time of 
occurrence: hyperacute rejection, acute rejection, and the development of chronic 
allograft injury. The main focus of this thesis is acute rejection of kidney allografts.
Hyperacute rejection
In hyperacute rejection, the transplanted organ is rejected within minutes or hours 
after vascularization of the graft. Hyperacute rejection results from preexisting 





































blood group antigens 51-53. These antibodies may have developed in recipients due to 
a previous transplantation, blood transfusion or pregnancy 54. Alloantibodies bind 
to vascular endothelium of the graft and activate the complement system, which 
causes thrombotic occlusion and loss of the allograft 53. To determine if a patient 
has preformed donor-specific antibodies, a serological crossmatch test is performed 
prior to the transplantation 55. Since the introduction of this test, the incidence of 
hyperacute rejection has fortunately been reduced dramatically.
Acute rejection
The most common form of rejection in the early post-transplant period is acute 
rejection. This type of rejection generally occurs within the first 6 months after 
transplantation, with the highest risk in the first 3 months. It is primarily a cellular 
immune response mediated by T cells directed against mismatched donor HLA 
antigens present on the cells of the allograft 56;57. APCs express donor antigens and 
activate antigen-specific T cells, which infiltrate the allograft. The activated T cells 
cause lysis of graft cells and produce cytokines that recruit other inflammatory cells, 
such as monocytes, macrophages, and dendritic cells 58. The infiltrating immune cells 
accumulate in the renal interstitium, and may penetrate the tubules (tubulitis) and/
or the vessels (endovasculitis) 56.
A second form of acute rejection is antibody-mediated rejection (AMR), which 
is a humoral immune response mediated by donor-specific antibodies (DSA) 56. The 
DSA are most often directed towards foreign HLA antigens, but may also target 
other antigens including minor histocompatibility antigens, endothelial cell specific 
antigens or other transplanted antigens 56;59. AMR can occur in patients with de novo 
DSA or in sensitized patients with undetectable DSA levels at time of transplantation 
60. Memory B cells of the recipient can become activated by the allograft and start 
the production of DSA which, in turn, can interact with antigens in the graft. This 
interaction may lead to complement-mediated allograft damage through cellular 
lysis and recruitment of inflammatory cells and/or antibody-dependent cellular 
cytotoxicity 59;61.
T cell mediated rejection (TCMR) and AMR can occur individually or may coincide. 
Besides acute rejection during the first months after transplantation, both TCMR and 
AMR can also occur at later time points after transplantation 56. These late acute 














































During the years after transplantation, the renal allograft can be subjected to 
a process of slow deterioration. This development of chronic allograft injury is 
characterized by renal interstitial fibrosis and tubular atrophy (IFTA), which was 
formerly known as chronic allograft nephropathy (CAN) 63-65. It is manifested clinically 
by a progressive decline in renal transplant function and, in many cases, by loss of the 
renal transplant. Chronic allograft injury may result from both non-immunological 
and immunological factors. Non-immunological factors include delayed graft 
function, donor-related factors (such as old age and hypertension), post-transplant 
infections, and nephrotoxic effects by immunosuppressive medication 65;66. The 
process of chronic immune activity towards the graft is clinically reflected by the 
presence of chronic transplant dysfunction (CTD) within the graft. CTD develops over 
a period of years and involves both cellular and humoral immune responses leading 
to a variety of fibrosing and sclerosing changes in the allograft 67-69. CTD may be the 
result of HLA incompatibility between the donor and the recipient, immunologic 
sensitization of the patient, and the occurrence of acute rejection episodes 65;70. In 
addition, alloimmune responses may lead to exposure of self-antigens, which may 
induce autoimmune responses involved in the pathogenesis of CTD 71. The underlying 
mechanisms of CTD have not been completely elucidated, making treatment difficult. 
Current therapeutic strategies focus on minimizing risk factors for CTD 64.
Diagnosis of allograft rejection
Serum creatinine
Reliable and timely detection of acute renal allograft rejection is important for the 
prevention of adverse graft outcome. Most patients who develop an acute rejection 
episode are asymptomatic and present only with an increase in serum levels of 
creatinine, a waste molecule that is generated during normal muscle metabolism. 
Phosphocreatine, an energy-storing molecule in muscles, is catalyzed by creatine 
kinases into creatine and adenosine triphosphate (ATP) molecules, which provide the 
phosphates needed for muscle contraction 72-74. This reversible reaction causes the 
spontaneous by-product creatinine. This production of creatinine is continuous and 
proportional to muscle mass. Approximately 2% of the body’s creatine is converted 
to creatinine each day, which is excreted from the body by the kidneys 72;74. The 





































is filtered out of the blood by the kidneys, and therefore the serum creatinine level 
depends on the glomerular filtration rate. In renal transplant recipients, an increase 
in serum creatinine levels reflects a decline in graft function 75. Significant histologic 
damage to the graft leads to a diminished ability to filter creatinine, resulting in a rise 
of the creatinine concentration in the serum.
Banff classification
A decline in renal function may result from a rejection episode, but may also be 
caused by other conditions such as medication toxicity or a viral infection 75;76. The 
cause of graft dysfunction is determined on the basis of nephropathologic criteria 
and histological assessment of a renal allograft biopsy. Due to the associated risk of 
procedural complications, renal biopsies are mainly performed after indication of 
functional graft impairment 77. To limit subjectivity of histological assessment, renal 
allografts are interpreted according to the Banff classification. This classification 
system originates from a meeting held in Banff, Canada in 1991, and was first published 
in 1993 78. The Banff scoring scheme was developed for the standardization of the 
histomorphologic criteria used for the diagnosis of graft rejection. In subsequent 
years, the histomorphologic grading scheme of the Banff classification has been 
updated and refined at regular Banff conferences on allograft pathology 63;79-81. 
Nowadays, the Banff classification system is universally applied for interpretation of 
renal graft biopsies, in relation to renal allograft dysfunction.
Histological parameters of acute rejection
The Banff classification is used to designate the rejection severity on the basis of 
the site and degree of inflammation in the renal allograft biopsy. Three important 
lesions are used for the diagnosis of acute T cell-mediated rejection 81. Interstitial 
inflammation (i-score) describes the infiltration of leukocytes in the interstitium 
of the kidney. Because focal or mild diffuse infiltrates of mononuclear cells can be 
present in biopsies from patients with well-functioning grafts, the i-score is not by 
itself indicative of acute rejection. The principal lesions indicative of acute renal 
allograft rejection are tubulitis and intimal arteritis 79;81. Tubulitis (t-score) indicates 
the presence of mononuclear cells within the tubular epithelium. The infiltrated 
leukocytes can recognize and lyse epithelial cells, resulting in tubular damage and 













































rejection (Banff grade I) 81-83. An additional lesion which may be present during acute 
rejection is intimal arteritis (v-score), which is defined as infiltration of lymphocytes 
and monocytes beneath the endothelium of arteries in the renal cortex. TCMR with 
intimal arteritis is indicated as acute vascular rejection (Banff grade II) 81;84;85.
Impact of acute rejection on graft outcome
In the 1960s, acute rejection was the most important cause of graft loss. Only 40% of 
the renal allograft recipients had a functioning graft at one year after transplantation 
86;87. The introduction of more potent immunosuppressive medications and 
refinement in treatment regimens have led to a reduction in the incidence of acute 
rejection from over 80% in the 1960s to below 15% nowadays 87;88. Over the same 
period, the short-term survival of kidney grafts has substantially improved, with one-
year graft survival rates in excess of 90% in current daily practice 5;89;90. Despite these 
advances in short-term outcome, long-term graft outcome improved only marginally 
over the past two decades 5;70;90. Approximately 50% of grafts from deceased donors 
and 30% of grafts from living donors fail within ten years after kidney transplantation 
91. The graft attrition rates after the first year are between 3% and 5% annually. This is 
mainly due to death with a functioning graft and chronic allograft failure 90;92;93.
Although most acute rejection episodes can be reversed with the currently 
available immunosuppressive therapies, it continues to be a primary cause of renal 
allograft failure. Approximately 10% of all graft losses are due to acute rejection 93. 
Furthermore, several studies have shown that the occurrence of acute rejection 
correlates with a significant reduction in long-term allograft survival 89;94-96. Besides 
the association with risk of graft loss, acute rejection is also associated with the 
development of chronic allograft failure. IFTA is the most prevalent cause of chronic 
allograft failure after the first post-transplant year 87;93. Analyses of factors related 
with the development of IFTA revealed acute rejection as one of the most important 
risk factors 92;97-99. In addition, it was shown that the acute rejection associated risk 
for chronic transplant failure has increased during the last decades 99. Although 
the incidence has decreased during this time period, the negative impact of acute 
rejection on the subsequent development of IFTA has become more prominent 99.
Important aspects of acute rejection associated with increased risk of adverse 
graft outcome include the timing, recurrence, severity, and therapy sensitivity of 





































of engraftment) and late (after 3 months) acute rejection episodes associate with a 
higher risk of graft failure. The risk increases as the time to acute rejection increases 
and was most pronounced with late acute rejection episodes 96;100-105. Similarly, 
patients experiencing repeated acute rejection episodes are at greater risk of 
adverse graft outcome than those with no or only one episode 106-109. In addition, 
patients with acute vascular rejection (Banff grade II) have a higher risk of graft 
failure compared to patients with acute tubulointerstitial rejection (Banff grade I) 
110-112. Acute rejection episodes unresponsive to anti-rejection treatment have been 
associated with increased risk of allograft failure 112-114.
Treatment of acute rejection
Despite the combination of HLA matching and maintenance immunotherapy, renal 
transplant recipients can still develop acute allograft rejection. Several therapeutic 
options are available for the reversal of acute rejection episodes, including pulse 
corticosteroid therapy and polyclonal and monoclonal antibody therapy.
High-dose corticosteroids
The first report on the use of immunosuppressive drugs for the treatment of acute 
renal allograft rejection was in 1960 115. A young female recipient of her mother’s 
kidney developed multiple rejection episodes, which were temporarily reversed 
with prednisone. This case sparked the interest in corticosteroid therapy for both 
the prevention and the treatment of acute rejection episodes. In 1963, Starzl and 
colleagues demonstrated in ten renal allograft recipients that acute rejection could 
readily be reversed by temporarily adding high doses of prednisone to the patients 
maintenance therapy 116. All ten patients showed an essentially complete recovery 
of their renal function. Based on these early findings, increasing the daily dose of 
oral prednisone became the main therapy for acute rejection 117;118. The treatment of 
acute rejection with high doses of oral prednisone was found to potentially induce 
toxic side effects, such as gastrointestinal hemorrhage and increased susceptibility 
to infection. To prevent these complications, the treatment was switched from oral 
prednisone to intravenous application of methylprednisolone during the early 1970s 
117;118. Comparison of the two regimens revealed that both forms of corticosteroids 
were equally successful in reversing acute rejection 119;120. However, pulse therapy 













































oral prednisone therapy 117;120. Since these early developments, pulse therapy with 
high-dose steroids has remained the typical approach to treat acute renal allograft 
rejection.
Polyclonal and monoclonal antibodies
Other therapy regimens for the treatment of acute rejection episodes imply the use of 
anti-lymphocyte antibodies. The first report on antibody-based immunosuppression 
was by Metchnikoff in 1899 121. His observations on the lymphocyte-depleting activity 
of heterologous anti-lymphocyte serum were validated in the 1960s 122-124. These 
findings resulted in the introduction of ATG as a treatment of allograft rejection 125-
127. ATG is the purified polyclonal antibody fraction of sera from horses or rabbits 
that have been immunized with human thymocytes or T cell lines 128;129. ATG contains 
antibodies specific for many common leukocyte antigens, including co-stimulation, 
adhesion, and cell trafficking molecules 130. ATG therapy causes the depletion of 
circulating T cells and other leukocytes through various mechanisms, including 
antibody- and complement-dependent lysis and the induction of apoptosis 130. ATG is 
an effective treatment of acute renal allograft rejection with high graft survival rates 
131-133. However, ATG can induce complications, such as leukopenia, cytokine release 
syndrome, and viral infections 129;132. ATG is mainly used for the treatment of steroid-
resistant acute rejection and recurrent acute rejection.
The development of cell-hybridization techniques provided the possibility to 
produce monospecific antibodies 134. The first monoclonal antibody used for the 
treatment of acute renal allograft rejection was OKT3 135;136. The murine-derived 
OKT3 is directed against the CD3 molecule, which is closely associated with the TCR. 
OKT3 treatment modulates the TCR, resulting in the depletion of circulating T cells. 
OKT3 has been used as primary treatment of acute rejection and as rescue therapy 
of steroid-resistant rejection 137;138. The use of OKT3 is associated with serious side 
effects, which include cytokine release syndrome, pulmonary edema, nephropathy, 
and infections. Due to its lower efficacy and higher incidence of side effects compared 






































Immunoregulatory effects of corticosteroids
A temporary treatment with high doses of corticosteroid is used to combat acute renal 
allograft rejection. A protective effect on the allograft is obtained by inhibiting T-cell 
proliferation and cytokine gene transcription (see Figure 2). Glucocorticoids (GC) act 
via the intracellular glucocorticoid receptor (GR), which is expressed by almost every 
cell in the body 141;142. Steroids diffuse across the cell membrane and bind to the 
GR in the cytoplasm. Upon ligand binding, the GR becomes activated and the GC-
GR complex translocates to the nucleus, where it directly or indirectly regulates the 
transcription of target genes 143;144. Corticosteroids regulate approximately 20% of all 
genes expressed in leukocytes 145. The estimated number of genes directly regulated 
by corticosteroids lies between 10 and 100 depending on the cell type 146. Many 
inflammatory genes are indirectly regulated through GR interference with activating 
transcription factors and their co-activators. The major action of corticosteroids is 
the suppression of inflammatory genes that are activated during acute rejection 
142;143;146;147. These include genes encoding for cytokines, chemokines, adhesion 
molecules, inflammatory enzymes, and receptors 146. Besides the downregulation 
of pro-inflammatory genes, high-dose corticosteroid therapy also upregulates the 
expression of anti-inflammatory genes, which include interleukin-10, mitogen-
activated protein kinase phosphatase-1 (MKP-1), secretory leukoprotease inhibitor, 
and annexin-1 146;148. In addition, glucocorticoid therapy can suppress acute rejection 
via its potential to prevent migration of leukocytes, induce cell death in lymphocytes, 













































Figure 2. Mechanism of glucocorticoid signaling. GR, glucocorticoid receptor; GRE, 
glucocorticoid responsive elements.
Steroid resistance
One of the main parameters determining graft outcome is therapy sensitivity of the 
acute rejection episode 112-114. Nowadays, the first-line therapy for acute rejection in 
most centers is pulse therapy with intravenous methylprednisolone. The majority of 
acute rejection episodes can be adequately treated with high-dose corticosteroids. 
However, in approximately 25 to 30% of the patients the rejection episode cannot 
be reversed with corticosteroid therapy alone 114;151-156. Similarly, poor or no response 
to steroid therapy for acute rejection reversal also occurs in a proportion of the 
recipients of other solid organ transplants, including liver, lung and cardiac allografts 
157-159. In case of steroid resistance, the patient requires more rigorous therapy with 
anti-lymphocyte antibodies to reverse the acute rejection episode. Renal allograft 
recipients with steroid-refractory rejection are generally treated with ATG, which 





































An acute rejection episode is considered steroid resistant when the patient’s 
serum creatinine levels do not return to within 120% of the pre-rejection baseline 
value after pulse therapy with high-dose steroids, and ATG treatment is required 
within 14 days after the start of the steroid therapy 57;162-164. The first few days after 
the start of the steroid treatment are crucial. Analysis of creatinine courses of 
steroid-resistant and steroid-responsive cases revealed that the minimal time period 
for assessment of the response to steroids is five days after the beginning of the 
treatment 151. The change in serum creatinine levels was similar between patients 
with steroid responsive and steroid resistant acute rejection until day 5, at which 
time the responders showed a significant decrease in serum creatinine, while the 
creatinine level of non-responders remained high. This 5 day period is also the 
average time delay used by clinicians before considering a rejection as being steroid 
resistant 165. The incomplete restoration of graft function in steroid resistant rejection 
may lead to progression of chronic damage to the graft and has a detrimental effect 
on graft outcome 66;112-114;153.
Assessment of risk for steroid resistance
Prediction of steroid resistance at the time of biopsy could prevent unnecessary 
exposure to high-dose corticosteroid therapy. More importantly, the development 
and progression of irreversible nephron loss during the period that steroid resistant 
acute rejection is undertreated with steroids alone could be avoided. This impact of 
steroid-refractory rejection on graft integrity stresses the need for tools to assess the 
response to anti-rejection treatment in an early stage.
Clinical and pathologic indicators of steroid resistant rejection
At present, clinical parameters and histopathologic assessment of kidney biopsies 
remain the golden standard for evaluating short- and long-term graft outcome. 
Several parameters have been associated with response to steroid treatment. 
Acute vascular rejection is related to resistance to high-dose steroid therapy and 
a subsequent higher chance of graft failure 163;166;167. In addition, unresponsiveness 
to steroid therapy has been associated with the presence of mononuclear cells at 
endothelial cells of large and small vessels in the graft 163. Another aspect associated 
with steroid resistance is the presence of an immune response directed against 













































respond less adequately to steroid therapy compared to patients with only mild 
destruction of the microvascular endothelium 167. Steroid-refractory acute rejection 
has been associated with more extensive leukocyte infiltration into the peritubular 
capillaries (PTC) 167. Circulating leukocytes target HLA molecules expressed on the 
PTC, which results into cellular rejection. In addition, the HLA molecules can also be 
targeted by donor-specific antibodies, leading to local complement activation and 
humoral rejection. The activation of the complement cascade leads to the formation 
of complement degradation factor C4d, which can covalently bind to the PTC 
endothelium 79. C4d deposition in PTC has been associated with steroid resistance 
168-171, although in a recent study this association was not found 172.
Cellular and molecular markers of steroid resistant rejection
It remains difficult to predict the risk of graft loss and the response to anti-rejection 
treatment on basis of histopathologic assessment and clinical parameters. Biomarkers 
for molecular and cellular mechanisms involved in graft survival and medication 
responsiveness could provide complementary parameters for assessing the risk of 
adverse graft outcome. Indeed, expression of various markers, particularly those 
of inflammatory cell types, was found to be informative with respect to therapy 
response. Analysis of gene expression patterns in acute rejection biopsies of pediatric 
renal transplant recipients revealed an association between the presence of distinct 
lymphocyte populations and poor graft outcome 154. Steroid resistance correlated 
with increased expression of B cell-, cytotoxic T cell-, and natural killer cell signatures 
compared to steroid responsiveness. The extent of B cell infiltration, investigated 
through immunostainings for B cell marker CD20, was associated with steroid 
resistant acute rejection 154;173;174. However, more recent studies failed to confirm that 
the presence of intragraft B cells is related to therapy response and/or graft function 
after rejection 155;164;175;176. High expression of cytotoxic T cell markers 177, high FasL 
mRNA expression 156, and dense granulysin staining 178 in renal allograft biopsies, as 
well as low FoxP3 expression in urinary sediments 179, have all been described to be 
associated with steroid resistant rejection. The infiltration of macrophages into the 
interstitium and glomeruli of the renal allograft was also found to be associated with 
steroid-refractory acute rejection 180-183. Although various markers for graft outcome 
have been proposed, the heterogeneity in transcriptional regulation observed among 





































Aim and outline of this thesis
The aim of this thesis was to identify cellular and molecular markers associated with 
and/or predictive for outcome of acute renal allograft rejection. The main focus was 
on the response to pulse therapy with high-dose steroids for the treatment of first 
acute rejection episodes. For this purpose, we also optimized molecular techniques 
required to define these biomarkers.
The optimal protocols for storage of clinical samples, RNA extraction, and cDNA 
synthesis were defined in studies described in chapter 2.
To identify cellular and molecular markers associated with risk of allograft failure 
or resistance to steroid treatment of acute rejection, we performed retrospective 
studies in a large cohort of renal transplant patients with a first acute rejection 
episode. In chapter 3, we evaluated a broad panel of immunological markers at 
the RNA level within the renal grafts, including previously reported biomarkers, 
and their relevance for the prediction of the response to corticosteroid treatment. 
In chapter 4, we used microarray analysis to identify novel molecular markers 
associated with steroid-refractory acute rejection, in order to gain further insight 
into the mechanisms underlying steroid resistance. Investigation of intragraft 
gene expression profiles revealed that the expression of metallothioneins in renal 
allografts is associated with response to steroid treatment. Chapter 5 describes the 
impact of DNA polymorphisms in genes involved in glucocorticoid signaling and drug 
metabolism as predisposing factors on the response to high-dose steroid therapy for 
acute renal allograft rejection.
In chapter 6, the association between the expression of S100A9 and S100A8 
during acute rejection and graft survival was studied. The study presents evidence 
that intragraft S100A9 and S100A8 expression levels are indeed predictive markers 
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Assessing mRNA and microRNA levels in peripheral blood cells may complement 
conventional parameters in clinical practice. Working with small, precious samples 
requires optimal yields of RNA and minimal extent of RNA degradation. Several 
procedures for RNA extraction and cDNA synthesis were compared for their efficiency. 
The effect of freeze-thawing peripheral blood cells and storage in preserving reagents 
on RNA quality was investigated. In terms of RNA yield, quality, qPCR signals per ng of 
total RNA, and convenience, the use of NucleoSpin and mirVana columns is preferable. 
The SuperScript III protocol results in the highest yields of cDNA. During conventional 
procedures of storing peripheral blood cells at -180°C and thawing them thereafter, 
RNA integrity is maintained. TRIzol preserves RNA in cells stored at -20°C. Detection 
of mRNA levels significantly decreases in degraded RNA samples, whereas microRNA 
molecules remain relatively stable. When standardized to reference targets, mRNA 
transcripts and microRNAs can be reliably quantified in moderately degraded (quality 
index 4-7) and severely degraded (quality index <4) RNA samples, respectively. We 
describe a strategy for obtaining high-quality and quantity RNA from fresh and stored 
cells from blood. The results serve as a guideline for sensitive mRNA and microRNA 














































Data generated with molecular techniques, when combined with clinical parameters 
and biopsy derived histopathology data, are instrumental for improved diagnostic 
and prognostic assessment.
In cancer biology, RNA derived gene expression signatures of peripheral blood 
cells or the tumor itself allowed the classification of breast carcinomas 1-3, skin 
melanomas 4, lung adenocarcinomas 5, and hematologic malignancies 6-8. These 
signatures were also useful to establish their relationship to prognosis. In solid organ 
transplantation, gene expression profiling of RNA from biopsied tissues has aided 
in distinguishing subtypes of acute rejection which respond differently to therapy 9. 
Using peripheral blood cells as a source of RNA is less invasive for the patient, and 
it enables frequent immunologic monitoring after transplantation 10-13. Messenger 
RNA biomarkers have been identified in peripheral blood from patients who show 
operational tolerance toward their graft 14-17.
MicroRNAs are small, non-coding RNA molecules that negatively regulate 
mRNA expression by degradation or translational repression 18;19. In recent years, 
microRNAs have gained interest for their usefulness in classification of (blood) cancer 
20-24, for their role in hematopoiesis and immune cell function 25-28 and for their role in 
rejection of solid organ transplants 29-31.
Reliable quantification of mRNA and microRNA levels for diagnostic and 
prognostic purposes requires optimal RNA quality and quantity. In the current study 
we compared the efficiency of various procedures for obtaining RNA and cDNA from 
peripheral blood cells. We examined the impact of storage of peripheral blood cells 
on RNA degradation. We also investigated the effect of RNA degradation on mRNA 
and microRNA signals.
Materials and methods
Cells and cell culture
Blood, anticoagulated with heparin, was obtained from anonymous donors (Sanquin 
blood bank, Leiden, the Netherlands) after informed consent, and mononuclear cells 





































blood lymphocyte (PBL) blasts were studied, since they are a readily available source 
of RNA for study. Lymphocyte blasts (PBL blasts) were generated by culturing PBMC 
from 4 donors at 1x106/mL for 7 days in RPMI1640 (Gibco, Grand Island NY, US), 
containing 15% human serum, and penicillin (100 U/mL)/streptomycin (100 µg/mL) 
(Gibco, cat.no. 15070-063). The medium was further supplemented with 10 U/mL 
IL-2 and 2 µg/mL phytohaemagglutinin (both from Remel Inc, Lenexa KS, US).
Performance of molecular methods was also tested on PBMC without any 
culturing, for which separate donors were used (n=3).
Cell storage and thawing
Freshly obtained PBMC were processed for RNA extraction, either directly or after 
storage for 6 days at -20°C in 25 µL of RNAlaterTM (RNA Stabilization Buffer, Qiagen) 
or 800 µL of TRIzol (see Figure 1). Alternatively, cells were cryopreserved in culture 
medium (RPMI1640) with 20% fetal calf serum (FCS) and 10% dimethylsulfoxide 
(DMSO) prior to RNA extraction. Storage of vials, containing 1 ml cell suspension 
each, was at -80°C for at least 24h, and at -180°C for 3 days.
Cells were thawed by two different methods (Figure 1): using a standard protocol 
or a protocol that includes benzonase-nuclease (Sigma-Aldrich, Zwijndrecht, the 
Netherlands, cat.no. E1014; henceforth called benzonase) 32. In the standard thawing 
protocol, cells are thawed in a 37°C water bath and are transferred dropwise to 3 
mL of FCS at room temperature. After adding 12 mL of culture medium, cells were 
pelleted and resuspended in 10 mL of culture medium with 10% FCS. In the benzonase 
thawing protocol, cells are thawed at 37°C and transferred dropwise to 2 mL of a 1:1 
FCS / culture medium mixture supplemented with 0.6 µL of benzonase. Cells were 
pelleted and resuspended in 5 mL of culture medium with 1 µL of benzonase. After 
washing steps, cells were resuspended in culture medium. After application of any 
thawing protocol, 1x106 PBMC were processed for RNA extraction either directly or 
after storage for 6 days at -20°C in 25 µL of RNAlater or 800 µL of TRIzol. RNA quality 































































































































































































































































































































































RNA was extracted using RNeasy spin columns (Qiagen, Venlo, the Netherlands), 
TRIzol® Reagent (Life TechnologiesTM, Grand Island NY, US), RNA-BeeTM (Tel-Test, 
Friendswood TX, US), the Ambion® mirVanaTM PARISTM kit (Life Technologies), and 
the NucleoSpin® miRNA kit (Macherey-Nagel, Düren, Germany). Protocols for the 
column-based kits (RNeasy, mirVana, NucleoSpin) were followed as described by the 
manufacturers. With mirVana and NucleoSpin, small and large RNAs were purified in 
one fraction, without separate enrichment of small RNAs. Since the RNeasy procedure 
does not allow efficient extraction of RNA molecules of less than 200 bases, it was 
not included in the comparison of microRNA yields. The TRIzol and RNA-Bee reagents 
were supplemented with 0.2 mL of chloroform per 1 mL of reagent. After rigorous 
mixing and centrifugation (15 min, 12,000g, 4°C), the upper layer was isolated. To 
pellet the RNA, 0.5 mL of isopropanol (per 1 mL of reagent) was added, followed by 
10 min incubation at room temperature and centrifugation (15 min, 12,000g, 4°C). 
The pellet was washed once in 0.5 mL of 75% ethanol.
RNA quantity and quality assessment
RNA quantity was determined on a NanoDrop 2000 Spectrophotometer (Thermo 
Fisher Scientific Inc, Asheville NC, US). Results are expressed as micrograms RNA per 
million cells. Furthermore, signals obtained from qPCR on cDNA that was synthesized 
(with SuperScript III; see below) from a fixed amount of RNA (i.e., 200 ng) per sample 
served as an additional criterion of suitability of the RNA extraction methods.
RNA quality was assessed using the StdSense Analysis kit and the ExperionTM RNA 
analyzer (Bio-Rad, Hercules CA, US). The dynamic range of StdSense chips is 5 to 500 
ng/µL. The RNA quality index (RQI), also known as RNA integrity number 33, was used 
as an indicator of RNA integrity, and it ranges from 10 (intact) to 0 (fully degraded). 
For RQI calculations the 28S ribosomal (r)RNA, 18S rRNA, and pre-18S region (below 
the 18S rRNA band) on electropherograms are taken into account. A high 28S:18S 
ratio (i.e., around 2:1) and a low number of shadow bands below and above the 18S 















































Complementary DNA synthesis from total RNA (extracted with mirVana) with an input 
of 100 ng, 500 ng, and 1500 ng was carried out with four different methods, following 
the manufacturers’ manuals: AMV-RT (Promega, Madison WI, US) (10 U of RT, 0.5 
mM dNTP, 20 U of rRNasin); the RevertAidTM kit (Fermentas, St.Leon-Rot, Germany; 
200 U of M-MuLV RT, 1 mM dNTP, 20 U of RiboLockTM RNAse inhibitor); BioScriptTM 
RT (Bioline, London, UK; 200 U of MMLV RT, 0.5 mM dNTP); and SuperScriptTM III RT 
(Invitrogen; 200 U of RT, 0.5 mM dNTP, 40 U of RNAse OUTTM rRNAse inhibitor, 5 mM 
DTT). RNA was combined with oligo dT (Invitrogen; 0.25 µg) and random nucleotide 
hexamers (Invitrogen; 0.25 µg) and incubated at 65°C (70°C for BioScript) for 5 min. 
Subsequently, the remaining constituents supplied by each manufacturer were 
added on ice, and the reactions were allowed to proceed at 25°C for 5 min and at 
42°C (50°C for SuperScript III) for 1 h. Reactions were terminated by increasing the 
temperature to 70°C for 5 min. 
microRNA
Complementary DNA synthesis of microRNAs (100 ng total RNA as input) was carried 
out with the miRCURY LNATM Universal cDNA kit from Exiqon (Vedbaek, Denmark; 
cat.no. 203300). The reverse transcription reaction was carried out according to the 
manufacturer’s manual. Reactions were allowed to proceed for 60 min at 42°C and 
were terminated by increasing the temperature to 95°C for 5 min.
Quantitative PCR assays
Specific mRNA targets (Table 1) and miRNA targets (Table 2) with various abundance 
in expression were analyzed. Signals for mRNA transcripts were determined by qPCR 
on 1:10 diluted cDNA. Optimal primers pairs were selected using Primer 3 (v. 0.4.0), 
which is an open source project hosted by SourceForge. To prevent amplification 
of genomic DNA, forward and reverse primers for each transcript were designed to 
target separate exons, spanning at least one intron with a size of 800 bp or more. 
To ensure high specificity of the primers without amplification of genomic DNA, 
all primer sets were tested before use on control cDNA (from Human Reference 
Total RNA; Clontech, Mountain View CA, US) and genomic DNA. All PCR efficiencies 





































1:40 diluted cDNA. Primer sequences were obtained from Exiqon (see Table 2 for 
catalogue numbers), and contained built-in locked nucleic acids (LNA) for enhanced 
sensitivity and specificity. Further details concerning the qPCR assays have been 
described elsewhere 34-37.
PCR assays were carried out using iQTM SYBR® Green Supermix and a MyiQ 
Real-Time PCR detection system (Bio-Rad). The PCR program consisted of 10 min 
hotstart at 95°C followed by 40 cycles of 15 seconds at 95°C and 1 min at 60°C. Upon 
completion of each run, a melting curve analysis was done to check specificity of the 
primers.
In real-time PCR the Cq (quantification cycle) value is a measure of the number 
of cDNA copies. Cq indicates the number of PCR cycles where fluorescence increases 
above the threshold. In experiments for evaluation of the effect of RNA degradation, 
Cq ratios of individual targets and reference targets (for mRNA: β-actin, GAPDH 38; 
for microRNA: miR-103, miR-191, SNORD38B, SNORD49A) were calculated using the 
2-∆∆Cq method 39.
Table 1. Characteristics of primers for detection of mRNA transcripts





β-actin 5’-accacaccttctacaatgag-3’ 5’-tagcacagcctggatagc-3’ 161 bp 13.9 ± 1.4
GAPDH 5’-acccactcctccacctttgac-3’ 5’-tccaccaccctgttgctgtag-3’ 110 bp 15.1 ± 1.4
Intermediate expression
TGF-β1 5’-cccagcatctgcaaagctc-3’ 5’-gtcaatgtacagctgccgca-3’ 101 bp 18.6 ± 0.8
Low expression
CD25 5’-gactgctcacgttcatcatggt-3’ 5’-aatgtggcgtgtgggatctc-3’ 82 bp 20.8 ± 2.8
HPRT-1 5’-agatggtcaaggtcgcaagc-3’ 5’-tcaagggcatatcctacaacaaac-3’ 165 bp 21.7 ± 2.6
FoxP3 5’-acagcacattcccagagttc-3’ 5’-caggtggcaggatggtttc-3’ 190 bp 21.9 ± 1.4













































Table 2. Characteristics of primers for detection of microRNAs and small RNAs.
microRNA Cat. Nr. 1 NCBI Accession Target size 2 Expression level (Cq) 3
High expression (Cq<20)
SNORD49A 203904 NR_002744 71 bp 19.0 ± 0.6
SNORD38B 203901 NR_001457 69 bp 19.1 ± 1.0
miR-155 204308 HC_040174 23 bp 19.6 ± 0.8
Intermediate expression (Cq: 20-25)
miR-191 204306 HC_040210 23 bp 21.9 ± 0.9
miR-103 204063 HC_885819 23 bp 22.2 ± 0.9
miR-142-5p 204722 HC_040142 21 bp 22.6 ± 1.6
Low expression (Cq>25)
miR-223 204256 HC_040280 22 bp 25.9 ± 1.5
miR-26b 204172 HC_885768 21 bp 26.5 ± 2.7
1 Catalogue numbers from Exiqon.
2 PCR amplicon size for all targets is between 60 and 70 bp on agarose gel.
3 Values represent mean Cq values (with standard deviation) in cells from three donors.
Effect of RNA degradation
RNA (extracted with mirVana) was diluted to 100 ng/µL and exposed to 90°C. At t=0 
and after 15 min, 30 min, 45 min, 1 h, 1.25 h, 1.5 h, 2 h, 2.5 h, and 3 h of heat exposure, 
RNA quality was determined (StdSense chips). Complementary DNA was synthesized 
on mRNA (SuperScript III RT) and microRNA (Universal cDNA kit, Exiqon). As read-
out for yields, PCR signals of six mRNA transcripts (Table 1) and eight microRNAs 
(Table 2) were assessed by qPCR. For each marker the PCR signal per time point was 
statistically compared to the mean signal of the first two time points (t=0, t=15 min). 
In addition, the ratios of individual mRNA transcripts and the mean signal of two 
reference transcripts were calculated. Similarly, ratios for individual microRNAs and 
the mean signal of four reference microRNAs were calculated.
We investigated the effect of RNA degradation on PCR signals for four different 
mRNA transcripts, while varying the amplicon size for each transcript. The reverse 
primer was selected to target a fixed sequence within the coding sequence of GAPDH 
(5’-TGC TGT AGC CAA ATT CGT TG-3’), TGF-β1 (5’-GTC CTT GCG GAA GTC AAT GT-3’), 
CD25 (5’-GAC GAG GCA GGA AGT CTC AC-3’), and FoxP3 (5’-CAG GTG GCA GGA TGG 
TTT C-3’). The location of the forward primer was varied to obtain primer pairs that 






































Experiments were performed with PBL blasts from three or more donors, and with 
uncultured PBMC from three additional donors. Results are presented as means ± 
standard deviation, unless stated otherwise. Graphs were made in GraphPad Prism 5 
(La Jolla, CA). Differences between groups were tested by independent t-tests using 
SPSS Inc software version 20 (IBM Corp, Armonk NY, US). P<0.05 was considered a 
statistically significant difference.
Results
Cell storage and thawing
The effect on RNA quality of freezing and thawing cells with various protocols, 
combined with the effect of storage of cells in several RNA-preserving reagents, was 
investigated. Freshly obtained cells were directly processed for RNA extraction or 
stored at -20°C in various RNA-preserving reagents (Figure 1A). RNA quality decreased 
with 0.6 points on the RQI scale (P<0.05) after storage in RNAlater (R) or TRIzol (T) 
(Figure 1B, open bars). Accordingly, qPCR signal with cDNA synthesized from the RNA 
samples was at least two-fold lower after storage in RNAlater or TRIzol, although this 
difference did not reach statistical significance (Figure 1C).
Freezing the cells in DMSO and thawing them with either a standard protocol 
(Figure 1B-C, first grey bar) or with the benzonase protocol (first black bar) did not 
negatively affect RNA quality compared to freshly-processed cells (first open bar; 
P=NS). Benzonase is reported to prevent cell clumping when PBMC are thawed 32. 
No adverse effect on RNA quality was observed when benzonase was included in 
the thawing procedure (Figure 1B-C: first black bar), compared with the standard 
thawing protocol (first grey bar; P=NS).
Storage of thawed cells for 6 days in the freezer in TRIzol (T) (Figure 1C: third grey 
and third black bar) had a slightly higher RNA-preserving effect for downstream qPCR 














































Various methods for extraction of RNA from PBL blasts were compared. The average 
RNA yield for all 5 methods tested was 2.8 ± 0.8 µg per 1x106 PBL blasts, and the 
average RQI was 9.7 ± 0.3. Yield and quality of RNA did not differ between extraction 
procedures (Figure 2A). Use of the TRIzol and RNA-Bee procedures in our hands led 
to suboptimal RNA yields in 50% of cases due to complete or partial loss (0.03 to 0.7 
µg per 1x106 cells) of the RNA pellet after precipitation. As an additional criterion for 
considering suitability of the procedures, qPCR signals of high-abundance (β-actin, 
green bars in Figure 2B), medium-abundance (TGF-β1, red bars), and low-abundance 
transcripts (CD25 and FoxP3, blue bars) were determined on a fixed amount of RNA 
(200 ng). Signals with NucleoSpin columns were similar to signals obtained with 
mirVana columns, but were on average 1.5 to 1.7 times higher than those obtained 
with RNeasy, TRIzol, and RNA-Bee (Figure 2B, P=NS). PCR signals for high-abundance 
(miR-155, green bars in Figure 2C), medium-abundance (miR-142-5p, red bars), and 
low-abundance (miR-223, blue bars) microRNAs were analyzed after RNA extraction. 
On average, mirVana and RNA-Bee gave highest signals per ng of RNA, followed 
closely by NucleoSpin (1.4-1.5 fold lower). We found the NucleoSpin columns the 
most convenient procedure to work with.
Efficiency of RNA extraction protocols was also tested on mononuclear cells 
obtained directly from peripheral blood (n=3), without subsequent culturing. The 
average RNA yield for the RNA extraction procedures was 0.9 ± 0.4 µg per 1x106 
cells and the average RQI was 8.8 ± 0.8. Use of mirVana gave the highest yield of 
RNA per million PBMC, but this was not significantly different from yield obtained 
with the other extraction procedures (Figure 2D, open bars). Although all procedures 
gave high-quality RNA with an RQI>8, the use of RNeasy and mirVana gave RNA that 
on average had the lowest RQI (Figure 2D, black bars). Results of qPCR signals on a 
fixed amount of RNA (200 ng) are shown for the column-based extraction protocols 
(RNeasy, mirVana, NucleoSpin) (Figure 2E). Signals obtained for the mRNA transcripts 
were higher for NucleoSpin compared with mirVana. Signals for microRNAs were 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































Four protocols for synthesizing cDNA from RNA (extracted with mirVana) were 
tested. The same mRNA transcripts were analyzed as those in the RNA extraction 
experiment above. With RNA from PBL blasts, the order of cDNA efficiency from 
highest to lowest was SuperScript III > BioScript > RevertAid > AMV-RT (Figure 3, 
upper panel). This was observed for high-, medium-, and low-abundance transcripts. 
With both 100 ng and 1500 ng of RNA as input for cDNA synthesis, the use of the 
SuperScript III protocol led to 2- to 32-fold higher yields of cDNA, as measured by 
qPCR, compared to the other protocols (Figure 3, upper panel).
Experiments were repeated with RNA from PBMC obtained directly from blood 
(Figure 3, lower panel). Results were comparable with the results obtained with PBL 
blasts. The use of SuperScript III resulted into the highest yields of cDNA, whereas 
AMV gave the lowest cDNA yields. BioScript and RevertAid did not significantly differ 
in the amount of cDNA yield that they rendered.
Effect of RNA degradation
RNA degradation was induced by exposing total RNA from PBL blasts to 90°C for 
various lengths of time. Over a period of 3 h the RQI decreased from 10.0 to 1.9, 
whereas the ratio of 28S rRNA (upper band) to 18S rRNA (lower band) decreased 
from 1.8 to 0.18 (Figure 4A). When RNA had reached an RQI of 7.0, the signal for all 
mRNA transcripts tested, irrespective of transcript abundance, was already at least 
two-fold lower than the mean signal of the first two time points (Figure 4B; P<0.05). 
At an RQI of 5.4 or lower, PCR signals for mRNA had 3- to 5-fold decreased (P<0.01). 
Thus, with decreasing RNA quality the amplification signals declined rapidly. In 
contrast, all microRNAs tested remained relatively stable (Figure 4C), except small 
nucleolar RNA SNORD49 which showed a decline of PCR signals at an RQI of 4.7 or 
lower (2- to 3-fold, P<0.01).
The ratio of each of three mRNA transcripts (TGF-β1, CD25, FoxP3) to reference 
gene signals was not significantly altered at an RQI as low as 4.2 (Figure 4D). Below 
this point, CD25 to reference ratios significantly deviated (>2-fold increase, P<0.05) 
from the ratio observed at the first time point (RQI=10.0). In contrast, ratio of each 
of four microRNAs tested (miR-155, miR-142-5p, miR-223, miR-26b) and the mean 
signal of reference microRNAs remained stable even in severely degraded RNA with 

















































































































































































































































































































































The effect of RNA degradation on qPCR signals for mRNAs and microRNAs 
was also tested with mononuclear cells obtained directly from peripheral blood. 
Similar results were seen as with the RNA from the PBL blasts. Below an RQI of 5, 
amplification signals for all mRNA transcripts tested had significantly declined (Figure 
4F; P<0.05). Signals for almost all microRNAs tested, except small nucleolar RNAs 38B 
and 49A, remained stable at an RQI as low as 3.5 (Figure 4G).
RNA degradation negatively affects PCR signals irrespective of mRNA amplicon size
It is expected that in degraded RNA samples, larger PCR amplicons cease 
amplification sooner than smaller amplicons. We examined the possibility that 
amplicon size differences account for the sustained stability of microRNA molecules 
vis-à-vis increasing degradation of RNA. Amplicon size of each of the miRNA targets 
tested was between 60 and 70 bp (examined on agarose gel, data not shown). For 
high, medium, and low-abundance mRNA transcripts, we varied the size of the PCR 
amplicon between 50 and 400 bp, and investigated the effect of RNA degradation 
on PCR signals. For the four transcripts tested, larger amplicon sizes resulted in 
quicker loss of PCR signal upon RNA degradation (Figure 5). However, with an mRNA 
amplicon size of between 45 and 60 bp (Figure 5, open triangles) the extent of loss of 






































Figure 4. Effect of RNA degradation. RNA was extracted from PBL blasts, and RNA degradation 
was induced by exposure to 90°C for times indicated. (A) Representative picture of RNA 
electropherogram showing impact of heat exposure on RNA integrity. (B) RQI, as an indicator 
of RNA quality, was analyzed (x-axis). The numbers 1 to 10 at the top of the graph indicate time 
points corresponding with the numbers in the RNA electropherogram. Messenger RNA levels 
were assessed by qPCR, targeting high-abundance (green), medium-abundance (red), and 
low-abundance (blue) markers. For each marker, the mean PCR signal at t=0 was set to 1. The 
graph shows means of four experiments. *, P<0.05; #, P<0.01; **, P<0.005 versus mean of the 
first two time points. (C) MicroRNA levels were assessed by qPCR, targeting high-abundance 
(green), medium-abundance (red), and low-abundance (blue) markers. The graph shows 
means of three experiments. **, P<0.005 versus mean of first two time points for SNORD49A. 
(D-E) PCR signals for individual mRNA transcripts and microRNAs were corrected for reference 
markers using the 2-∆∆Cq method. The upper and lower boundaries of the shaded areas 
indicate maximum and minimum values, respectively. *, P<0.05 versus first time point. (F-G) 
Experiments investigating the effect of RNA degradation on PCR signals were repeated with 
RNA from PBMC obtained directly from blood. Messenger RNA transcripts (F) and microRNAs 
(G) were analyzed. *, P<0.05 versus mean of the first two time points (F: each mRNA transcript; 













































Figure 5. RNA degradation negatively affects PCR signals irrespective of mRNA amplicon size. 
RNA from PBL blasts was degraded by exposure to 90°C. PCR signals for high-abundance 
(green), medium-abundance (red), and low-abundance (blue) mRNA transcripts were 
assessed. For each transcript, size of the amplicon was varied (50 bp, 100 bp, 200 bp or 400 
bp). For each condition, the mean PCR signal at t=0 was set to 1. Graph represents means of 
four experiments, with third-order polynomial lines drawn through the data points. *, P<0.05; 
#, P<0.01; **, P<0.001 versus mean of first two time points for the smallest amplicon.
Discussion
Molecular techniques are vital for identification and validation of markers at the 
RNA level. Novel molecular markers are needed for improving current conventional 
diagnostic practice. Faced with the challenge of small sizes of clinical samples, 
researchers optimize their protocols for isolation of mRNA and microRNA. Here we 
describe an optimized protocol for RNA extraction, cDNA synthesis, and storage of 
peripheral blood cells for obtaining high yields of high quality mRNA and microRNA.
RNA integrity was maintained upon freezing and thawing cells, following 
conventional procedures, when compared to RNA from freshly isolated cells. 





































needs to be postponed, and enables retrospective RNA analysis of cells that were 
cryopreserved for cellular assays. We used the RNA quality index from nanochips 
to determine RNA quality. This is a suitable means to reliably assess RNA integrity, 
as was also reported by others 33;40. In addition, we compared two commonly 
used protocols for thawing cells, one of which incorporates benzonase-nuclease. 
Benzonase has no negative effect on the preservation of high-quality RNA, and 
has the additional benefit of preventing clumping of PBMC during thawing 32. In 
daily laboratory practice, functional cellular tests are often performed with PBMC 
recovered from cryopreservation. With the additional goal of molecular analyses, 
one may obviously proceed with RNA extraction from thawed cells immediately. 
Alternatively, the thawed cells may be stored again for RNA extraction on a later day, 
for instance when functional tests need to be performed and interpreted first. In that 
case, TRIzol (at -20°C) is recommended, since its use leads to preservation of RNA 
integrity, as reflected by RNA quality index and qPCR signal. Since storage time of cell 
pellets at -20°C in our experiments did not exceed 6 days, a negative impact on RNA 
quality of extended cell storage cannot be ruled out.
In terms of RNA yield, quality, qPCR signals per ng of total RNA, and convenience, 
the use of NucleoSpin and mirVana columns is preferable. TRIzol and RNA-Bee, 
which have been used in many studies for RNA extraction, offer rapid procedures but 
showed a relatively high failure rate in our laboratory, due to (partial) loss of the RNA 
pellet in the precipitation step. Four of the 5 RNA extraction procedures tested were 
comparable in the amount of PCR signal generated for microRNA targets per ng of 
total RNA. RNeasy spin columns are not suitable for efficient microRNAs extraction 
(data not shown and 41). The miRNeasy kit may better suit this goal, but it was not 
available at the start of our tests.
Of the cDNA synthesis protocols that we tested, SuperScript III resulted in the 
highest yield of cDNA. This is in line with the recommendation of using a thermostable 
reverse transcriptase enzyme for cDNA synthesis 42. Of note, SuperScript III was 
considerably superior to the first generation of SuperScript (data not shown) that we 
reported on in a previous study 43.
Finally, we showed that RNA degradation has a major negative impact on mRNA 
expression levels, which were determined by qPCR. This finding is in line with the 
highly negative correlation found between the RNA integrity number (RNA quality 













































44-46. After correction of individual mRNA transcripts to reference genes, the ratio 
was not significantly altered with an RQI as low as 4.2. Below this value, the 
signal to reference ratio was significantly altered for one of the three transcripts 
studied, indicating different rates of degradation for different mRNA molecules. 
We recommend that the RQI of RNA samples should be 4.2 or higher for reliable 
quantification of standardized transcript levels. In another study, an index of 5 or 
higher was regarded as suitable for downstream qPCR application 46. In contrast, we 
observed that individual microRNAs, and especially microRNA signals standardized to 
reference microRNA signals, remained stable even in severely degraded RNA samples 
(having an RQI as low as 1.9). In an earlier study, microRNAs did not suffer from 
degradation during storage of lymphocytes at -80°C 41, but the quality of the RNA was 
not investigated in that study. Even with mRNA amplicons of approximately 50 bp we 
observed significant loss of PCR signals at an RQI of 5.4 or lower. This shows that the 
increased stability of microRNAs, compared to that of mRNAs, cannot be explained 
by smaller amplicon sizes. MicroRNAs remain stable in different human bodily fluids 
47;48. Our observations and those from others hold promise for reliable quantification 
of microRNA expression in specimens that are prone to RNA degradation such as 
blood plasma, serum, and urine.
In summary, we described an optimized protocol for extracting and preserving 
RNA molecules from blood cells. The results serve to enhance sensitivity of mRNA 
and microRNA expression assessment for clinical purposes.
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Background. Steroid resistant acute rejection is a risk factor for inferior renal allograft 
outcome.
Methods. From 873 kidney transplant recipients (1995-2005) 108 patients with a first 
rejection episode were selected for study using strict inclusion criteria and clinical 
end point definition. We aimed to predict response to corticosteroid treatment using 
gene expression of 65 transcripts. These reflect cytokines, chemokines, and surface 
and activation markers of various cell types including T cells, macrophages, B cells, and 
granulocytes. Steroid resistance (40% of the patients) was defined as requirement for 
anti-thymocyte globulin treatment within two weeks after corticosteroid treatment.
Results. None of the clinical and histomorphologic parameters showed a significant 
association with response to treatment. Univariate logistic regression analysis 
resulted in eleven mRNA markers, including T cell-related transcripts CD25, LAG-3, 
Granzyme B, and IL-10, and macrophage-specific transcripts MannoseR and S100A9, 
which significantly discriminated steroid resistant from steroid responsive rejections 
(P<0.05). In multivariate logistic regression the combination of T cell activation 
markers CD25:CD3e ratio (OR=8.7, CI: 2.4-31.2) and LAG-3 (OR=3.3, CI: 1.4-7.7) 
represented the best predictive model for steroid response (P<0.0001). Specificity 
and sensitivity were 78% and 60%, respectively. After internal stratified ten-fold 
cross-validation the model remained significant. Inclusion of clinical variables into 
the model with molecular variables did not enhance prediction. 
Conclusions. Differences in intragraft expression profiles reflect variability in 
the response to anti-rejection treatment. In acute rejection, molecular markers, 
particularly those reflecting T cell activation, offer superior prognostic value 














































After kidney transplantation, the occurrence of acute rejection is one of the most 
important risk factors for adverse graft outcome 1-3. Acute rejection is a complex 
process in which infiltrating cells of the host immune system cause injury to the 
allograft. The Banff classification 4-7 represents histomorphologic criteria to determine 
the severity of the acute rejection based on the site and degree of inflammation in 
the renal allograft biopsy.
A main parameter determining graft outcome is therapy sensitivity of the acute 
rejection episode 3;8;9. In most cases a first rejection episode can be adequately 
treated with high-dose corticosteroids. However, in approximately 30% of the 
patients the rejection episode cannot be reversed with corticosteroid therapy alone 
2;8;10. In these cases of steroid resistance the patient requires more rigorous therapy 
with anti-thymocyte globulin (ATG). Acute rejection episodes leading to incomplete 
restoration of graft function upon treatment may lead to progression of chronic 
damage to the graft, and have a detrimental effect on graft outcome 8;9;11.
Once the diagnosis acute rejection has been made, it is difficult to predict the 
response to anti-rejection treatment using clinical parameters and histopathologic 
assessment of the biopsy. Availability of molecular markers could help to assess 
which patients will respond to steroid treatment and which patients are in need 
of immediate ATG treatment. Indeed, several studies have described cellular and 
molecular markers in the graft tissue, of which the expression was found to be 
associated with therapy resistance (reviewed in 11). Sarwal and colleagues found 
increased expression of B cell-, cytotoxic T cell-, and natural killer cell signatures 
in steroid resistant acute rejection in renal allografts of children 12. In more recent 
studies investigators have not been able to confirm that the presence of intragraft 
B cells, on basis of CD20 expression, is associated with therapy response and/or 
graft function after rejection 13-16. It has further been shown that high FasL mRNA 
expression 17 and dense granulysin staining 18 in renal allograft biopsies, as well as low 
FoxP3 expression in urinary sediments 19, were associates of steroid resistance. The 
presence of macrophages during acute rejection within the graft was also found to 
be associated with steroid resistance 20-23. Together, these results give an indication 
of the complexity in accurately predicting the response of kidney transplant patients 





































In the current study we investigated a broad panel of immunological markers, 
measured by quantitative PCR (qPCR), in a large cohort of patients suffering from 
a first acute rejection episode. We aimed to predict response to anti-rejection 
treatment on the basis of molecular markers in the allograft biopsy.
Materials and methods
Patients
We reviewed all 873 patients who received a renal allograft in our center between 
1995 and 2005. All patients who had suffered from histologically proven acute 
rejection were included in the study. Further criteria for this study were: 1) only first 
rejection episode biopsy specimens were included; 2) only patients who received 
corticosteroids as anti-rejection treatment were included; 3) patients who received 
ATG as induction therapy were excluded; 4) all studied biopsy cores had been obtained 
prior to the start of anti-rejection treatment. Frozen material, for RNA extraction 
and quantitative PCR (qPCR), was available from 108 patients who met the criteria. 
Nine samples were excluded from analysis: 1 sample due to RNA degradation and 8 
samples due to too low RNA yield from the biopsy. In total, 99 patients were included 
in the statistical analysis (Figure 1).
Seventy patients (70.7%) received no induction therapy and 29 patients (29.3%) 
received induction therapy with an IL-2 receptor blocker (Daclizumab). Maintenance 
immunosuppressive medication consisted of a calcineurin inhibitor (Cyclosporine A or 
Tacrolimus) and prednisone. Fifty-six patients (56.6%) also received an antimetabolite 
(Mycophenolate Mofetil) as part of the maintenance immunosuppression. 
Immunosuppression for the treatment of acute rejection consisted of pulse therapy 
for 3 days with a 1-g bolus of intravenous methylprednisolone daily.
Definition of primary clinical endpoint
The primary clinical endpoint was response to anti-rejection treatment with 
methylprednisolone. Steroid resistant acute rejection was defined as lack of clinical 
response (serum creatinine level did not return to within 120% of the pre-rejection 
baseline value 16;24;25) to steroid pulse therapy, and a requirement for anti-thymocyte 













































resistant group, the time between initiation of steroid treatment and ATG treatment 
was on average 7.3 ± 3.5 days (in 82% of the patients an interval of ≥ 5 days 25;26). In 
seven cases, ATG was given within 5 days after initiation of steroid treatment. Reason 
was insufficient decline in serum creatinine, stagnation of the decline above the 
120% level, or a rising serum creatinine level despite the steroid treatment. A total 
of 59 patients with steroid responsive acute rejection and 40 patients with steroid 
resistant acute rejection were evaluated in the study (Figure 1).
Figure 1. Flow diagram of the sample selection. All patients who received a renal allograft in 
our center between 1995 and 2005 were reviewed (n=873). All patients who had suffered 
from histologically proven acute rejection were considered for study. Further selection criteria 
led to 59 patients with steroid responsive acute rejection and 40 patients with steroid resistant 
acute rejection for investigation in the study.
Biopsy samples
At least two biopsy cores were collected from each patient. One core was formalin 
fixed, embedded in paraffin, and used for histochemical stainings. Three independent 
pathologists (I.B., N.G. and M.G.) blinded to the clinical data of the patients and 
outcome of the acute rejection revised individual Banff lesions on all biopsies according 
to Banff 2011 criteria 7. The pathologists highly agreed on acute and chronic changes 
and reached a satisfactory inter-observer agreement. The second biopsy core was 
immediately snap frozen in liquid nitrogen and stored at -80°C. Immunofluorescent 
staining for C4d was performed on frozen sections from 93 of the 99 (94%) patients 
with mouse anti-human C4d antibody, as described previously 13;27. Biopsies with 
diffuse C4d+ staining were assessed for histomorphologic characteristics indicative 





































RNA extraction and quality assessment
Eight to ten 10-μm sections were cut with a cryomicrotome from each snap frozen 
biopsy core. Total RNA from the renal tissue was extracted using the RNeasy Mini Kit 
(Qiagen, Chatsworth, CA). RNA quality was determined on Nano LabChips with the 
Aligent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). The RNA concentration 
was 2.75 ± 1.13 μg, mean 28S:18S ratio was 2.1 ± 0.05, and mean RIN was 8.00 ± 0.98.
Real-time quantitative PCR analysis
An average of 0.89 ± 0.19 µg of RNA from each frozen biopsy core was transcribed 
into cDNA, according to a previously described protocol 28. To prevent amplification 
of genomic DNA, forward and reverse primers for each transcript targeted separate 
exons, spanning at least one intron with a size of 800 bp or more. Primer sequences 
can be provided on request. All primer sets were tested before use on control 
cDNA and genomic DNA to ensure optimal performance and no amplification of 
genomic DNA. Reactions and PCR conditions have been described previously 28. All 
PCR efficiencies were between 90% - 110%. Relative gene expression levels were 
determined on the basis of a standard curve (in duplicate) of five serial dilution points 
of reference cDNA (qPCR Human Reference Total RNA, Clontech, France). Differences 
in mRNA expression levels were normalized either to the geometric mean signal of 
the reference genes GAPDH, 18S rRNA and β-actin (inter-correlation ranged between 
0.88 and 0.95), or normalized to the signal of CD3e. For each marker reference-gene-
normalized mRNA levels and CD3e-normalized mRNA levels were calculated.
Statistical analysis
Comparison of categorical data between patient groups was evaluated using 
Pearson chi-square tests. With respect to steroid response of the acute rejection, the 
predictive value of individual mRNA markers and of clinical and histomorphologic 
parameters was analyzed using univariate logistic regression analysis. Multivariate 
logistic regression analysis was used to test if multiple markers combined could 
provide a model with a higher predictive value. Markers were included stepwise in 
the model based on the likelihood ratio statistics. The obtained candidate marker set 
was validated using stratified ten-fold cross-validation. All logistic regression analyses 
were performed using a classification cutoff of 0.5, and logistic regression data is 













































characteristics (ROC) analysis was performed to evaluate the predictive value of 
multivariate parameters.
All statistical tests were two-sided and P values less than 0.05 were considered 
as significant. Statistical analyses were performed using the SPSS statistical package 
(SPSS Inc., version 17.0.2, Chicago, IL, US).
Results
Demographics and clinical data
Demographic and clinical characteristics were not significantly different between 
the steroid responsive (n=59) and steroid resistant (n=40) patients (Table 1). No 
significant differences were found in rejection severity (P=0.64, Table 2) and C4d 
positivity (P=0.40, Table 1). In the 13 biopsies showing C4d positivity we investigated 
histomorphologic characteristics (granulocytic infiltrate, microthrombi, peritubular 
capillaritis, and necrotizing vascular rejection) indicative of a possible antibody-
mediated rejection. None of these biopsies showed such features.
The steroid resistant group had significantly higher serum creatinine levels at 6 
months (P=0.008) and 12 months (P=0.008) after the transplantation compared with 
the steroid responsive group. The graft survival after 12 years was 60.4% for the 





































Table 1. Demographic and clinical data of patients with steroid responsive and steroid resistant 
acute rejection.
Variable Steroid responsive Steroid resistant P value
(N=59) (N=40)
Patient age 0.69
≥ 50 years 26 (44.1%) 16 (40.0%)
Patient gender 0.89
Female 20 (33.9%) 13 (32.5%)
Donor age 0.35
≥ 50 years 21 (35.6%) 18 (45.0%)
Donor gender 0.66
Female 38 (64.4%) 24 (60.0%)
Year of transplantation 0.15
1995 through 1999 36 (61.0%) 30 (75.0%)
2000 through 2005 23 (39.0%) 10 (25.0%)
Donor type 0.30
Living 11 (18.6%) 11 (27.5%)
Post mortal 48 (81.4%) 29 (72.5%)
HLA-A matching 0.75
≥ 1 mismatch 38 (64.4%) 27 (67.5%)
HLA-B matching 0.89
≥ 1 mismatch 45 (76.3%) 31 (77.5%)
HLA-DR matching 0.36
≥ 1 mismatch 36 (61.0%) 28 (70.0%)
Virtual PRA 0.74
Immunized (6-100%) 17 (29.3%) 13 (32.5%)
Cold ischemia time 0.46
> 18 hours 32 (66.7%) 26 (74.3%)
Induction therapy 0.44
Daclizumab 19 (32.2%) 10 (25.0%)
None 40 (67.8%) 30 (75.0%)
Maintenance therapy 0.28
Double therapy 23 (39.0%) 20 (50.0%)
Triple therapy 36 (61.0%) 20 (50.0%)
Delayed graft function 0.18
Yes 17 (29.3%) 7 (17.5%)
Rejection time 0.80
<3 months post Tx 57 (96.6%) 39 (97.5%)
3-6 months post Tx 2 (3.4%) 1 (2.5%)
C4d staining 0.40
Positive 6 (11.3%) 7 (17.5%)
Vascular rejection 0.25
Yes 17 (28.8%) 16 (40.0%)













































Table 2. Diagnostic categories according to Banff 2011 criteria of patients with steroid 
responsive and steroid resistant acute rejection 1.
Diagnostic category Steroid responsive Steroid resistant
(N=54) (N=36)
Borderline changes 25 (46.3%) 12 (33.3%)
TCMR grade IA 6 (11.1%) 2 (5.6%)
TCMR grade IB 6 (11.1%) 6 (16.7%)
TCMR grade IIA 12 (22.2%) 10 (27.8%)
TCMR grade IIB 2 (3.7%) 3 (8.3%)
TCMR grade III 3 (5.6%) 3 (8.3%)
1 No significant differences were found between groups (P=0.64). In each group, three biopsies 
did not contain sufficient cortex to determine a Banff score. Three additional patients had a 
clinical rejection (with i- and t-scores of 0). TCMR, T-cell mediated rejection
Evaluation of predictive value of clinical and molecular variables with respect to 
steroid response
Univariate analysis
We questioned whether differences in the expression of immunomarkers between 
the treatment response groups could predict steroid-refractory acute rejection. No 
significant differences in the RNA concentration, purity, and quality between the 
groups were found (data not shown). Expression of 73 markers was quantified by 
qPCR (see Table S1). Eight markers were excluded from further analysis due to an 
inferior melt curve in the PCR assay or due to low expression in all biopsies.
We tested whether clinical and histomorphologic parameters influenced 
the response to steroid treatment. None of these parameters had a significant 
relationship with steroid response in univariate logistic regression analysis (Table 
3). We tested whether mRNA expression of molecular markers can predict response 
to corticosteroid treatment by using univariate logistic regression analysis. Eleven 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4. Univariate and multivariate logistic regression analysis of predictive value of molecular 
markers for steroid response.




OR 95% CI P value
Univariate analysis
CD25:CD3e 86.4% 37.5% 65.5% 67.1% 5.76 1.76 – 18.80 0.004
CD25 83.1% 40.0% 61.5% 67.1% 3.70 1.41 – 9.70 0.008
MannoseR 81.4% 30.0% 52.2% 63.2% 4.67 1.42 – 15.36 0.011
S100A9 83.1% 42.5% 63.0% 68.1% 2.33 1.22 – 4.44 0.011
LAG-3:CD3e 81.4% 22.5% 45.0% 60.8% 3.80 1.30 – 11.15 0.015
CXCL13:CD3e 81.4% 37.5% 57.7% 65.8% 2.06 1.10 – 3.83 0.023
LAG-3 84.7% 25.0% 52.6% 62.5% 2.43 1.12 – 5.26 0.025
RORγT:CD3e 84.7% 25.0% 52.6% 62.5% 0.48 0.24 – 0.94 0.032
IL-10 83.1% 25.0% 50.0% 62.0% 3.02 1.07 – 8.63 0.038
STAT6:CD3e 88.1% 20.0% 53.3% 61.9% 0.28 0.09 – 0.93 0.038
Granzyme B 83.1% 17.5% 41.2% 59.8% 2.05 1.01 – 4.17 0.048
Multivariate analysis
Multivariate model 78.0% 60.0% 64.9% 74.2% 0.00008
CD25:CD3e 8.66 2.40 – 31.21 0.001
LAG-3 3.29 1.41 – 7.69 0.006
All molecular markers with a significant P value in the univariate logistic regression analysis, 
and the clinical and histomorphological parameters were included in the multivariate logistic 
regression analysis. Only markers and parameters that reached significance and represent 
independent variables in the multivariate analysis are shown in the table. PV, predictive value; 
OR, odds ratio; CI, confidence interval
Multivariate analysis
Multivariate analysis with logistic regression resulted in a predictive model 
(P=0.00008) that contained the CD25:CD3e ratio (OR=8.7; P=0.001) and LAG-3 
(OR=3.3; P=0.006) as independent covariates (Table 4). The specificity and sensitivity 
of this multivariate predictive model were 78% and 60%, respectively. The receiver 
operating characteristics (ROC) analysis showed that the predictive value of the 
multivariate model was significant (P=0.00002). Area under the curve (AUC) was 0.76 
with a 95% CI of 0.66 – 0.85 (Figure 2). Inclusion of the clinical and histomorphologic 
parameters in the multivariate logistic regression model containing the molecular 





































Figure 2. Predictive value of the multivariate logistic regression model for steroid resistant 
acute rejection. The receiver operating-characteristic (ROC) curve shows the percentage of 
true-positive results (sensitivity) and false-positive results (100 – specificity) for various cut-
off levels of the multivariate logistic regression model, containing the molecular markers 
CD25:CD3e and LAG-3. The area under the curve of the ROC curve is 0.76 (P<0.001) with a 
95% CI of 0.66 – 0.85.
Cross-validation model
For internal validation of the findings, a stratified ten-fold cross-validation was 
performed. The multivariate logistic regression analysis with cross-validation resulted 
in the same significant predictive model as before, containing the CD25:CD3e ratio 
and LAG-3 as independent covariates (mean P-value of 0.0004 ± 0.0004). The 
specificity and sensitivity of the cross-validated multivariate predictive model were 
76% ± 20% and 43% ± 22%, respectively. ROC analysis for the model was significant 
(P=0.037).
Discussion
Steroid-refractory acute rejection is a risk factor for adverse renal allograft 
outcome 8;9. To identify molecular associates of steroid resistant acute rejection, 
we performed a retrospective cohort study in a large cohort of renal transplant 
patients with a first rejection episode. None of the clinical and histomorphologic 
parameters tested showed significant association with treatment response. Eleven 













































responsive rejections in univariate analysis. In multivariate logistic regression, the 
combination of T cell activation markers CD25:CD3e ratio and LAG-3 represented 
the best predictive model for steroid response. The specificity and sensitivity of this 
multivariate predictive model were 78% and 60%, respectively. After internal cross-
validation the predictive model remained significant.
For the current study, we selected a panel of immune-related genes, which 
included markers previously reported in association with steroid response 12;17-23;29-33, 
and which together reflected the full immune repertoire that may be present in the 
grafts (Table S1). These included cytokines, chemokines, and surface and activation 
markers of various cell types including cytotoxic T cells, T helper cells, regulatory 
T cells, classically and alternatively activated macrophages, B cells, plasma cells, 
natural killer cells, granulocytes, and mast cells. We found that the combination of 
the CD25:CD3e ratio and LAG-3 represented the best predictive model for steroid 
response. These markers are mainly expressed by activated T cells and regulatory 
T cells and represent cell surface proteins involved in signal transduction 34-38. CD25 
is the α-subunit of the IL-2 receptor (IL-2R), which is important in the regulation 
of the survival and proliferation of T cells 35;36. Lymphocyte activation gene-3 (LAG-
3 or CD223) is an activation-induced marker involved in the negative regulation of 
homeostasis and T cell function 34;38. It is for the first time that these markers are 
linked to steroid resistance in renal transplantation. Interestingly, several studies 
have demonstrated that T cell characteristics, through disparities in IL-2 responses, 
play a role in steroid resistance 30;31. Lee and colleagues identified in patients with 
steroid refractory ulcerative colitis a characteristic subgroup of peripheral CD25int T 
helper cells, which continued to proliferate in vitro upon activation, despite exposure 
to glucocorticoids 32. This finding together with observations from the current study 
may suggest that steroid resistance resides in specific activated T cell populations 
and is not a feature of all lymphocytes. Hueso and colleagues have shown that low 
pretransplant levels of CD3+CD25high lymphocytes were associated with an increased 
risk for early acute renal allograft rejection 39, which is likely a reflection of low 
levels of regulatory T cells 40;41. The CD25:CD3e ratio at the mRNA level, associating 
with steroid resistant acute rejection, is probably more a reflection of activated 
T cells, comparable to the CD25int cells described by Lee and colleagues, rather 
than of regulatory T cells. A potential clinical implication of current findings is the 
identification of patients who do not respond to steroid treatment and may benefit 





































In other studies, the presence of B cells (CD20) 12;29;33, macrophages (CD68) 20-23, 
and cytotoxic T cells (Granzyme B, FasL) 17 was associated with steroid resistant acute 
rejection. With did find by univariate analyses association between expression of 
Granzyme B and macrophage-specific transcripts (Mannose receptor, S100A9) with 
steroid resistant rejection. We could not confirm, however, the predictive value of 
CD20 expression. Complementary B cell specific transcripts, including CD19, CD22 
and CD252, gave similar results. Besides the set of immunomarkers, transcripts 
of glycine amidinotransferase (GATM), phytanoyl-CoA hydroxylase (PHYH), and 
epidermal growth factor (EGF), of which relatively high levels were related to steroid 
responsive acute rejection in a previous study 12, were not of prognostic relevance 
in the current study. One aspect that may have influenced the discrepancy between 
findings from the current study and some findings from others could be differences 
in the age of the patients (for example, adults versus adolescents and children), type 
of immune suppression, the number of HLA mismatches, the sensitization grade of 
the patients, and the time between transplantation and the rejection episode. Of 
note, several other investigators also have not been able to confirm the association 
of CD20 expression with steroid response of the acute rejection 13-16. Although not 
significant, in our study a higher percentage of vascular rejection was seen in the 
steroid resistant group (40%) compared to the steroid sensitive group (29%) (Table 
1). Vascular rejection was found to be associated with steroid resistance in previous 
studies 24;42;43, and its presence may have had an influence on therapy sensitivity in 
the current study.
We handled strict inclusion criteria, clinical end point definition, and quality 
controls for RNA processing and PCR assays. We decided to use qPCR rather than 
microarray analysis to measure intragraft mRNA expression, since the former 
technique is the best tool to quantify expression. Furthermore, expression of most of 
the interleukins and chemokines studied cannot be detected by microarray analysis. 
To have defined clinical criteria for response to anti-rejection therapy, steroid 
resistance of the acute rejection was adopted when the patient required ATG within 
two weeks after initiation of the steroid administration.
Some comments need to be made with regard to the current findings. In this 
retrospective study, none of the C4d-positive biopsies showed histomorphologic 
characteristics indicative of a possible antibody-mediated rejection. However, 













































of rejection. Therefore, we were unable to firmly conclude on the contribution of 
antibody-mediated rejection. Furthermore, we observed, as pointed out previously 
12, a considerable heterogeneity in transcriptional regulation among the acute 
rejection biopsies. Presence of multiple mechanisms underlying steroid resistance 
probably accounts for the restricted predictive power. Firstly, the outcome of 
acute rejection may be determined by the response of the renal parenchyma to 
inflammation besides the composition of the infiltrate itself. Secondly, interaction 
of the glucocorticoid receptor (GR) with its ligand might in part determine therapy 
response. Polymorphisms in NR3C1, the gene encoding for the GR, may affect 
the ability of this receptor to bind glucocorticoids 44;45. Further research needs to 
be performed to test the impact of polymorphisms in the NR3C1 gene on therapy 
response during acute rejection.
In conclusion, we evaluated a broad panel of immunological markers by qPCR 
profiling in a large cohort of renal allografts with acute rejection. Differences in 
intragraft expression profiles reflect variability in the response to anti-rejection 
treatment. With respect to therapy response of the rejection episode, molecular 
markers offer superior prognostic value compared to conventional parameters. The 
combination of the CD25:CD3e ratio and LAG-3 expression represents the best model 
for risk assessment of steroid resistance in patients suffering from acute rejection. 
This is of interest in terms of the pathogenic mechanism of steroid resistance. In the 
future, the results could be used to identify which patients will not respond to steroid 
treatment and may benefit from immediate ATG treatment. Our findings indicate 
that steroid resistance resides in specific T cell populations and is not a feature of all 
lymphocytes.
Acknowledgements
The authors are grateful to Erik van Zwet (Department of Medical Statistics, Leiden 
University Medical Center) for his advice in the statistical analyses. This study was 






































 1.  Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Improved 
graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 
342:605-612, 2000
 2.  Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB: Strategies to improve long-
term outcomes after renal transplantation. N Engl J Med 346:580-590, 2002
 3.  Wu O, Levy AR, Briggs A, Lewis G, Jardine A: Acute rejection and chronic nephropathy: a 
systematic review of the literature. Transplantation 87:1330-1339, 2009
 4.  Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, 
Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, 
Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad 
AS, Yamaguchi Y, .: The Banff 97 working classification of renal allograft pathology. Kidney 
Int 55:713-723, 1999
 5.  Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, 
Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar 
SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, 
Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M: Banff 07 
classification of renal allograft pathology: updates and future directions. Am J Transplant 
8:753-760, 2008
 6.  Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Baldwin WM, III, 
Bracamonte ER, Broecker V, Cosio F, Demetris AJ, Drachenberg C, Einecke G, Gloor J, Glotz 
D, Kraus E, Legendre C, Liapis H, Mannon RB, Nankivell BJ, Nickeleit V, Papadimitriou JC, 
Randhawa P, Regele H, Renaudin K, Rodriguez ER, Seron D, Seshan S, Suthanthiran M, 
Wasowska BA, Zachary A, Zeevi A: Banff ‘09 meeting report: antibody mediated graft 
deterioration and implementation of Banff working groups. Am J Transplant 10:464-471, 
2010
 7.  MengeL M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Cendales L, Demetris 
AJ, Drachenberg CB, Farver CF, Rodriguez ER, Wallace WD, Glotz D: Banff 2011 Meeting 
Report: New Concepts in Antibody-Mediated Rejection. Am J Transplant 12:563-570, 2012
 8.  Madden RL, Mulhern JG, Benedetto BJ, O’Shea MH, Germain MJ, Braden GL, O’Shaughnessy 
J, Lipkowitz GS: Completely reversed acute rejection is not a significant risk factor for the 
development of chronic rejection in renal allograft recipients. Transpl Int 13:344-350, 2000
 9.  Vereerstraeten P, Abramowicz D, de Pauw L, Kinnaert P: Absence of deleterious effect on 
long-term kidney graft survival of rejection episodes with complete functional recovery. 
Transplantation 63:1739-1743, 1997
 10.  Petrie JJ, Rigby RJ, Hawley CM, Suranyi MG, Whitby M, Wall D, Hardie IR: Effect of OKT3 in 
steroid-resistant renal transplant rejection. Transplantation 59:347-352, 1995
 11.  Eikmans M, Roelen DL, Claas FHJ: Molecular monitoring for rejection and graft outcome in 
kidney transplantation. Expert Opin Med Diagn 2:1365-1379, 2008
 12.  Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, Salvatierra O, Jr.: 
Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray 
profiling. N Engl J Med 349:125-138, 2003
 13.  Eikmans M, Roos-van Groningen MC, Sijpkens YW, Ehrchen J, Roth J, Baelde HJ, Bajema IM, 
de Fijter JW, de Heer E, Bruijn JA: Expression of surfactant protein-C, S100A8, S100A9, and 
B cell markers in renal allografts: investigation of the prognostic value. J Am Soc Nephrol 
16:3771-3786, 2005
 14.  Doria C, di Francesco F, Ramirez CB, Frank A, Iaria M, Francos G, Marino IR, Farber JL: The 
presence of B-cell nodules does not necessarily portend a less favorable outcome to therapy 
in patients with acute cellular rejection of a renal allograft. Transplant Proc 38:3441-3444, 
2006
 15.  Kayler LK, Lakkis FG, Morgan C, Basu A, Blisard D, Tan HP, McCauley J, Wu C, Shapiro R, 
Randhawa PS: Acute cellular rejection with CD20-positive lymphoid clusters in kidney 













































 16.  Scheepstra C, Bemelman FJ, van der Loos C, Rowshani AT, van Donselaar-Van der Pant KA, 
Idu MM, ten Berge IJ, Florquin S: B cells in cluster or in a scattered pattern do not correlate 
with clinical outcome of renal allograft rejection. Transplantation 86:772-778, 2008
 17.  Desvaux D, Schwarzinger M, Pastural M, Baron C, Abtahi M, Berrehar F, Lim A, Lang P, Le 
Gouvello S: Molecular diagnosis of renal-allograft rejection: correlation with histopathologic 
evaluation and antirejection-therapy resistance. Transplantation 78:647-653, 2004
 18.  Sarwal MM, Jani A, Chang S, Huie P, Wang Z, Salvatierra O, Jr., Clayberger C, Sibley R, Krensky 
AM, Pavlakis M: Granulysin expression is a marker for acute rejection and steroid resistance 
in human renal transplantation. Hum Immunol 62:21-31, 2001
 19.  Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB, Hartono C, Li B, Sharma 
VK, Seshan SV, Kapur S, Hancock WW, Schwartz JE, Suthanthiran M: Messenger RNA for 
FOXP3 in the urine of renal-allograft recipients. N Engl J Med 353:2342-2351, 2005
 20.  Vergara E, Gomez-Morales M, Osuna A, O’Valle F, Aguilar D, Masseroli M, Martinez T, 
Higueras M, Bravo J, Asensio C, Del Moral RG: Immunohistochemical quantification of 
leukocyte subsets in the long-term prognosis of kidney transplants. Transplant Proc 
30:2380-2383, 1998
 21.  Ozdemir BH, Demirhan B, Gungen Y: The presence and prognostic importance of glomerular 
macrophage infiltration in renal allografts. Nephron 90:442-446, 2002
 22.  Ozdemir BH, Bilezikci B, Haberal AN, Demirhan B, Gungen Y: Histologic evaluation, HLA-
DR expression, and macrophage density of renal biopsies in OKT3-treated acute rejection: 
comparison with steroid response in acute rejection. Transplant Proc 32:528-531, 2000
 23.  Tinckam KJ, Djurdjev O, Magil AB: Glomerular monocytes predict worse outcomes after 
acute renal allograft rejection independent of C4d status. Kidney Int 68:1866-1874, 2005
 24.  Haas M, Kraus ES, Samaniego-Picota M, Racusen LC, Ni W, Eustace JA: Acute renal allograft 
rejection with intimal arteritis: histologic predictors of response to therapy and graft 
survival. Kidney Int 61:1516-1526, 2002
 25.  Bock HA: Steroid-resistant kidney transplant rejection: diagnosis and treatment. J Am Soc 
Nephrol 12 Suppl 17:S48-S52, 2001
 26.  Shinn C, Malhotra D, Chan L, Cosby RL, Shapiro JI: Time course of response to pulse 
methylprednisolone therapy in renal transplant recipients with acute allograft rejection. 
Am J Kidney Dis 34:304-307, 1999
 27.  Botermans JM, de Kort H, Eikmans M, Koop K, Baelde HJ, Mallat MJ, Zuidwijk K, van Kooten 
C, de Heer E, Goemaere NN, Claas FH, Bruijn JA, de Fijter JW, Bajema IM, van Groningen MC: 
C4d staining in renal allograft biopsies with early acute rejection and subsequent clinical 
outcome. Clin J Am Soc Nephrol 6:1207-1213, 2011
 28.  Heidt S, Roelen DL, Eijsink C, Eikmans M, van Kooten C, Claas FH, Mulder A: Calcineurin 
inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp 
Immunol 159:199-207, 2010
 29.  Hippen BE, DeMattos A, Cook WJ, Kew CE, Gaston RS: Association of CD20+ infiltrates with 
poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant 
5:2248-2252, 2005
 30.  Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY: Combination IL-2 and IL-4 reduces 
glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 
151:3460-3466, 1993
 31.  Leung DY, Martin RJ, Szefler SJ, Sher ER, Ying S, Kay AB, Hamid Q: Dysregulation of interleukin 
4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp 
Med 181:33-40, 1995
 32.  Lee RW, Creed TJ, Schewitz LP, Newcomb PV, Nicholson LB, Dick AD, Dayan CM: CD4+CD25(int) 
T cells in inflammatory diseases refractory to treatment with glucocorticoids. J Immunol 
179:7941-7948, 2007
 33.  Hwang HS, Song JH, Hyoung BJ, Lee SY, Jeon YJ, Kang SH, Chung BH, Choi BS, Choi YJ, Kim JI, 
Moon IS, Kim YS, Yang CW: Clinical impacts of CD38+ B cells on acute cellular rejection with 





































 34.  Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali DA: Lymphocyte 
activation gene-3 (CD223) regulates the size of the expanding T cell population following 
antigen activation in vivo. J Immunol 172:5450-5455, 2004
 35.  Letourneau S, Krieg C, Pantaleo G, Boyman O: IL-2- and CD25-dependent immunoregulatory 
mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol 123:758-762, 2009
 36.  Driesen J, Popov A, Schultze JL: CD25 as an immune regulatory molecule expressed on 
myeloid dendritic cells. Immunobiology 213:849-858, 2008
 37.  Triebel F: LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. 
Trends Immunol 24:619-622, 2003
 38.  Haudebourg T, Dugast AS, Coulon F, Usal C, Triebel F, Vanhove B: Depletion of LAG-3 positive 
cells in cardiac allograft reveals their role in rejection and tolerance. Transplantation 
84:1500-1506, 2007
 39.  Hueso M, Mestre M, Benavente Y, Bas J, Grinyo JM, Navarro E: Pretransplant low 
CD3+CD25high cell counts or a low CD3+CD25high/CD3+HLA-DR+ ratio are associated with 
an increased risk to acute renal allograft rejection. Transplantation 92:536-542, 2011
 40.  Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA: CD4+CD25high regulatory cells in human 
peripheral blood. J Immunol 167:1245-1253, 2001
 41.  Nadal E, Garin M, Kaeda J, Apperley J, Lechler R, Dazzi F: Increased frequencies of CD4(+)
CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation 
for chronic myeloid leukemia. Leukemia 21:472-479, 2007
 42.  Regele H, Exner M, Watschinger B, Wenter C, Wahrmann M, Osterreicher C, Saemann MD, 
Mersich N, Horl WH, Zlabinger GJ, Bohmig GA: Endothelial C4d deposition is associated 
with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial 
Transplant 16:2058-2066, 2001
 43.  Nickeleit V, Zeiler M, Gudat F, Thiel G, Mihatsch MJ: Detection of the complement 
degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am 
Soc Nephrol 13:242-251, 2002
 44.  Bray PJ, Cotton RG: Variations of the human glucocorticoid receptor gene (NR3C1): 
pathological and in vitro mutations and polymorphisms. Hum Mutat 21:557-568, 2003
 45.  Miura M, Inoue K, Kagaya H, Saito M, Habuchi T, Satoh S: Inter-individual difference 
determinant of prednisolone pharmacokinetics for Japanese renal transplant recipients in 
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Steroid-refractory acute rejection is a risk factor for inferior renal allograft outcome. 
We aimed to gain insight into the mechanisms underlying steroid resistance by 
identifying novel molecular markers of steroid-refractory acute rejection. Eighty-three 
kidney transplant recipients (1995-2005), who were treated with methylprednisolone 
during a first acute rejection episode, were included in this study. Gene expression 
patterns were investigated in a discovery cohort of 36 acute rejection biopsies, and 
verified in a validation cohort of 47 acute rejection biopsies. In the discovery set, 
expression of metallothioneins (MT) was significantly (P<0.000001) associated with 
decreased response to steroid treatment. Multivariate analysis resulted in a predictive 
model containing MT-1 as an independent covariate (AUC=0.88, P<0.0000001). In 
the validation set, MT-1 expression was also significantly associated with steroid 
resistance (P=0.029). Metallothionein expression was detected in macrophages 
and tubular epithelial cells. Parallel to the findings in patients, in vitro experiments 
of peripheral blood mononuclear cells from 11 donors showed that non-response 
to methylprednisolone treatment is related to highly elevated MT levels. High 
expression of metallothioneins in renal allografts is associated with resistance to 
steroid treatment. Metallothioneins regulate intracellular concentrations of zinc, 















































The occurrence of steroid-refractory acute rejection is a risk factor for adverse 
outcome in renal allograft recipients 1-5. First rejection episodes are most of the time 
treated by high-dose steroids, leading to reversal of the acute rejection. However, 
approximately 30% of patients have no or an inadequate response to corticosteroid 
therapy alone and require therapy with anti-thymocyte globulin (ATG) 2;5-7. Such 
steroid resistant patients may show progression of chronic damage to the graft, 
which has a detrimental effect on graft outcome 4;5;8.
Cellular and molecular markers in the graft tissue may complement clinical 
parameters and histomorphology when assessing steroid resistance of the acute 
rejection episode. Indeed, expression of markers, particularly those of inflammatory 
cell types, was found to be associated with therapy response (reviewed in 8). Recently, 
we showed that the combination of T-cell activation markers CD25:CD3 ratio and 
LAG-3 offers a superior prognostic value for assessing steroid response, compared 
with conventional parameters 9. We observed considerable molecular heterogeneity 
among the biopsy samples with acute rejection, underlining the complexity of the 
mechanisms involved in response to steroid therapy.
In the current study we aimed to gain further insight into the mechanisms 
underlying steroid resistance by identifying novel molecular markers of steroid-
refractory acute rejection using genome wide expression profiling. Our results reveal 
that relatively high intragraft expression of metallothioneins (MT), a group of small 
cysteine-rich molecules that regulate intracellular zinc concentrations, during acute 
rejection is associated with resistance to steroid treatment. These proteins were 
further studied in biopsies and steroid-treated leukocyte cultures.
Materials and methods
Patient information
We reviewed all 873 patients who received a renal allograft in our center between 
1995 and 2005. We selected patients suffering from a histologically proven, first 
rejection episode, from whom a renal biopsy had been taken prior to the start of anti-





































(3 days with 1 g bolus) as anti-rejection treatment were included. The primary 
clinical endpoint was response to anti-rejection treatment with methylprednisolone, 
as described previously 9. Steroid resistant acute rejection was defined as lack of 
clinical response to methylprednisolone, and a requirement for anti-thymocyte 
globulin treatment within 14 days after the start of the steroid therapy. The response 
to steroid therapy was monitored by creatinine concentration measurements. 
Maintenance immunosuppression consisted of prednisone and a calcineurin inhibitor 
(Cyclosporine A or Tacrolimus), with or without Mycophenolate Mofetil.
In total, 83 patients were included in the study. For genome-wide expression 
profiling, a discovery set (n=36) was studied: 18 patients with steroid responsive 
acute rejection and 18 patients with steroid resistant acute rejection. As microarray 
analysis requires high-quality RNA 10-13, biopsy samples that had generated the 
highest quality of RNA were included in the discovery set. Four biopsies, taken during 
acute decrease of graft function but with no histomorphologic indication of rejection, 
were included as controls. Results from the discovery set were verified in a validation 
set (n=47): 31 patients with steroid responsive acute rejection and 16 patients with 
steroid resistant acute rejection.
Biopsy samples
Rejection severity of all biopsy specimens was assessed on paraffin-embedded biopsy 
tissue according to Banff 2011 criteria 14. A second biopsy core was snap frozen in 
liquid nitrogen and stored at -80°C. In addition to the biopsies taken on clinical 
indication, paired pretransplant biopsy samples (stored at -80°C) were available from 
14 steroid resistant and nine steroid responsive patients.
RNA extraction and quality assessment
Eight to ten 10-μm sections were cut with a cryomicrotome from each snap frozen 
biopsy core. Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Chatsworth, 
CA). RNA quality was determined on Nano LabChips with the Aligent 2100 Bioanalyzer 
(Agilent Technologies, Palo Alto, CA). The mean RNA concentration was 2.76 ± 1.11 















































Gene expression profiling was performed with Illumina HumanRef-8 v3.0 BeadChips 
(Illumina, San Diego, CA), as previously described 15. Only samples with a RNA quality 
index > 8 were included in the microarray analysis. Illumina GenomeStudio software 
was used to verify the adequacy of signal-background ratio and hybridization 
controls. All data have been deposited in the Gene Expression Omnibus public 
database, accession number: GSE47097.
Real-time quantitative PCR analysis
Synthesis of cDNA, primer design, and quantitative PCR (qPCR) analysis were 
performed according to previously described protocols 9;16. An average of 0.92 ± 0.15 
µg of RNA from each frozen biopsy core was transcribed into cDNA. Primer sequences 
can be provided on request. PCR efficiencies were between 90% - 110%. Differences 
in mRNA expression levels were normalized to the geometric mean signal of the 
reference genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin.
Immunohistochemistry
Immunohistochemical analyses were performed on 32 paraffin-embedded biopsy 
samples: 17 from steroid responsive patients and 15 from steroid resistant patients. 
Protein staining for metallothionein, CD68, and CD163 was performed on 4-μm thick 
sections. Primary monoclonal mouse anti-human antibodies against metallothionein 
(Abcam, Cambridge, UK; clone UC1MT), CD163 (Abcam; clone 10D6, prediluted), and 
CD68 (Dako, Glostrup, Denmark; clone KP1) were used for immunohistochemistry. 
Standardized protocols 17 were applied. Details concerning antigen retrieval and 
staining procedure are provided in Table 1. Photos were taken with a Leitz DMRD 








































































































































































































































































































































In situ hybridization for Y chromosome
The presence of male, Y-chromosome-expressing cells was determined by in situ 
hybridization, as described previously 18. Briefly, 4-μm sections were hybridized 
overnight with digoxigenin (DIG) labeled, Y-chromosome-specific DNA probe, 
followed by consecutive incubations with mouse anti-DIG monoclonal antibody 
(Sigma-Aldrich, St. Louis, MO) and rabbit anti-mouse Ig-horseradish peroxidase (anti-
mouse Envision-HRP, Dako). Sections were developed with Nova Red and counter-
stained with hematoxylin. Photos were taken with a Leitz DMRD microscope (Leica 
Microsystems).
Investigation of metallothionein expression in various cell types
Metallothionein expression was investigated in RNA from a panel of various cell 
types 19. This panel included peripheral blood mononuclear cell (PBMC) fractions 
(n=9), cultured dendritic cells (n=6), monocytes (n=3), differentiated macrophages 
(n=7), stimulated macrophages (n=6), T cells (n=5), stimulated T cells (n=5), B cells 
(n=6), proximal tubular epithelial cells (n=2), human aorta endothelial cells (n=5), 
and human umbilical vascular endothelial cells (n=5). RNA from pretransplant biopsy 
samples (n=65) was included as a reference.
In vitro methylprednisolone response experiments
Blood was obtained from healthy blood bank donors (n=11; Sanquin, Leiden, the 
Netherlands) after informed consent. PBMC were isolated by Ficoll Hypaque density 
gradient centrifugation, cultured in 96-well plates (105/well) in RPMI 1640 medium 
with 10% fetal calf serum (Gibco), and stimulated for 50 h with PHA (2 µg/ml). This 
was done either in the absence or presence of 10-4 M methylprednisolone (Solu-
Medrol® from Pfizer, Capelle a/d IJssel, the Netherlands; powder for intravenous 
infusion). After the culture, the cells were harvested and stored in RNAlater (Qiagen) 
until RNA extraction and qPCR analysis.
Statistical analysis
Comparison of categorical data between groups was evaluated using the Fisher’s 
Exact test. Microarray data were normalized using the Quantile Normalization 
method. Only genes showing expression above background (P<0.05) in at least 20 





































gplots R package (version 2.10.1). The Mann-Whitney U-test was performed to select 
differentially expressed genes between the steroid response groups. Multiple testing 
correction was performed with the Benjamini-Hochberg method 20.
Lasso regression analysis, performed with the penalized R package (version 0.9-
33) 21, was used to analyze the discriminative value between groups of genes analyzed 
in the microarrays. Leave-one-out cross-validated receiver operating characteristics 
(ROC) analysis, using the R package ROCR (version 1.0-2) 22, was applied to evaluate 
the robustness of the multivariate model from the lasso regression analysis. The 
enrichment of specific functional groups of genes was analyzed on the basis of 
hypergeometric tests using the online gene set analysis toolkit WebGestalt (http://
bioinfo.vanderbilt.edu/webgestalt/) 23;24.
PCR data are expressed as mean ± standard error of the mean. Differences in 
mean mRNA and protein expression between groups were tested with independent 
samples t-tests and Mann-Whitney U-tests. Logistic regression analysis and ROC 
analysis were performed for multivariate analysis of qPCR data. All statistical tests 
were two-sided, and P values less than 0.05 were considered as significant. Statistical 
analyses were performed using the IBM SPSS statistical package (version 20.0.0, 
Amsterdam, the Netherlands) and the R statistical package (version 2.12.0, http://
www.r-project.org/).
Results
Demographics and clinical data
No significant differences in the demographic and clinical characteristics were found 
between steroid responsive and steroid resistant patient groups in the discovery 
cohort (n=36) and validation cohort (n=47) (Table 2 and Table S1). There was no 
significant difference in the RNA concentration, purity, and quality of the samples 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Transcriptional profiles of 40 renal allograft biopsy samples were analyzed using whole 
genome microarray slides. Expression profiles were investigated in the discovery 
cohort of 18 steroid resistant rejections and 18 steroid responsive rejections, and 
in 4 control biopsy samples. Six thousand eight hundred and thirty two genes with 
significant expression (P<0.001) above background were included for further analysis.
To test for associations between the gene expression profile in the biopsy 
samples and clinical parameters, we first clustered the patients based on similarities 
in the expression pattern of the corresponding kidney allograft biopsies (Figure 1A). 
This unsupervised hierarchical clustering analysis did not result in a clear distinction 
between steroid responsive and steroid resistant acute rejection biopsies. The control 
biopsies largely clustered together. Comparison of patients in different clusters did 
not reveal differences of the clinical parameters (Figure 1B).
Relation between molecular variables and steroid response
The expression of 249 genes differed significantly (P<0.05 with the unadjusted Mann-
Whitney U-test) between steroid responsive and steroid resistant rejections: 158 
transcripts were upregulated and 91 transcripts were downregulated in the steroid 
resistant rejections.
The 50 genes with the most significant differences between the two groups were 
included in two-way hierarchical clustering analysis (Figure 2). The dendrogram 
above the heatmap shows four clusters of patients: two clusters with mainly samples 
from steroid responsive patients (clusters 1 and 2), one cluster with mainly samples 
from steroid resistant patients (cluster 3), and one cluster containing only samples 
from steroid resistant patients (cluster 4). Comparison of the Banff scores from the 
steroid resistant patients in cluster 4 with the Banff scores of the steroid resistant 
patients in the other three clusters revealed no significant differences (data not 
shown). The dendrogram on the vertical axis revealed two distinct clusters of genes. 
A large number of genes from the metallothionein 1 (MT-1) family cluster together 

































































































































































































































































































































Figure 2. Hierarchical clustering and heatmap display of the 50 genes with the highest 
significant difference in expression between steroid responsive and steroid resistant acute 
rejection. Genes (rows) and samples (columns) were clustered in an unsupervised manner 
on the basis of the overall similarity in expression pattern between subjects in the discovery 
cohort. The dendrograms represent how close the relationship is between biopsy samples 
(x-axis) or different genes (y-axis). The color (scale indicated top left) in each cell reflects 
the level of expression of the corresponding gene in the corresponding sample. Color scale 
runs from bright green (relatively low mRNA expression) to bright red (relatively high mRNA 
expression). Patients with steroid responsive acute rejection are shown in light blue; patients 
with steroid resistant acute rejection are shown in dark blue.
Gene ontology
To gain insight into the function of differentially expressed genes, we included all 249 
genes for pathway analysis by hypergeometric test in WebGestalt. One molecular 
function showed high enrichment in steroid resistant patients: cadmium ion binding 













































significant (ratio of enrichment of 20.1, P<0.000001; Table S2). Seven of the nine 
genes involved in this molecular function were significantly higher expressed in 
steroid resistant rejection, and they were all members of the MT-1 gene family (MT-1A, 
MT-1E, MT-1F, MT-1G, MT-1H, MT-1M, MT-1X). Other pathways concerned amongst 
others the extracellular region (P=0.0003), extracellular matrix part (P=0.0038), and 
copper ion binding (P=0.0082). The complete list of significant pathways is shown in 
Table S2.
Multivariate regression analysis
Multivariate analysis with lasso regression resulted in a model discriminating patient 
groups, containing as independent covariates MT-1G in combination with CYP4A11, 
TIMP1, FTHL7, and F2R. The predictive value of the multivariate model was significant 
(AUC=0.92, P=0.00002) when tested with receiver operating characteristics (ROC) 
curve analysis (Figure 3A). The predictive value of the multivariate model remained 
significant when validated with a leave-one-out cross-validated analysis (AUC=0.72, 
P=0.048; Figure 3B).
Quantitative PCR validation
Using real-time quantitative PCR (qPCR) we validated the microarray results for six 
mRNA transcripts, including the covariates from the multivariate lasso regression, in 
the acute rejection biopsy samples of the discovery cohort: MT-1, CYP4A11, TIMP1, 
F2R, AGT, and PHLDB1 (Figure 4). The qPCR results corresponded with the findings by 
microarray. The expression levels of MT-1 (P=0.018, Figure 4A) and TIMP1 (P=0.002, 
Figure 4C) were significantly increased in steroid resistant acute rejection, whereas 
those of PHLDB1 were significantly decreased (P=0.016, Figure 4F) compared with the 
steroid responsive group. The steroid resistant samples showed higher expression of 
AGT (P=0.058, Figure 4E) and of CYP4A11 (P=0.107, Figure 4B), and lower expression 
of F2R (P=0.195, Figure 4D).
The expression of the six transcripts was measured in pretransplant biopsies 
available from 23 of the patients studied during acute rejection (14 steroid resistant 
and nine steroid responsive). No significant differences were found in intragraft 
expression levels before transplantation, except for CYP4A11. The steroid resistant 






































Figure 3. Predictive value of the lasso regression model for steroid resistant acute rejection. 
Multivariate regression analysis of the microarray data from the discovery set resulted in a 
predictive model with MT-1, CYP4A11, TIMP1, FTHL7, and F2R as independent covariates. A) 
The receiver operating characteristics (ROC) curve shows the true positive rate (sensitivity) and 
false positive rate (100 – specificity) for various cut-off levels of the multivariate model. The 
area under the curve (AUC) was 0.92 (P=0.00002). B) The predictive value of the multivariate 
model remained significant when validated with a leave-one-out cross-validated analysis 
(AU=0.72, P=0.048).
Validation cohort
To verify the findings that high MT-1 expression associates with resistance to steroid 
treatment, we used qPCR to analyze the expression of MT-1 in a validation cohort 
(n=47). The MT-1 expression level was significantly increased in steroid resistant 
acute rejection compared to steroid responsive acute rejection (P=0.029, Figure 5).
To validate the multivariate model obtained with microarray analysis, we 
performed multivariate logistic regression analyses on the qPCR measurements in 
the discovery and validation cohorts. The predictive value of the multivariate model, 
containing MT-1, CYP4A11, TIMP1, and F2R, was significant in both the discovery 














































Figure 4. Quantitative real-time PCR validation of microarray results in the discovery patient 
cohort. RNA expression levels of MT-1 (A), CYP4A11 (B), TIMP1 (C), F2R (D), AGT (E), and 
PHLDB1 (F) measured in pretransplant biopsy samples (Pre-Tx) and acute rejection biopsy 
samples (AR) from the steroid resistant and steroid responsive patient groups in the discovery 





































Figure 5. Metallothionein expression in the validation patient cohort. MT-1 mRNA levels were 
measured with qPCR in acute rejection (AR) biopsy samples from the steroid resistant and 
steroid responsive patients in the validation cohort. Data are expressed as mean ± SEM.
Figure 6. Predictive values of the multivariate regression model in the discovery set and 
validation set. Receiver operating characteristics (ROC) curve analysis of the multivariate 
regression model, containing MT-1, CYP4A11, TIMP1, and F2R, measured with qPCR. The area 
under the ROC curve was 0.89 (P=0.00008) in the discovery set (A) and 0.80 (P=0.0009) in the 
validation set (B). The ROC curves show the true positive rate (sensitivity) and false positive 
rate (100 – specificity) for various cut-off levels of the multivariate model.
Comparison of multivariate models
To investigate how the multivariate MT-1 model (MT-1, CYP4A11, TIMP1, and F2R) 













































ratio and LAG-3) 9, we combined the discovery and validation cohorts. The predictive 
value of the MT-1 model was slightly higher (AUC=0.81, P=0.000002; Figure 7) than 
the predictive value of the T-cell activation model (AUC of 0.79, P=0.000007; Figure 
7). Combination of the two models resulted in a predictive model with MT-1, TIMP1, 
F2R, CD25:CD3e ratio and LAG-3 as independent covariates (AUC=0.88, P<0.0000001; 
Figure 7).
Figure 7. Comparison of the predictive values of the metallothionein and T-cell activation 
models for steroid resistant acute rejection. Receiver operating characteristics (ROC) curve 
analysis was used to compare the predictive value of the multivariate metallothionein-1 
(MT-1) model (containing MT-1, CYP4A11, TIMP1, and F2R) and of the previously described 
multivariate T-cell activation model (containing CD25:CD3e ratio and LAG-3) 9. The area under 
the ROC curve was 0.81 (P=0.000002, dotted line) for the MT-1 model and 0.79 (P=0.000007, 
striped line) for the T-cell activation model. Combination of the two models resulted in a 
multivariate model with MT-1, TIMP1, F2R, CD25:CD3e ratio and LAG-3 as independent 
covariates (AUC=0.88, P<0.0000001, solid line).
Localization of metallothionein expression in cell types and transplant biopsies
In order to determine which cell types express MT-1, we quantified MT-1 expression 
in a panel of various cell types (Figure 8). High MT-1 expression was seen in activated 
macrophages and proximal tubular epithelial cells (PTECs). The expression in PTECs 
was comparable to that in pretransplant biopsies (first bar). Endothelial cells from 
human aortas and umbilical veins showed intermediate MT-1 expression.
To investigate which cells express MT proteins within the grafts, we performed 
immunohistochemical stainings for MT on paraffin-embedded kidney allograft 





































protein expression of MT was detected in tubular epithelial cells and inflammatory 
cells (Figure 9A-D). Co-localization of MT staining (Figure 9C and D) with expression 
of pan-macrophage marker CD68 (Figure 9E and F) and macrophage activation 
marker CD163 (Figure 9G and H) supported the observation that MT is expressed by 
activated macrophages. Stainings for the human Y-chromosome in a female-to-male 
transplantation revealed that MT is expressed by macrophages that are derived from 
the recipient (Figure 10).
No differences were found in the mRNA expression levels of macrophage marker 
CD68 in pretransplant (P=0.75) and acute rejection (P=0.95) biopsy samples, and in 
the CD68 protein expression (P=0.58) between the steroid response groups (data not 
shown).
Figure 8. Localization of metallothionein (MT) expression in cell types. MT-1 expression was 
quantified by qPCR in mRNA from a panel of organs and cell types. High MT-1 expression was 
seen in activated macrophages (MΦ stim) and proximal tubular epithelial cells (PTECs). Data 
are expressed as mean ± SEM. Pre-Tx, pretransplant biopsy samples; PBMCs, peripheral blood 
mononuclear cells; DCs, dendritic cells; MΦ, differentiated macrophages; HAECs, human aorta 













































Figure 9. Immunohistochemical staining pattern of metallothionein (MT), CD68 and CD163 
in sections from renal transplant biopsies with acute rejection. MT protein was detected in 
tubular epithelial cells and infiltrating lymphocytes (A-D). Sequential sections stained for MT 
protein (C and D), the pan-macrophage marker CD68 (E and F), and the macrophage activation 
marker CD163 (G and H) confirm that MT is expressed by activated macrophages. A, C, E, 






































Figure 10. Analysis of the origin of MT positive macrophages. To detect the origin (donor 
or recipient) of the MT positive macrophages within renal transplant biopsies with acute 
rejection, we used in situ hybridization for the detection of the Y chromosome in transplant 
conditions where a male patient received a renal allograft from a female donor. Red-brown 
dots indicate the presence of Y chromosome-positive cells (yellow arrows) within the allograft 
(A-B). Sequential sections stained for MT protein (C-D), the pan-macrophage marker CD68 
(E-F), and the macrophage activation marker CD163 (G-H) revealed that MT is expressed by 
macrophages that are derived from the patient. A, C, E, and G: overview recordings at 50x 













































In vitro methylprednisolone response experiments
To further investigate the relationship between MT and response to steroid 
treatment of immune cells, peripheral blood mononuclear cells (PBMC) from 
healthy blood donors (n=11) were activated with PHA and cultured in the absence 
or presence of methylprednisolone. Using the in vitro cytokine response under the 
influence of methylprednisolone treatment, a distinction could be made between 
non-responders (n=3) and responders (n=8). Upon PHA stimulation, IFNγ and TNFα 
mRNA expression were increased compared to medium controls (Figure 11A and 
B). Responders to treatment (n=8) showed normalization of both IFNγ and TNFα 
expression levels when 10-4 M methylprednisolone was added during the PHA 
stimulation. Non-responders (n=3) still showed elevated IFNγ and TNFα mRNA 
expression even after methylprednisolone treatment (Figure 11A and B). Non-
response to methylprednisolone treatment was associated with a significantly 
stronger increase in MT expression (48.8 fold) compared with what was seen in the 





































Figure 11. In vitro methylprednisolone (MP) response experiments. PBMC from healthy 
blood donors (n=11) were stimulated (50 h) with PHA or a combination of PHA and 10-4 
methylprednisolone (PHA + MP). PBMC cultured in medium without a stimulus (50 h) were 
included as a control. After the culture period, RNA expression levels of IFNγ (A), TNFα (B), 
and MT-1 (C) were quantified by qPCR. Using the in vitro IFNγ and TNFα responses under the 
influence of methylprednisolone treatment, a distinction was made between non-responders 
(n=3) and responders (n=8). Data are expressed as mean ± SEM. Mean signals of PHA-














































We aimed to identify novel molecular markers associated with steroid-refractory 
acute rejection, and to gain insight into the mechanisms underlying steroid resistance. 
For this, we investigated intragraft gene expression profiles of renal allograft 
recipients with a first rejection episode. Our study reveals that the expression of 
metallothioneins (MT) within the renal allograft may distinguish patients with steroid 
resistant acute rejection from patients with steroid responsive acute rejection. The 
findings, which were generated in a discovery cohort of 36 patients, were validated 
in a validation cohort of 47 patients.
Until now, research in the field of steroid-refractory acute rejection in renal 
allografts has been focused on markers of inflammatory cells (reviewed in 8). Recently, 
we found that the combination of T-cell activation markers CD25:CD3 ratio and 
LAG-3 offers a superior prognostic value for assessing steroid response compared 
with conventional parameters 9. In the current study, we found that relatively high 
intragraft MT expression during acute rejection is associated with steroid resistance, 
and that MT-1 isoforms are expressed in activated macrophages and in tubular 
epithelial cells. These findings are in line with earlier findings in lung allograft 
recipients with steroid-refractory acute rejection. Yousem and colleagues found 
increased percentages of MT-positive macrophages in transbronchial biopsy samples 
of lung allograft recipients who experienced steroid-refractory acute rejection 25. 
Interestingly, several studies in the oncological research field have also demonstrated 
that elevated expression of MT is related to treatment resistance 26-28.
In multivariate analysis, the combination of MT-1 with CYP4A11, TIMP1 and F2R 
represented the best predictive model. This multivariate MT-1 model has a slightly 
higher predictive value than the T-cell activation model found in our previous study 
(see Figure 7) 9. Combination of the two models resulted in a predictive model with 
MT-1, TIMP1, F2R, CD25:CD3e ratio and LAG-3 as independent covariates, showing 
that our current findings strengthen the risk assessment of steroid resistance in 
patients having acute rejection. Patients with steroid-refractory acute rejection may 
benefit from immediate ATG treatment after the diagnosis of acute rejection.
Metallothioneins are a family of eleven proteins involved in the homeostasis 
of biologically essential metals 29-33. Under physiological conditions MT are mainly 





































zinc-donor or zinc-acceptor they can control cellular zinc distribution 29;30. A variety 
of DNA-binding proteins rely on zinc finger motifs to bind to their target sequences 
29;34. Metallothioneins can influence the DNA-binding capacity of zinc-proteins by 
controlling the amount of zinc that is available for zinc finger domains 35;36.
The glucocorticoid receptor (GR) is also a zinc-dependent protein 37. Glucocorticoid 
effects depend on GR-mediated transcriptional regulation of genes encoding for 
pro-inflammatory proteins. Binding of GR to glucocorticoid response elements 
(GRE) in the promoter region of target genes relies on two zinc finger motifs 29;34;37. 
Increased expression of metallothioneins may lead to removal of zinc ions that are 
normally complexed in the zinc finger domains of GR, preventing its binding to GRE 
and inhibiting the immunomodulatory effects of the steroid-based anti-rejection 
treatment.
Another mechanism of action of the GR that may be affected by increased MT 
expression is its recruitment of histone deacetylase (HDAC)-2 38. Upon ligand binding 
the GR becomes a target for HDAC-2, which in turn allows the GR to associate with 
and suppress the pro-inflammatory transcription factor NF-κB 38;39. In addition, 
the recruited HDAC-2 represses transcription from promoters through histone 
deacetylation, resulting in suppression of activated inflammatory genes within the 
nucleus 38;40. As the recruitment of HDAC-2 to the GR relies on zinc, anti-inflammatory 
effects of this process may also be inhibited by MT.
In vitro tests with PBMC have been used to correlate gene expression profiles 
with clinical disorders, including steroid responsiveness 41-43. Following this strategy, 
we compared the RNA level of pro-inflammatory cytokine responses (TNFα, IFNγ) 
between stimulated PBMC and stimulated PBMC treated with methylprednisolone. 
This allowed distinction between responders and non-responders to the steroid 
treatment. The concentration of 10-4 M methylprednisolone approximates the i.v. 
dosage of 1 g/day given in clinical practice. In all PBMC donors tested, treatment with 
methylprednisolone led to an increase in MT expression, which corresponds with 
earlier observations of MT as a steroid responsive gene 44;45. However, non-responders 
displayed a significantly higher fold of MT upregulation upon methylprednisolone 
treatment than responders. These results are in line with the observation that 
patients who are steroid-resistant upon anti-rejection treatment have elevated MT 
expression. Further studies are needed to show that in vitro cultures of patient PBMC 













































Some comments need to be made with regard to the current findings. First, 
MT expression can be induced by the glucocorticoids 44. To prevent an influence 
of steroid-based anti-rejection treatment on the intragraft mRNA and protein 
expression levels, the biopsy samples investigated in our study were collected before 
the patients received high-dose methylprednisolone. All patients did receive low-
dose steroids as part of the maintenance therapy. Second, due to high homology in 
the gene sequence of the MT-1 subtypes, it has proven difficult to distinguish the 
MT-1 subtypes from each other. As our microarray assays rely on 50-bp long probes to 
measure specific mRNA transcripts, we were able to measure the mRNA expression 
of the individual MT-1 isotypes. However, no distinction could be made between the 
MT-1 isoforms with qPCR or immunohistochemistry. The finding by microarray, that 
most MT-1 isoforms were upregulated in steroid resistant acute rejection, shows that 
the difficulty to distinguish between MT-1 isoforms likely will not have affected our 
findings.
In conclusion, resistance to steroid treatment is associated with a relatively high 
intragraft expression of zinc-regulating MT during acute rejection. MT are mainly 
expressed by activated macrophages and tubular epithelial cells within the kidney. 
The relationship between MT and steroid resistance was confirmed in vitro by 
treatment of activated PBMC with corticosteroids. An increased expression of MT 
may lead to regulation of intracellular zinc concentrations, and to inactivation of the 
DNA binding capacity of the glucocorticoid receptor. The current findings point to MT 
as potentially novel therapeutic targets.
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Table S1: Demographic and clinical data of the discovery set and validation set.
Variable Discovery set Validation set P value
(n=36), n (%) (n=47), n (%)
Patient age 1.00
≥ 50 years 16 (44.4%) 21 (44.7%)
Patient gender 0.36
Female 10 (27.8%) 18 (38.3%)
Donor age 0.36
≥ 50 years 11 (30.6%) 20 (42.6%)
Donor gender 0.48
Female 22 (61.1%) 33 (70.2%)
Year of transplantation 0.80
1995 through 1999 26 (72.2%) 36 (76.6%)
2000 through 2005 10 (27.8%) 11 (23.4%)
Donor type 0.79
Living 9 (25.0%) 10 (21.3%)
Post mortal 27 (75.0%) 37 (78.7%)
HLA-A matching 0.36
≥ 1 mismatch 25 (69.4%) 27 (57.4%)
HLA-B matching 0.62
≥ 1 mismatch 28 (77.8%) 34 (72.3%)
HLA-DR matching 1.00
≥ 1 mismatch 23 (63.9%) 30 (63.8%)
Virtual PRA 1.00
Immunized (6-100%) 9 (25.7%) 13 (27.7%)
Cold ischemia time 0.30
> 18 hours 20 (64.5%) 30 (76.9%)
Induction therapy 1.00
Daclizumab 8 (22.2%) 11 (23.4%)
None 28 (77.8%) 36 (76.6%)
Maintenance therapy 0.66
Double therapy 16 (44.4%) 24 (51.1%)
Triple therapy 20 (55.6%) 23 (48.9%)
Delayed graft function 0.18
Yes 5 (13.9%) 13 (27.7%)
Rejection time 1.00
<3 months post Tx 35 (97.2%) 46 (97.9%)
3-6 months post Tx 1 (2.8%) 1 (2.1%)
C4d staining 0.10
Positive 15 (41.7%) 11 (23.4%)
Vascular rejection 1.00
Yes 7 (38.9%) 8 (44.4%)
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Steroid-refractory acute rejection is an important risk factor for inferior renal 
allograft outcome. We investigated the relationship between the genotype of 
glucocorticoid signaling and metabolism genes and the response to steroid 
treatment in renal allograft recipients with acute rejection. One hundred and 
fifty three kidney transplant recipients (1995-2005), who were treated with high 
dose i.v. methylprednisolone during a first acute rejection episode, were included 
in the retrospective study. Maintenance therapy consisted of a double regimen 
(prednisone, calcineurin inhibitor: Cyclosporine or Tacrolimus) or triple regimen 
(also with MMF). We analyzed single nucleotide polymorphism genotypes of genes 
involved in glucocorticoid signaling (Glucocorticoid Receptor, GLCCI1) and drug 
metabolism (CYP3A5, ABCB1, and PXR) in both recipients and donors. CYP3A5 
genotype of the donor kidney was the only variable showing a significant association 
(P=0.039) with response to steroid treatment. In subanalyses, similar trends were 
observed between patients receiving Cyclosporine and patients receiving Tacrolimus. 
Patients who had received a renal allograft from a CYP3A5*1-allele-expressing donor 
had a 3.3 times lower risk of resistance to steroid treatment during acute rejection 
(odds ratio=0.3; 95% confidence interval, 0.10–1.0; P=0.047). CYP3A5*1 donor grafts 
(n=20) displayed significantly higher intragraft CYP3A5 mRNA expression levels than 
allografts from CYP3A5*3/*3 carriers (n=105; P<0.00001). Accordingly, significantly 
higher CYP3A5 mRNA levels were seen in steroid responsive patients compared to 
steroid resistant patients (P=0.006). By immunohistochemistry, distal and proximal 
tubules were found to abundantly express CYP3A5 protein. In a panel of different 
cell types, proximal tubular epithelial cells and activated macrophages showed the 
highest CYP3A5 mRNA expression. No differences were observed for glucocorticoid 
signaling or other drug metabolism-related genes. Our study shows that resistance 
to steroid treatment during acute rejection is associated with donor genotype and 
intragraft expression levels of CYP3A5. We speculate that recipients receiving kidneys 
with a high expressing CYP3A5*1 genotype are better protected against rejection 














































High-dose glucocorticoids (GC) is the preferred immunosuppressive treatment of 
acute rejection (AR) after kidney transplantation. Approximately 30% of the patients 
show no or an inadequate response to steroid AR therapy alone 1-3. This occurrence 
of steroid-refractory AR is an important risk factor for inferior renal allograft outcome 
4-7. Current diagnostic procedures have demonstrated poor prediction for steroid 
resistance. The role of glucocorticoid signaling and drug metabolism in steroid-
refractory AR has not been thoroughly examined. Differences in response to steroid 
treatment during AR may be explained by genetic polymorphisms in genes involved 
in glucocorticoid signaling and drug metabolism.
GC exert their anti-inflammatory and immunosuppressive action via the 
glucocorticoid receptor (GR) 8;9. Single nucleotide polymorphisms (SNPs) in NR3C1, 
the gene encoding the GR, may affect the ability of this receptor to bind GC 10;11. 
NR3C1 polymorphisms have been associated with both enhanced sensitivity to GC 
(N363S, BclI) as well as GC resistance (ER22/23EK, GR-9β) (reviewed in 12). A recently 
identified gene linked to steroid response is the glucocorticoid-induced transcript 1 
gene (GLCCI1). The rs37972 SNP in the promoter region of GLCCI1 was associated 
with the response to glucocorticoid treatment in asthma 13, COPD 14, and bacterial 
meningitis 15.
Other potential genes involved in steroid responsiveness are drug metabolism-
related genes. The widely expressed CYP3A enzymes metabolize 50% to 60% of 
all xenobiotics, including glucocorticoids 9;16. CYP3A5 is the predominant drug 
metabolizing enzyme expressed within the kidney 17;18. A SNP in intron 3 of the CYP3A5 
gene (CYP3A5*3) correlates with the level of renal CYP3A5 expression 19-21. The efflux 
transporter P-glycoprotein, encoded by the ABCB1 gene, is mainly expressed in the 
kidney and small intestine where it limits the absorption of xenobiotics, including 
glucocorticoids 16;22;23. Three ABCB1 SNPs (C3435T, G2677T, and C1236T) have been 
associated with increased graft loss 24, increased susceptibility to chronic allograft 
damage 25 in renal transplant recipients, and with steroid resistance in patients with 
nephrotic syndrome 26. The pregnane X receptor (PXR), encoded by the NR1I2 gene, 
is a master transcriptional regulator of genes involved in metabolism and transport of 
xenobiotics 16;27;28. Ligand activation of PXR leads to upregulation of a system of drug 





































been associated with altered CYP3A4 regulation 31, and higher metabolic activity for 
prednisolone in renal transplant recipients 11;16.
In this study we investigated the impact of polymorphisms in genes involved in 
glucocorticoid signaling (GR and GLCCI1) and drug metabolism (CYP3A5, ABCB1, and 
PXR) upon the response to high-dose steroid treatment of AR and death-censored 
graft survival in renal allograft recipients.
Materials and methods
Patient information
All patients who underwent kidney transplantation in the Leiden University Medical 
Center (Leiden, the Netherlands) between 1995 and 2005, and who suffered from 
a histologically proven first rejection episode were considered for investigation. 
Only patients who received corticosteroids as anti-rejection treatment were 
included (n=153). Maintenance immunosuppression consisted of a calcineurin 
inhibitor (Cyclosporine A or Tacrolimus) and prednisone, with or without an 
antimetabolite (Mycophenolate Mofetil). Immunosuppression for the treatment of 
acute rejection consisted of pulse therapy for 3 days with a 1-g bolus of intravenous 
methylprednisolone daily.
Clinical endpoints
The primary clinical endpoint was response to anti-rejection treatment with 
methylprednisolone, as described previously 7. Briefly, steroid resistant acute 
rejection was defined as lack of clinical response to steroid pulse therapy, and a 
requirement for anti-thymocyte globulin treatment within 14 days after the start of 
the steroid therapy. The response to steroid therapy was monitored by creatinine 
concentration measurements. A second clinical endpoint was graft survival, defined 
as time from transplant to graft failure, censoring for death with a functioning graft 
and grafts still functioning at time of analysis.
Patient materials
For SNP analysis, DNA was extracted from peripheral blood cells or splenocytes by 













































patients and 125 donors. From each patient, at least two renal biopsy cores were 
collected on clinical indication of acute rejection. One biopsy core was formalin fixed 
and embedded in paraffin. The second biopsy core was immediately snap frozen 
in liquid nitrogen and stored at -80°C. Rejection severity of all patients was blindly 
scored by two independent pathologists (I.B. and M.G.) on paraffin-embedded biopsy 
tissue according to Banff 2011 criteria 32.
All biopsy specimens obtained prior to the start of anti-rejection treatment were 
investigated further for mRNA and protein expression levels. Frozen biopsy material 
for gene expression analysis was available from 106 patients. Paraffin embedded 
biopsy material for protein stainings was available from 123 patients. In addition 
to the biopsies obtained during acute rejection (AR biopsy samples), snap frozen 
pretransplant (Pre-Tx) biopsy samples (stored at -80°C) were available from 77 
patients.
Quantitative real-time PCR detection of SNPs
SNPs characterization was performed using quantitative real-time PCR (qPCR) 
assays. A total of 10 SNPs were investigated in DNA from both recipients and donors. 
Five SNPs were analyzed using SYBR Green-based qPCR assays, and 5 SNPs were 
analyzed using TaqMan-based qPCR assays. The primers and qPCR approach used 
are summarized in Table S1.
SYBR Green qPCR assay
Genotyping for the NR3C1 1184+646C>G (rs41423247) and G68A (rs6190) SNPs, 
and ABCB1 C3435T (rs1045642), G2677T (rs2032582), and C1236T (rs1128503) SNPs 
was performed using SYBR Green-based qPCR with in-house developed primers (see 
Table S1A). PCR was performed using a Bio-Rad MyiQ (Bio-Rad, Veenendaal, the 
Netherlands). Each PCR reaction contained 20 ng of DNA. The PCR program consisted 
of one cycle at 94°C for 10 min; 10 cycles of 94°C for 15 sec and 66°C for 45 sec; 30 
cycles of 94°C for 15 sec, 63°C for 45 sec, and 72°C for 30 sec; and was finalized with 
a melting curve analysis.
TaqMan qPCR assay
Genotyping for the NR3C1 A1088G (rs56149945), NR3C1 A6167G (rs6198), 





































(rs6785049) polymorphisms was performed using TaqMan SNP genotyping assays 
(C_26841917_40, C_8951023_10, C_970132_10, C_26201809_30, C_29280426_10; 
Applied Biosystems, Carlsbad, CA) and qPCR methodology on a StepOne Real-Time 
PCR System (Applied Biosystems). Each TaqMan assay was used according to the 
protocol recommended by the manufacturer. PCR reactions contained between 10 
and 45 ng of DNA. The PCR program consisted of one cycle at 50°C for 2 min; one 
cycle at 95°C for 10 min; 50 cycles of 92°C for 15 sec and 60°C for 90 sec. Genotypes 
were determined based on the emission pattern of the fluorescent reporter dyes 
(VIC or FAM) attached to the primers (see Table S1B).
Gene expression analysis
Real-time qPCR was used to analyze the mRNA expression of CYP3A5, ABCB1, and 
glucocorticoid receptor α (GRα) in the pretransplant and AR biopsy samples. RNA 
isolation and cDNA synthesis procedures have previously been described 7. Briefly, 
RNA was extracted from eight to ten 10-μm sections of renal cortex from each snap 
frozen biopsy core. On average, 0.89 ± 0.19 µg of isolated RNA was transcribed into 
cDNA. The cDNA samples were diluted 25 times. Primer design, reactions and PCR 
conditions have been described previously 7;33. Primer sequences are provided in 
Table S2. PCR efficiencies were between 90% and 110%. Relative gene expression 
levels were determined on the basis of a standard curve (in duplicate) of five serial 
dilution points of reference cDNA (qPCR Human Reference Total RNA, Clontech, 
France). Differences in mRNA expression levels were normalized to the geometric 
mean signal of reference genes glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and β-actin.
CYP3A5 and ABCB1 expression in various tissues and cell types
Expression levels of CYP3A5 and ABCB1 were investigated in a panel of various 
tissues and cell types 34. Included in this panel were liver, spleen, peripheral 
blood mononuclear cell fractions (n=9), cultured dendritic cells (GM-CSF and IL-4, 
without or with IFN-γ/IFN-β/LPS stimulation for 6 h, n=6), CD14+ monocytes (n=3), 
differentiated macrophages (5 to 8 days with GM-CSF or M-CSF, n=7), stimulated 
macrophages (10 ng IFN-γ or 100 ng LPS for 24 h, n=6), T cells (n=5), CD19+ B 
cells (n=6), proximal tubular epithelial cells (PTECs; n=2), human aorta endothelial 













































Measurements in pretransplant biopsy samples (n=77) and acute rejection biopsy 
samples (n=84) were included as references.
Protein expression of GR and metabolism-related genes
Immunohistochemical analyses were performed on paraffin-embedded biopsy 
samples from the patients. Protein stainings for CYP3A5 and ABCB1 were performed 
on sequential sections (4 μm). Polyclonal rabbit anti-human antibodies against CYP3A5 
(Abcam, Cambridge, UK; ab22692) and monoclonal mouse anti-human antibodies 
against ABCB1 (Tebu-bio, Heerhugowaard, the Netherlands; clone JSB-1) were used 
for immunohistochemical stainings. Standardized protocols 35 were followed. Details 
concerning antigen retrieval and staining procedure are provided in Table S3. After 
endogenous peroxidase blocking with 0.1% H2O2, non-specific antibody binding was 
blocked with normal goat serum (NGS; Dako, Glostrup, Denmark). Visualization was 
performed with Rabbit-EnVision+ or Mouse-EnVision+ System-HRP (DAB) according 
to the manufacturers’ (Dako) protocols. Protein stainings were scored by two 
independent researchers (N.R. and M.E.) using a semi-quantitative scoring system. 
Photos were taken with a Leica Leitz DMRD microscope with Leica DFC420 C camera 
and Leica Application Suite software (Leica Microsystems, Rijswijk, the Netherlands).
Statistics
Comparison of categorical data between steroid response groups was evaluated 
using the Pearson chi-square test. Comparison of SNP genotypes between steroid 
response groups was evaluated using the Pearson chi-square test or Fisher’s Exact 
test, depending on the genotype distribution. Univariate logistic regression analysis 
was used to analyze the discriminative value of the SNPs. Kaplan-Meier curves with 
log-rank testing and Cox regression analyses were used to test for associations of SNP 
genotypes with death-censored graft loss. Genotypes were analyzed for deviations 
from Hardy-Weinberg equilibrium. Differences in mRNA expression between steroid 
response groups were analyzed with the independent samples t-test, and differences 
between mRNA levels measured in pretransplant and acute rejection biopsy samples 
were analyzed with the paired samples t-test. Differences in mRNA expression 
between SNP genotypes were analyzed with the Mann-Whitney U-test. The 
Spearman’s rho and Kruskal-Wallis test were used to analyze the correlation between 





































are presented as means ± standard error of the mean (SEM). All statistical tests 
were two-sided, and P values less than 0.05 were considered significant. Statistical 
analyses were performed using the SPSS statistical package (IBM SPSS Statistics., 
version 20.0.0, IBM, Amsterdam, the Netherlands).
Results
Demographics and clinical data
Demographic and clinical characteristics of the study cohort have been summarized 
in Table 1. No associations were found between the characteristics and the response 
to steroid treatment, except for vascular rejection. Steroid-resistant patients (n=60) 
experienced more vascular rejection compared with steroid-responsive patients 














































Table 1. Demographic and clinical data of patients with steroid responsive and steroid resistant 
acute rejection.
Variable Steroid responsive Steroid resistant P value
(N=93), n (%) (N=60), n (%)
Patient age 0.54
≥ 50 years 45 (48.4%) 26 (43.3%)
Patient gender 1.00
Female 31 (33.3%) 20 (33.3%)
Donor age 0.34
≥ 50 years 38 (41.3%) 29 (49.2%)
Donor gender 0.27
Female 61 (65.6%) 34 (56.7%)
Year of transplantation 0.10
1995 through 1999 58 (62.4%) 45 (75.0%)
2000 through 2005 35 (37.6%) 15 (25.0%)
Donor type 0.50
Living 23 (24.7%) 12 (20.0%)
Post mortal 70 (75.3%) 48 (80.0%)
HLA-A matching 0.57
≥ 1 mismatch 66 (71.0%) 40 (66.7%)
HLA-B matching 0.80
≥ 1 mismatch 68 (73.1%) 45 (75.0%)
HLA-DR matching 0.45
≥ 1 mismatch 58 (62.4%) 41 (68.3%)
Virtual PRA 0.31
Immunized (6-100%) 28 (30.4%) 23 (38.3%)
Cold ischemia time 0.13
> 18 hours 48 (62.3%) 39 (75.0%)
Induction therapy 0.40
Daclizumab 29 (31.2%) 14 (23.3%)
None 64 (68.8%) 46 (76.7%)
Maintenance therapy 0.15
Double therapy 31 (33.3%) 27 (45.0%)
Triple therapy 62 (66.7%) 33 (55.0%)
Delayed graft function 0.96
Yes 28 (30.4%) 18 (30.0%)
Rejection time 0.96
<3 months post Tx 87 (93.5%) 56 (93.3%)
3-6 months post Tx 6 (6.5%) 4 (6.7%)
C4d staining 0.28
Positive 6 (9.7%) 8 (16.7%)
Rejection severity a 0.08
Borderline rejection 39 (45.9%) 22 (40.0%)
T cell mediated rejection 25 (29.4%) 10 (18.2%)
Vascular rejection 21 (24.7%) 23 (41.8%)
a Nine biopsies did not contain sufficient cortex to determine a Banff score. Four additional 
patients had a clinical rejection (with i- and t-scores of 0).





































Association of polymorphisms with graft outcome
Using quantitative real-time PCR (qPCR) we characterized the genotype of 10 SNPs in 
a cohort of renal allograft recipients (n=143) and the corresponding donors (n=125). 
Genotype distribution of the SNPs has been summarized in Table S4. Due to the low 
frequency of homozygosity for the mutant variant of the CYP3A5*1 SNPs (rs776746) 
and NR3C1 GR-9β (rs6198), we combined the homozygous mutant variants with 
the heterozygous groups of these two SNPs for all statistical analyses. The allele 
frequencies of the SNPs were in Hardy-Weinberg equilibrium, except for the recipient 
allele frequencies of NR3C1 Bcl1, NR3C1 GR-9β, and ABCB1 G2677T (see Table S5).
Analysis of the polymorphisms in drug metabolism and detoxification genes 
showed that the expression of the CYP3A5*1 allele variant in the donors is associated 
with steroid responsiveness (P=0.039, Table 2). Fifty five percent of the patients with 
a CYP3A5*3/*3 allograft were steroid responsive, while 80% of the patients who 
received a renal allograft from a CYP3A5*1 variant expressing donor were steroid 
responsive (Table 3). No association was observed between steroid response and the 
CYP3A5*1 variant in the recipients (Table 2). In univariate logistic regression analysis, 
the donor CYP3A5*1 variant predicted lower risk of steroid resistant AR (odds ratio = 
0.3; 95% confidence interval, 0.10–1.0; P=0.047).
None of the ABCB1 or NR1I2 allele variants in the recipients or donors showed 
a significant association with response to steroid treatment (Table 2). We found no 
association between the response to steroid therapy and polymorphisms in genes 
involved in glucocorticoid signaling. None of the NR3C1 or GLCCI1 allele variants in 
the recipients or donors showed a significant association with steroid response (see 
Table 2).
Analysis of the relation between polymorphisms and death-censored graft survival 
at 6 years after transplantation revealed no associations between SNP genotypes in 
the recipients or donors and the risk of graft loss. In addition, graft survival showed 
no association with recipient- or donor-expression of the ABCB1 variant haplotype 













































Table 2. Associations between single nucleotide polymorphisms and response to steroid 
therapy.
Gene SNP rs number Recipient Donor
NR3C1 N363S rs6195 1.00 a 0.44 a
NR3C1 ER22/23EK rs6189/rs6190 0.37 a 0.74 a
NR3C1 Bcl1 rs41423247 0.68 0.41
NR3C1 GR-9β rs6198 0.16 b 0.36 b
GLCCI1 -1473 C>T rs37972 0.61 0.42
CYP3A5 CYP3A5*3 rs776746 0.49 b 0.039 b
ABCB1 C1236T rs1128503 0.16 0.87
ABCB1 G2677T rs2032582 0.45 0.99
ABCB1 C3435T rs1045642 0.69 0.40
NR1I2 A7635G rs6785049 0.87 0.87
a P values were obtained with the Pearson chi-square test, except for the N363S and ER22/23EK 
SNPs, which were obtained with the Fisher’s Exact test. This was due to the low genotype 
frequency of the mutant variant (see Table S4).
b Due to too few patients homozygous for the mutant variant of the SNP, we combined this 
patient group with the heterozygous patient group for all statistical analyses.
Table 3. Associations between donor CYP3A5 genotype and response to steroid therapy.
Genotype Steroid responsive Steroid resistant Total
(N=74), n (%) (N=51), n (%)
Donor CYP3A5*1 16 (80.0%) 4 (20.0%) 20
Donor CYP3A5*3/*3 58 (55.2%) 47 (44.8%) 105
Total 74 (59.2%) 51 (40.8%) 125
Donor CYP3A5*1 genotype indicates that the donor expressed the CYP3A5*1 variant. This 
group includes both CYP3A5*1/*1 homozygous and CYP3A5*1/*3 heterozygous donors.
Genotype dependent CYP3A5 mRNA expression
We analyzed whether donor CYP3A5 genotype is associated with CYP3A5 mRNA 
expression levels in the graft. Comparison between genotype groups showed a 
significant effect of the donor CYP3A5*1 allele on CYP3A5 mRNA levels (Figure 1A). 
The expression levels of CYP3A5 in the AR biopsy samples were significantly higher in 
patients who had received a renal allograft from a CYP3A5*1/*1 (n=2; P=0.0042) or 
a CYP3A5*1/*3 (n=18; P=0.000001) donor compared with patient who had received 
a CYP3A5*3/*3 allograft (n=105). Similar results were observed in the pretransplant 
biopsy samples (P=0.0012, Figure 1A). No significant differences in characteristics 
were observed between donor CYP3A5*1 allele carriers and donor CYP3A5*3/*3 





































Table 4. Characteristics according to the presence or absence of the donor CYP3A5*1 allele.
Donor CYP3A5 genotype a
Variable CYP3A5*3/*3 CYP3A5*1 P value
(N=105), n (%) (N=20), n (%)
Patient age 0.38
≥ 50 years 48 (45.7%) 7 (35.0%)
Patient gender 0.86
Female 39 (37.1%) 7 (35.0%)
Donor age 0.13
≥ 50 years 53 (51.5%) 14 (70.0%)
Donor gender 0.92
Female 59 (56.2%) 11 (55.0%)
Donor type 1.00
Living 11 (10.5%) 2 (10.0%)
Post mortal 94 (89.5%) 18 (90.0%)
HLA-AB matching 0.52
≥ 1 mismatch 86 (81.9%) 18 (90.0%)
HLA-DR matching 0.44
≥ 1 mismatch 64 (61.0%) 14 (70.3%)
Maintenance therapy 0.60
Double therapy 38 (36.2%) 6 (30.0%)
Triple therapy 67 (63.8%) 14 (70.0%)
Rejection time 0.036
<3 months post Tx 100 (95.2%) 16 (80.0%)
3-6 months post Tx 5 (4.8%) 4 (20.0%)
Rejection severity b 0.43
Borderline rejection 43 (44.8%) 6 (31.6%)
T cell mediated rejection 19 (19.8%) 6 (31.6%)
Vascular rejection 34 (35.4%) 7 (36.8%)
a Donor CYP3A5*1 genotype indicates that the donor expressed the CYP3A5*1 variant. This 
group includes both CYP3A5*1/*1 homozygous and CYP3A5*1/*3 heterozygous donors.
b Nine biopsies did not contain sufficient cortex to determine a Banff score. Four additional 
patients had a clinical rejection (with i- and t-scores of 0).
Tx, transplantation
mRNA expression of metabolism-related genes and the glucocorticoid receptor
No significant differences were found in pretransplant intragraft mRNA expression 
levels of CYP3A5, ABCB1 and GRα between the steroid responsive and steroid resistant 
groups (Figures 1B and 2). CYP3A5 mRNA expression was significantly higher in the 
steroid responsive AR group compared with the steroid resistant AR group (P=0.006, 
Figure 1B). Steroid resistant patients showed significantly lower CYP3A5 mRNA levels 
in the AR biopsy samples compared with the pretransplant biopsy samples (P<0.001, 













































responsive AR group compared with the steroid resistant AR group (P=0.036, Figure 
2A). No significant differences were observed in intragraft GRα mRNA expression 
between the steroid responsive and steroid resistant patient groups. The GRα 
expression level was significantly increased in the AR biopsy samples compared with 
the pretransplantation graft biopsies (P<0.00001, Figure 2B).
Figure 1. RNA expression of the metabolism-related gene CYP3A5 in renal allograft biopsy 
samples. Expression levels of CYP3A5 mRNA, measured with qPCR in pretransplant (Pre-Tx) 
and acute rejection (AR) biopsy samples, according to the respective donor CYP3A5 genotype 
group (A) and the steroid response groups (B). Data are expressed as means ± SEM. **, P<0.01; 





































Figure 2. RNA expression of metabolism-related gene ABCB1 and the glucocorticoid receptor 
in renal allograft biopsy samples. RNA expression levels of ABCB1 (A) and GRα (B) measured 
in pretransplant (Pre-Tx) and acute rejection (AR) biopsy samples from steroid resistant and 
steroid responsive patients. Data are expressed as means ± SEM. *, P<0.05; $, P<0.00001.
Localization of CYP3A5 and ABCB1 expression
We quantified the expression of CYP3A5 and ABCB1 on a panel of mRNA samples 
from various tissues and cell types (Figure 3). We observed relatively high expression 
levels of both CYP3A5 and ABCB1 in pretransplant and AR rejection biopsies from 
renal allografts, which were similar to the expression levels seen in the liver. CYP3A5 













































(see Figure 3A), while ABCB1 was highly expressed by T cells and to a lesser extent by 
peripheral blood mononuclear cells, B cells and PTECs (see Figure 3B).
Figure 3. Localization of CYP3A5 and ABCB1 expression in various tissues and cell types. 
CYP3A5 (A) and ABCB1 (B) expression was quantified by qPCR in mRNA from a panel of organs 
and cell types. A) High CYP3A5 expression was seen in the liver, the kidney (both before and 
after transplantation), and in macrophages and proximal tubular epithelial cells (PTECs). B) 
ABCB1 was highly expressed in the liver, the kidney (both before and after transplantation), 
and in T cells. Intermediate ABCB1 expression was seen in peripheral blood mononuclear cells 





































Using immunohistochemical stainings we investigated the expression of CYP3A5 
and ABCB1 proteins within the graft. In accordance with the mRNA expression levels 
in the cell panel, CYP3A5 protein expression was detected in inflammatory cells and 
tubular epithelial cells (Figure 4). The level of intragraft expression of CYP3A5 protein 
observed in the patient cohort varied between high (Figure 4A and B) and low (Figure 
4C and D), but showed no significant difference between the steroid response groups 
(data not shown). Correlation analysis showed a weak correlation between the mRNA 
and protein expression of CYP3A5 (P<0.05, ρ=0.21). ABCB1 protein expression was 
detected in inflammatory cells and tubular epithelial cells (Figure 5). No correlation 
was found between ABCB1 staining and the response to steroid treatment (data not 
shown).
Figure 4. Immunohistochemical staining pattern of CYP3A5 in sections from renal transplant 
biopsies with acute rejection. CYP3A5 protein was detected in infiltrating lymphocytes and 
tubular epithelial cells. Intragraft expression of CYP3A5 protein varied from high (A-B) to low 













































Figure 5. Immunohistochemical staining pattern of ABCB1 in sections from renal transplant 
biopsies with acute rejection. ABCB1 protein was detected in infiltrating lymphocytes and 
tubular epithelial cells. A: overview recording at 20x magnification; B: enlarged recording at 
50x magnification.
Discussion
Research in the field of steroid-refractory AR in renal allografts has been mainly 
focused on markers of inflammatory cells 36. The role of glucocorticoid signaling 
and drug metabolism as predisposing factors towards responsiveness for high-dose 
steroid therapy during AR has not been thoroughly examined. We investigated if 
polymorphisms in genes involved in glucocorticoid signaling (GR and GLCCI1) and 
drug metabolism (CYP3A5, ABCB1, and PXR) are associated with response to steroid 
treatment.
Our study shows for the first time that the donor CYP3A5*1 genotype and 
intragraft CYP3A5 expression levels are associated with responsiveness to steroid 
treatment. Earlier studies have shown that patients homozygous for CYP3A5*3 
require lower doses of immunosuppression, such as Tacrolimus and Cyclosporine 
A, due to a lower capacity to metabolize the therapeutic compound 37;38. We found 
that donor CYP3A5*3/*3 is associated with resistance to steroid treatment during 
AR. The CYP3A5*3 variant creates an alternative splice site resulting in truncated 
CYP3A5 protein. Carriers of the CYP3A5*1 variant were shown to produce high levels 
of CYP3A5 mRNA and protein, while individuals homozygous for CYP3A5*3 were low 
expressors of CYP3A5 18;19;21. In line with these findings, we observed a genotype-
dependent level of CYP3A5 mRNA expression in the grafts from renal allograft 
recipients. Furthermore, intragraft expression of CYP3A5 protein was detected in 
inflammatory cells and tubular epithelial cells, which is in line with earlier findings in 





































A potential mechanism for the correlation between CYP3A5 and the response 
to steroid treatment may be that CYP3A5*1 expression within the kidney results 
in improved metabolism of methylprednisolone into a more effective metabolite, 
increasing the immunosuppressive effect of the treatment. An alternate hypothesis 
is that the increased metabolic capacity of CYP3A5*1 carriers may prevent toxic side 
effects of the high concentration of steroids within the allograft, while leaving the 
immunosuppressive effects intact. Further research will be needed to gain insight 
into how CYP3A5 affects the response to steroid treatment.
Another highly expressed member of the CYP3A family of metabolizing enzymes 
is CYP3A4. Similar to CYP3A5, polymorphisms in the CYP3A4 gene may contribute to 
inter-individual variability in drug metabolism 18;40. Due to the low expression levels 
of CYP3A4 within the kidney, we did not include the CYP3A4*1B SNP in our study 
17;18;41. Further research in a larger patient cohort may be needed to see if CYP3A4 
associates with response to steroid treatment during AR.
Other important drug metabolism-related genes expressed in the kidney encode 
P-glycoprotein (ABCB1) and the pregnane X receptor (NR1I2) 16;23. SNP genotyping 
revealed no associations between polymorphisms in ABCB1 or NR1I2 and steroid-
refractory AR. We did find significantly higher ABCB1 mRNA expression in AR biopsy 
samples of steroid resistant patients. Earlier studies in children with nephrotic 
syndrome have linked the expression of ABCB1 polymorphisms and ABCB1 gene 
expression levels with resistance to steroid therapy 26;42. Discrepancies with respect 
to the relation between ABCB1 polymorphisms and steroid responsiveness may 
be caused by differences in the age of the patients studied (children versus adults) 
and the type of steroids used as treatment. The nephrotic syndrome patients were 
treated with 60 mg / m2 / d prednisone for four weeks, while acute renal allograft 
rejection is treated for 3 days with a 1-g bolus of methylprednisolone.
In addition to drug metabolism-related genes, we investigated genes involved 
in glucocorticoid signaling. We found no associations between steroid-refractory 
AR and the glucocorticoid receptor or GLCCI1. Both the genotype distribution of 
the NR3C1 and GLCCI1 polymorphisms and the GR mRNA expression in the renal 
allograft showed no correlation with the patient’s response to methylprednisolone. 
Earlier studies showed that NR3C1 SNPs associated with increased (N363S 43 and BclI 
44) or reduced (23EK 45 and GR-9β 46) sensitivity to glucocorticoids (reviewed in 12), and 













































Some comments need to be made with regard to the current findings. In this 
retrospective study, we included 153 renal transplant patients with a first rejection 
episode who received corticosteroids as anti-rejection treatment. We handled strict 
inclusion criteria and clinical endpoint definitions for the patient selection. Although 
this is a relatively large cohort to study the response to steroid treatment, it is a 
relatively small patient cohort for the study of the effect of genotypes. In addition, 
recent studies have shown the importance of replicating the findings of molecular 
studies in kidney transplantation 47. In order to increase the cohort size and test the 
validity of our findings, the study should be repeated in a second patient cohort. 
Furthermore, we observed only a weak correlation between the mRNA and protein 
expression of CYP3A5, and no correlation between ABCB1 mRNA and protein 
expression. This lack of correlation may have been caused by the biopsy material 
used to analyze the mRNA and protein expression. RNA was isolated from eight to ten 
10-μm sections of renal cortex from snap frozen biopsy cores, while protein stainings 
were performed on 4-μm sections from formalin fixed and paraffin embedded biopsy 
cores.
In conclusion, we investigated the impact of genes involved in glucocorticoid 
signaling and drug metabolism as predisposing factors on the response to high-dose 
steroid treatment of AR in renal allograft recipients. Our study shows for the first 
time that resistance to steroid treatment during AR is associated with the donor 
CYP3A5*1 genotype and CYP3A5 expression levels within the renal allograft. The 
current findings show that gene variations in drug metabolism-related genes, but 
not in the GR, predispose to responsiveness to high-dose steroid therapy.
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Table S1. Primers used for characterization of GR and metabolism SNPs.
A. SYBR Green PCR assays
Gene rs number SNP Primers (5’ – 3’)
NR3C1 rs6189/rs6190 ER22/23EK Forward 1 5’-GTGTGCTTGCTCAGGAGAG-3’
Forward 2 5’-CAGTGTGCTTGCTCAGGAAAA-3’
Reverse 5’-TTTGGACAGATCTGGCTGCT-3’
NR3C1 rs41423247 BclI Forward 5’-TGACCTTTTTGGGTCAGACAA-3’
Reverse 1 5’-AGACAAGTTATGTCTGCTGATC-3’
Reverse 2 5’-AGACAAGTTATGTCTGCTGATG-3’
ABCB1 rs1128503 C1236T Forward 5’-CCCATCTCGAAAAGAAGTTAAGG-3’
Reverse 1 5’-TGCACCTTCAGGTTCAGG-3’
Reverse 2 5’-TGCACCTTCAGGTTCAGA-3’
ABCB1 rs2032582 G2677T Forward 5’-GGTTCCAGGCTTGCTGTAAT-3’
Reverse 1 5’-TAGTTTGACTCACCTTCCTAGC-3’
Reverse 2 5’-AGTTTGACTCACCTTCCCAGA-3’
ABCB1 rs1045642 C3435T Forward 5’-AGGAGCCCATCCTGTTTGAC-3’
Reverse 1 5’-CTCCTTTGCTGCCCTCACA-3’
Reverse 2 5’-CTCCTTTGCTGCCCTCACG-3’
B. TaqMan PCR assays
Gene rs number SNP Primers (5’ – 3’)
NR3C1 rs6195 N363S 5’-TCCAGATCCTTGGCACCTATTCCAA[T/C]TTTCGGAACCAACGGGAATTGGTGG-3’
(rs56149945) C: VIC labeled T: FAM labeled
NR3C1 rs6198 GR-9β 5’-GTAATACCAGAACAGCAAATTTAAA[T/C]GAAAAAATAAAAGTTAAACATTTCC-3’
C: VIC labeled T: FAM labeled
GLCCI1 rs37972 -1473 C>T 5’-CTCTTGAAAATTAATGAAAGTTATC[C/T]GATGAAGATCCTTACATTAATTGCT-3’
A: VIC labeled G: FAM labeled
CYP3A5 rs776746 CYP3A5*3 5’-ATGTGGTCCAAACAGGGAAGAGATA[T/C]TGAAAGACAAAAGAGCTCTTTAAAG-3’
(A6986G) C: VIC labeled T: FAM labeled
NR1I2 rs6785049 A7635G 5’-AGGAGCCATCCTCCCTCTTCCTCTC[A/G]CCCCCAACTTCTGGATTATGGGATG-3’
A: VIC labeled G: FAM labeled
ABCB1, ATP-binding cassette B1; CYP3A5, cytochrome P450 3A5; GLCCI1, glucocorticoid-
induced transcript 1; NR3C1, nuclear receptor 3C1 (glucocorticoid receptor); NR1I2, nuclear 





































Table S2. Primers used for gene expression analysis.






ABCB1, ATP-binding cassette B1; CYP3A5, cytochrome P450 3A5; GRα, glucocorticoid receptor 











































































































































































































































































































































































































































































































































































































































































































































































































































Table S5. SNP genotypes analyzed for deviations from Hardy-Weinberg equilibrium.
Gene SNP rs number Recipient Donor
NR3C1 N363S rs6195 0.95 0.92
NR3C1 ER22/23EK rs6189/rs6190 0.99 0.90
NR3C1 Bcl1 rs41423247 0.029 0.57
NR3C1 GR-9β rs6198 0.014 0.59
GLCCI1 -1473 C>T rs37972 0.54 0.69
CYP3A5 CYP3A5*3 rs776746 0.76 0.68
ABCB1 C1236T rs1128503 0.67 0.61
ABCB1 G2677T rs2032582 0.021 0.43
ABCB1 C3435T rs1045642 0.64 0.66
NR1I2 A7635G rs6785049 0.98 0.58
ABCB1, ATP-binding cassette B1; CYP3A5, cytochrome P450 3A5; GLCCI1, glucocorticoid-
induced transcript 1; NR3C1, nuclear receptor 3C1 (glucocorticoid receptor); NR1I2, nuclear 
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Occurrence of acute rejection is a risk factor for adverse kidney graft outcome. We 
found in a recent patient cohort that relatively high S100A8 and S100A9 mRNA 
expression during acute rejection (>2 times the median; n=36) led to a 12-year graft 
survival of 91.5%, whereas low expression (n=61) led to 69.2% graft survival (P<0.05). 
S100A9 mRNA expression levels corresponded with the extent of S100A9 protein 
in the grafts. High S100A8 and A9 expression was related to elevated expression of 
anti-inflammatory IL-10 (P<0.01) and regulatory T cell marker FoxP3/CD3 (P<0.0001). 
Triple immunostaining showed that 85% of the total myeloid cell population (CD68+) 
consisted either of S100-positive cells or CD163+ activated macrophages. In cultured 
monocytes S100 expression was especially elevated when the cells were stimulated 
with IL-10. Overexpression of the S100A8 and S100A9 genes in the monocytic cell 
line THP-1 led to de novo production of IL-10 for at least four days after transfection. 
These findings indicate that renal allograft survival is related to the presence of 
distinct myeloid cell subsets within the graft during acute rejection, and that high 
expression of S100 positive cells leads to increased local regulation of the immune 














































Kidney transplantation is the preferred treatment for patients suffering from end-
stage renal disease. At present, more than 36,500 kidney transplantations are 
performed annually in Europe and the United States 1;2. Fifteen percent of renal 
allograft recipients experience an acute rejection (AR) episode 3;4, and approximately 
40% of the renal grafts fail within ten years after kidney transplantation 2. During AR 
immune cells of the host infiltrate the donor kidney and cause injury to the allograft. 
The occurrence of AR is an important risk factor for adverse graft outcome and graft 
loss 5-9. Until now, it has proven difficult to differentiate between patients having a 
high or low risk profile for adverse graft outcome. Identification of biomarkers for 
assessing the risk of graft failure may lead to improved monitoring and intervention 
strategies and may contribute to improved long-term renal allograft outcome.
Molecular markers in transplant biopsies with acute rejection may be helpful 
to predict the risk of graft loss (reviewed in 10). Previously, we found that patients 
experiencing AR with relatively high intragraft expression levels of S100A8 and S100A9 
show favorable long-term graft outcome 11. S100A8 and S100A9 belong to a large 
family of calcium-binding proteins and are expressed by neutrophils, monocytes, 
and early differentiated macrophages, but absent in resident macrophages and 
lymphocytes 12-16. Both S100A8 and A9 have been found to be biomarkers for a variety 
of inflammatory disorders, including complications in organ transplantation 12;13;17. 
Increased serum levels of these S100 molecules predict the occurrence of AR 18;19. 
The elevated levels prior to an AR episode could indicate either counter-regulatory 
responses or pro-inflammatory effects by these molecules.
In the current study on a large cohort of patients suffering from AR, we verified 
that the presence of relatively high levels of S100A8 and S100A9 in inflammatory 
infiltrates during AR is associated with favorable graft outcome. We found that 
S100A8 and S100A9 proteins are expressed by a specific subset of myeloid cells. In 
further experiments we provide evidence that the S100 proteins are directly related 








































The study cohort consisted of 142 patients who received a renal allograft in our 
center between 1995 and 2005. Biopsy samples were taken within 6 months after 
transplantation because of acute decrease in graft function: 137 patients suffered from 
a histologically proven acute rejection, and five patients showed no histomorphologic 
indication of rejection 20. All rejection biopsy samples were obtained prior to the 
start of anti-rejection treatment. As a control group for graft survival analyses, 100 
renal allograft recipients from our center who did not experience an acute rejection 
episode, and matched for transplantation date and donor type (living, deceased), 
were selected.
The second cohort consisted of 65 patients from the CANNES trial, who were 
enrolled in an open-label randomized control trial on calcineurin inhibitor based 
maintenance immunosuppressive therapies 21;22. The 65 patients received a renal 
allograft in our center between October 2000 and October 2002, and had undergone 
biopsies before transplantation (pretransplant biopsy), and at 6 and 12 months after 
transplantation. None of these patients had experienced an acute rejection episode. 
All patients gave informed consent to take part in the study.
Medication
Maintenance immunosuppressive medication consisted of double- (25.1%) or 
triple-drug (74.9%) therapy: glucocorticoids (prednisone) and a calcineurin inhibitor 
(Cyclosporine A or Tacrolimus), with or without an antimetabolite (Mycophenolate 
Mofetil). One hundred and five (50.7%) patients received induction therapy with 
an IL-2 receptor blocker (Daclizumab or Basiliximab). High-dose intravenous 
methylprednisolone was used as initial treatment of acute rejection (1-g bolus/day 
x 3 days). Steroid resistant acute rejection was treated with anti-thymocyte globulin. 
Patients from the CANNES trial with subclinical acute rejection did not receive 
additional medication.
Clinical endpoints
The primary clinical endpoint was graft survival, defined as time from transplant 















































Biopsy cores were obtained by percutaneous, ultrasound-guided biopsy with an 
18-gauge needle. At least two cores were collected from each patient. One core was 
formalin fixed, embedded in paraffin, and used for histological analysis (Banff score) 
and immunohistochemical stainings. The second biopsy core was immediately snap 
frozen in liquid nitrogen and stored at -80°C.
Banff score
In the patient cohort suffering from acute rejection, rejection severity was assessed 
on paraffin-embedded biopsy tissue according to Banff 2011 criteria 23, as described 
previously 20.
Protocol biopsy samples fulfilling the criteria of acute rejection in the absence 
of clinical symptoms were classified as subclinical acute rejection (SAR). SAR was 
defined by a tubulitis score of ≥ 2 and interstitial infiltrate score ≥ 0. Eleven cases of 
SAR were observed in the protocol biopsy specimens: four at 6 months and seven at 
12 months post transplantation.
RNA extraction and cDNA synthesis
RNA extraction was performed on snap frozen biopsy samples from 99 patients 
having acute rejection, five patients with no indication of rejection, and 65 patients 
from the CANNES trial 20;21. Eight to ten 10-μm thick sections of renal cortex were 
cut with a cryomicrotome from each frozen biopsy core. Total RNA from the renal 
tissue was extracted using the RNeasy Mini Kit (Qiagen, Chatsworth, CA) according 
to the manufacturer’s protocol. RNA concentration was measured by NanoDrop 
spectrophotometer (Nanodrop Products, Wilmington, DE) and RNA quality was 
determined on Nano LabChips with the Aligent 2100 Bioanalyzer (Agilent Technologies, 
Palo Alto, CA). The A260/A280 ratio was between 1.8 and 2.1. A maximum of 1 µg of 
isolated RNA from each frozen biopsy core was transcribed into cDNA, according to a 
previously described protocol 24. The cDNA samples were 25-times diluted.
Quantitative real-time PCR analysis
Primer sequences for real-time qPCR assays are provided in Table S1. To prevent 
amplification of genomic DNA, forward and reverse primers for each transcript 





































All primer sets were tested before use on control cDNA and genomic DNA to ensure 
optimal performance and no amplification of genomic DNA. Reactions and PCR 
conditions have been described previously 24. All PCR efficiencies were above 90%. 
Relative gene expression levels were determined on the basis of a standard curve (in 
duplicate) of five serial dilution points of reference cDNA (qPCR Human Reference 
Total RNA, Clontech, France). Differences in mRNA expression levels were normalized 
to the geometric mean signal of the reference genes GAPDH, 18S rRNA and β-actin 
(inter-correlation ranged between 0.88 and 0.95).
Microarray Analysis
Gene expression profiles were analyzed in 36 acute rejection biopsy samples with 
Illumina HumanRef-8 v3.0 BeadChips (Illumina, San Diego, CA), as previously described 
25. All samples had a RNA quality index > 8. Illumina GenomeStudio software was 
used to verify the adequacy of signal to background ratio and hybridization controls. 
All data have been deposited in the Gene Expression Omnibus public database, 
accession number: GSE47097.
Immunohistochemistry
Immunohistochemical analyses were performed on 123 paraffin-embedded biopsy 
samples from the patients having acute rejection. Sequential serial sections (4 μm) 
of formalin-fixed paraffin-embedded biopsy samples were used to detect S100A9 
monomers, S100A8/A9 heterodimers (Ab 27E10), CD68, and CD163. Primary 
monoclonal rabbit anti-human antibodies against S100A9 and primary monoclonal 
mouse anti-human antibodies against 27E10 have been described previously 26. 
Primary monoclonal mouse anti-human antibodies against CD68 were obtained 
from Dako (Glostrup, Denmark; clone KP1), and against CD163 were obtained from 
Abcam (Cambridge, UK; clone 10D6, prediluted). Antibodies and staining protocols 
have been described previously 26;27. Details concerning antigen retrieval and staining 
procedure are provided in Table S2. For S100A9 and 27E10, peroxidase-conjugated 
second-stage antibodies were purchased from Dianova (Hamburg, Germany), 
and peroxidase activity was detected with 3-amino-9-ethylcarbazole (AEC; Sigma-
Aldrich, St. Louis, MO). For CD68 and CD163, Mouse-Envision+ System (DAB) was 
used according to the manufacturers (Dako) protocol. Photos were taken with a 













































camera (Carl Zeiss Microscopy GmbH, Germany) and Pannoramic Viewer software 
(3DHISTECH). Quantification of immunohistochemical stainings was performed using 
Image-J software (National Institutes of Health, Bethesda, MD).
Immunofluorescence staining
To investigate the presence of macrophage subtypes, a triple immunofluorescence 
staining was performed for S100A9, CD163 and CD68. Paraffin-embedded sections 
(4 μm) were deparaffinized in xylene and hydrated via graded ethanols to purified 
H2O. After blocking of endogenous peroxidase with 0.1% H2O2, heat-induced antigen-
retrieval was performed with a citrate buffer (pH 6.0) for 30 minutes, followed by 
washing in PBS. Sections were incubated overnight with a mix of primary antibodies: 
monoclonal rabbit anti-human IgG against S100A9 (dilution 1:4000; Abcam; clone 
EPR3555), monoclonal mouse anti-human IgG1 against CD163 (dilution 1:20; Abcam; 
clone 10D6, prediluted), and monoclonal mouse anti-human IgG2a against CD68 
(dilution 1:100; Abcam; clone 514H12). Thereafter, the sections were washed with PBS 
three times for 5 minutes each, and incubated for 30 minutes with a mix of secondary 
antibodies: Alexa Fluor 488 goat-anti-mouse IgG1 (dilution 1:200; Life Technologies, 
Bleiswijk, the Netherlands), Alexa Fluor 546 goat-anti-rabbit IgG (dilution 1:200; 
Life Technologies), and Alexa Fluor 647 goat-anti-mouse IgG2a (dilution 1:200; Life 
Technologies). After rinsing of the sections three times with PBS, slides were covered 
with Vectashield (Vector Laboratories ltd., Burlingame, CA). Photos were taken with 
Leica TCS SP8 confocal microscope (Leica Microsystems, Rijnsburg, the Netherlands). 
S100A9 and CD163 staining patterns were graded by N.V.R. and M.E. together on 
a – tot ++ scale. On average, 994 ± 279 cells were scored positive in 14 ± 3 locations.
S100A8 and S100A9 expression in cultured human monocytes
Procedures for isolation of monocytes and generation of different subsets of polarized 
human macrophages have been described previously 28. Monocytes were isolated 
from peripheral blood of six healthy volunteers and cultured in 6-well culture plates 
(0.5 x 106 / ml) in Iscove’s modified Dulbecco’s medium (IMDM; Invitrogen, Breda, 
the Netherlands) containing 10% fetal bovine serum (FBS; PAA Laboratories, Cölbe, 
Germany). Monocytes were cultured for 4 days in medium only or were polarized with 
GM-CSF (50 ng/ml; R&D Systems, Abingson, UK), M-CSF (50 ng/ml; R&D Systems), 





































Germany), or IL-10 (50 ng/ml; R&D Systems). LPS (100 ng/ml; E. coli 0111:B4, Sigma 
Aldrich, Zwijndrecht, the Netherlands) was added in cultures with IFN- γ, IL-4, and 
IL-10 as an additional stimulant. After the culture, the cells were harvested and RNA 
was extracted. Expression of S100A8 and S100A9 was measured by qPCR.
Transient overexpression of S100A8 and S100A9 in monocytes
THP-1 (human leukemic monocyte cell line) cells were cultured in IMDM (Lonza, 
Verviers, Belgium) containing 10% heat-inactivated FBS (Life Technologies), 1 U/
ml penicillin (Lonza), 1 U/ml streptavidin (Lonza) and 3 mM L-glutamine (Life 
Technologies). For the construction of pVITRO-S100A8/A9, both hS100A8 and 
hS100A9 PCR fragments were cloned into pVITRO2-hygro-mcs (InvivoGen, San Diego, 
CA) according to previously described protocols 29. Empty pVITRO2-hygro-mcs vector 
was used to control for potential effects of the transfection procedure. Lipofectamine 
LTX transfection reagent was obtained from Invitrogen (Karlsruhe, Germany). The 
transfection was performed as described previously 29, with some modifications. 
THP-1 cells were seeded in 24-well plates (100 x 106 cells/well) 24 hours before 
transfection. Six μl Lipofectamine and 1.5 μg of total plasmid DNA were diluted to 
a final volume of 800 μl with pure IMDM and added to the cells. The medium was 
changed 5 hours after the transfection. The cells were cultured for 24 hours, 48 hours, 
4 days, or 6 days. Expression of S100A8, S100A9, TNFα, and IL-10 was measured by 
qPCR.
Statistical analysis
Differences in mean mRNA expression between patient groups were tested with the 
Mann-Whitney U-test. Comparison of categorical data between patient groups was 
evaluated using the Pearson chi-square test. Association with death-censored graft 
loss was tested using Kaplan-Meier curves and log-rank testing. All statistical tests 
were two-sided, and P values less than 0.05 were considered as significant. Statistical 
analyses were performed using the SPSS statistical package (IBM SPSS Statistics., 














































S100A8 and S100A9 expression in renal allograft biopsy samples
We quantified S100A8 and S100A9 mRNA expression levels in six groups of biopsy 
specimens obtained at different time points before and after transplantation. Biopsy 
samples with histologically confirmed AR had significantly higher mRNA expression 
levels of S100A8 and S100A9 compared with biopsies taken before transplantation 
(Pre-Tx) (P<0.00001), biopsies with no morphologic signs of rejection (P<0.001), and 
protocol biopsies taken at 6 months (P<0.00001) and 12 months (P<0.00001) (Figure 
1 and Table S3). AR biopsy samples did not differ from biopsies with subclinical acute 
rejection (SAR) with respect to S100A8. We conclude from these results that S100A8 
and S100A9 expression levels in the graft are specifically elevated during conditions 
of increased inflammation.
Figure 1. Expression levels of S100A9 and S100A8 in renal allograft biopsy specimens. The mRNA 
expression S100A9 (A) and S100A8 (B) measured with qPCR in six groups of biopsy specimens 
obtained at different time points before and after transplantation: pretransplant biopsy 
samples (Pre-Tx Bx), biopsies taken on clinical indication within 3 months post transplantation 
with no signs of rejection (No rej. (<3 mo)), or with histologically confirmed acute rejection 
(AR (<3 mo)), protocol biopsies taken at 6 months (Prot. Bx (6 mo)) or 12 months (Prot. Bx (12 
mo)) with no signs of rejection, or with histological indication of subclinical acute rejection SAR 





































Relationship of S100A8 and S100A9 mRNA expression during acute rejection with 
graft outcome
In a small case-control study of patients transplanted between 1986 and 1992 11, 
relatively high intragraft expression levels of S100A8 and S100A9 during AR were 
found to be related to improved graft outcome at a later time point. We could 
confirm and extend these data in a much larger and more recent cohort of patients, 
transplanted between 1995 and 2005: S100A9 mRNA expression levels were 3.3 
fold higher in patients retaining their graft for at least 6 years (non-progression [NP] 
group) compared to patients showing progression to graft loss (PR group) (P<0.05; 
Figure 2).
Figure 2. Association between S100A9 expression and graft outcome in patients with acute 
renal allograft rejection. Comparison of the intragraft S100A9 mRNA expression level during 
AR between patients retaining their graft for at least 6 years (non-progression [NP] group) and 
patients showing progression to graft loss (PR group).
The patients suffering from AR were divided into a S100A9high (n=36; at least 
two times the median S100A9 expression of the whole group) and a S100A9low 
(n=61; expression level lower than 2 times the median) expresser group. Six years 
after transplantation, graft survival was 97.2% in the S100A9high group and 79.9% in 
the S100A9low group (P=0.032, Figure 3A). At the end of follow-up, i.e. 12.5 years 
after transplantation) this difference remained significant, with 91.5% graft survival 
in the S100A9high group and 69.2% graft survival in the S100A9low group (P=0.046, 
Figure 3A). The graft survival in the S100A9high group was similar to the graft survival 
observed in a group of 100 matched patients, who were transplanted within the 













































Figure 3A). The S100A9low group showed significantly more graft loss compared to the 
patients without acute rejection (P=0.010, Figure 3A). Demographic and clinical data 
were not significantly different between the patients in the S100A9low and S100A9high 
groups (Table 1), even though that virtual PRA did show an association with graft 
survival (see Table S4 and Figure S1). In the whole group, S100A9 expression is 
highly correlated to S100A8 expression (r=0.94, P<0.000001 and Figure 3B). Thus, 
S100A9 and S100A8 levels in renal allografts with acute rejection predict prognosis. 
Acute rejection episodes with relatively high levels of these molecules have a similar 
impact on late graft outcome as situations where no acute rejection episode was 
experienced by the patient.
We next investigated whether expression of markers related to immune 
regulation and immunity are associated with the S100 expression. Expression of the 
anti-inflammatory cytokine IL-10 (P<0.01, Figure 3C) and regulatory T cell marker 
FoxP3:CD3e ratio (P<0.0001, Figure 3D) was significantly higher in the S100A9high 
group compared to the S100A9low group. In contrast, kidney injury molecule (KIM)-1 
(P<0.05, Figure 3E), pan-T cell marker CD3e (P<0.005, data not shown), and T helper 
cell marker CD4 (P<0.05, data not shown) showed lower expression in the S100A9high 
group compared to the S100A9low group.
S100A9 protein expression in renal allograft biopsy samples
Intragraft S100A9 mRNA expression was related to the extent of S100A9 protein in 
the AR biopsy specimens: significantly higher protein expression was seen in the 
S100A9high group compared to the S100A9low group (P<0.005, Figure 4A). Infiltrating 
lymphocytes in the tubulointerstitial compartment stained positive for S100A9 
(Figure 4). Similar findings were observed for staining of 27E10, which is the epitope 
specifically recognized on S100A8-A9 heterodimer protein (data not shown). Protocol 
biopsy samples obtained at 6 or 12 months after transplantation expressed low levels 
of S100A9 protein (Figure 4B). The AR biopsy samples showed a wide range in the 






































Figure 3. S100A9 expression and renal allograft survival. (A) Graft survival (censored for death 
with functioning graft) analyzed in renal allograft recipients with low (striped line) or high 
(straight line) mRNA expression levels of S100A9 during acute rejection, and in patients having 
no acute rejection (dotted line). The graft survival of the S100A9high expresser group was 
significantly better compared to the S100A9low expresser group. Patients with high S100A9 
expression showed significantly better graft survival compared to S100A9low expressers (log-
rank = 3.978; P=0.046). The graft survival in the S100A9high group was similar to the graft 
survival observed in patients without acute rejection (log-rank = 0.206; P=0.65). The S100A9low 
group showed significantly more graft loss compared to the patients without acute rejection 
(log-rank = 6.651; P=0.010). (B-E) Relative mRNA expression levels of S100A8 (B), IL-10 (C), 














































Table 1: Demographic and clinical data of AR patients with high or low S100A9 mRNA expression
Variable S100A9low S100A9high P value
(n=63), n (%) (n=36), n (%)
Patient age 0.91
≥ 50 years 27 (42.9%) 15 (41.7%)
Patient gender 0.38
Female 19 (30.2%) 14 (38.9%)
Donor age 0.61
≥ 50 years 26 (41.3%) 13 (36.1%)
Donor gender 0.29
Female 37 (58.7%) 25 (69.4%)
Year of transplantation 0.18
1995 through 1999 39 (61.9%) 27 (75.0%)
2000 through 2005 24 (38.1%) 9 (25.0%)
Donor type 0.32
Living 12 (19.0%) 10 (27.8%)
Post mortal 51 (81.0%) 26 (72.2%)
HLA-AB matching 0.64
≥ 1 mismatch 52 (82.5%) 31 (86.1%)
HLA-DR matching 0.75
≥ 1 mismatch 40 (63.5%) 24 (66.7%)
Virtual PRA 0.66
Immunized (6-100%) 18 (29.0%) 12 (33.3%)
Cold ischemia time 0.63
> 18 hours 38 (71.7%) 20 (66.7%)
Induction therapy 0.10
Daclizumab 22 (34.9%) 7 (19.4%)
None 41 (65.1%) 29 (80.6%)
Maintenance therapy 0.32
Double therapy 25 (39.7%) 18 (50.0%)
Triple therapy 38 (60.3%) 18 (50.0%)
Delayed graft function 0.06
Yes 19 (30.6%) 5 (13.9%)
Rejection time 0.18
<3 months post Tx 60 (95.2%) 36 (100.0%)
3-6 months post Tx 3 (4.8%) 0 (0%)
C4d staining 0.19
Positive 6 (10.3%) 7 (20.0%)
Interstitial inflammation 0.09
Low inflammation (<25%) 33 (55.0%) 12 (36.4%)
>25% parenchyma inflamed 27 (45.0%) 21 (63.6%)
Rejection severity a 0.11
Borderline rejection 28 (49.1%) 9 (27.3%)
T cell mediated rejection 12 (21.1%) 8 (24.2%)
Vascular rejection 17 (29.8%) 16 (48.5%)
a Six biopsies did not contain sufficient cortex to determine a Banff score. Three additional 
patients had a clinical rejection (with i- and t-scores of 0).





































Figure 4. S100A9 protein expression in renal allograft biopsy samples. (A) Comparison of S100A9 
protein expression between AR biopsy samples with low and high S100A9 mRNA expression. 
(B-D) Immunohistochemical staining pattern of S100A9 in patient groups. S100A9 protein was 
mainly detected in infiltrating lymphocytes in the interstitial compartment. (B) Protocol biopsy 
samples obtained at 6 (pictured) or 12 months (not shown) after transplantation expressed low 
levels of S100A9 protein. (C-D) Infiltrating lymphocytes in the tubulointerstitial compartment 
stained positive for S100A9. The AR biopsy samples showed a wide range in the extent of 
staining for S100A9. Recordings at 10x magnification.
Macrophage markers CD163 and CD68
As S100A8 and S100A9 are mainly expressed by myeloid cells 13-16, we investigated 
the expression of activated macrophage marker CD163 and pan-macrophage marker 
CD68 in the AR biopsy specimens. Patients with acute rejection having relatively 
high CD163 mRNA expression (n=27; at least two times the median of the whole 
group) had a significantly higher risk of losing their graft compared to patients having 
relatively low CD163 mRNA expression (n=74; lower than two times the median). Six 
years after transplantation the graft survival was 75.0% in the CD163high group and 
89.4% in the CD163low group (P=0.054, Figure 5A). Immunohistochemical analysis in 
the AR biopsy specimens showed a significant correlation between CD163 mRNA 













































was seen in infiltrating lymphocytes in the tubulointerstitial compartment (Figure 
5C and D). We found no significant differences in CD68 protein staining between the 
S100A9high and S100A9low groups, or between the CD163high and CD163low groups (data 
not shown).
Figure 5. CD163 expression in biopsy samples with acute rejection. (A) Graft survival (censored 
for death with functioning graft) analyzed in renal allograft recipients with low (straight line) 
or high (striped line) mRNA expression levels of CD163 during acute rejection. (B) Comparison 
of CD163 protein expression between AR biopsy samples with low and high CD163 mRNA 
expression. (C-D) Immunohistochemical staining of CD163 protein was detected in infiltrating 
lymphocytes. AR biopsy samples showed a wide range in the extent of staining for CD163. 
Recordings at 10x magnification.
Macrophage subtypes in AR biopsy samples
To gain further insight into the relationship between S100A9 and CD163 expression, 
double immunofluorescence staining was performed on a subset of the AR biopsy 
samples (n=6) (Figures 6A-C and 7A-C). Counting of almost 1,000 positively-stained 





































(32.2% ± 9.2%, Figure 6D, red bar) or only CD163 (50.3% ± 12.4%, Figure 6D, green 
bar). A limited number of cells showed expression of both S100A9 and CD163 (Figure 
6D, grey bars). At the same time, we saw by triple immunofluorescence staining 
including CD68, that each cell positive for S100A9, CD163 or both also stained 
positive for CD68 (see Figure 7D).
The results suggest that S100A9 and CD163 represent different myeloid cell 
subsets within the total CD68+ cell population infiltrating the graft during acute 
rejection.
Figure 6. Relationship between S100A9 and CD163 expression. Immunofluorescence staining 
on sections from renal transplant biopsies with acute rejection for S100A9 (red) and CD163 
(green). Shown are the single stainings for CD163 (A) and S100A9 (B), the combined double 
staining containing S100A9 and CD163 (C), and the quantification of the percentage single and 
double positive cells for S100A9 and CD163 expression (D). Bars represent the mean ± SEM of 













































Figure 7. Colocalization of S100A9, CD163, and CD68 protein expression. Triple 
immunofluorescence staining on sections from renal transplant biopsies with acute rejection 
for S100A9 (red), CD163 (green), and CD68 (blue). Shown are the single stainings for CD163 
(A), S100A9 (B), and CD68 (D), and the combined double staining containing S100A9 and 
CD163 (C). Recordings at 100x magnification.
S100 expression is related to genes involved in immune regulation
We wanted to acquire further insight in the biologic effect of the S100 proteins in 
vivo in the grafts. Therefore, we analyzed multiple acute rejection biopsies (n=36) 
by microarray analysis, and characterized genes of which the expression correlated 
best with that of S100A9. Thirty-nine genes showed an r≥0.65. As expected, the 
highest correlation was found with S100A8 (r=0.93). The theme of the list reflects 
genes expressed by the granulocyte-monocyte lineage (CD11b, CEBPB, FPR1, HCK, 





































is a component of the NADPH oxidase complex, which generates reactive oxygen 
species (ROS) by myeloid cells. Several of the genes on the list are involved in 
immune regulation (Table S5). For instance, the FPR1-ANXA1 axis (r=0.78 and 
r=0.66, respectively) regulates the biosynthesis of inflammation mediators, exerting 
anti-inflammatory effects through a similar pathway as glucocorticoids do 30. CD44 
mediates matrix adhesion and activation of leukocytes, and plays a critical role in 
resolving inflammation, as found in the lung 31. MAP3K8/TPL2 (r=0.68) is a negative 
regulator of Th1 adaptive immunity 32.
Effect of cytokines and growth factors on S100 expression in human monocytes
We wanted to know whether cytokines and growth factors affect the S100A8 and 
S100A9 expression in monocytes. When compared with untreated monocytes in 
culture, the largest extent of increase in expression of the S100A8 and S100A9 was 
seen when monocytes were stimulated with IL-10, either in the presence or absence 
of LPS (Figure 8). Stimulation with IL-4 resulted in a decreased expression of the S100 
molecules.
Figure 8. Effect of cytokines and growth factors on S100A8 and S100A9 expression in in vitro 
cultured monocytes. Healthy peripheral blood monocytes were cultured in medium alone 
(monocytes) or polarized with GM-CSF, M-CSF, IFNγ, IL-4, or IL-10 for 4 days, with or without 
additional LPS stimulation. IL-10 stimulation resulted in the largest extent of increase in S100A8 
(light grey bars) and S100A9 (dark grey bars) mRNA expression, IL-4 stimulation resulted in a 













































Effect of overexpression of S100A8 and S100A9 in human macrophages
Transfection of the pVITRO-S100A8/A9 expression vector into THP-1 monocytic cells 
resulted in a sustained overexpression of S100A8 and S100A9 (Figure 9A). This led to 
de novo IL-10 mRNA expression by the cells for at least four days after the transfection 
(Figure 9B). We also observed an increase of TNFα mRNA after transfection, but the 
extent of upregulation was less pronounced compared to IL-10, and had normalized 
by day four (data not shown).
Figure 9. Effect of S100A8 and S100A9 overexpression upon IL-10 mRNA expression. RNA 
expression levels of S100A8 and S100A9 (A), and IL-10 (B) were measured with qPCR in THP-1 
monocytic cells after transfection with the pVITRO-S100A8/A9 expression vector. Cells were 
transfected with empty vector (mock) or pVITRO-S100A8/A9 expression vector, and incubated 
for 24 hours, 48 hours, 4 days, or 6 days. Mean signal of the mock transfected THP-1 cells with 






































We aimed to study the relevance of intragraft S100A9 and S100A8 expression levels 
as predictive markers for graft outcome and to investigate the mechanism by which 
these molecules exert their biologic effects. In this study we show that determination 
of S100A8 and S100A9 expression levels in renal allograft tissue is clinically relevant 
and may be used for assessing the risk of adverse graft outcome.
It has been shown that increased serum levels 18;19 of S100A9 and S100A8 are 
associated with the occurrence of AR. In line with this, we found significantly higher 
S100A9 and S100A8 expression in biopsy samples from patients with histologically 
proven AR compared with patients having taken biopsy specimens that showed 
no signs of AR (Figure 1). As S100A9 and S100A8 are mainly expressed during the 
early stages of monocyte/macrophage differentiation 13;15, the observed increase in 
expression is likely a reflection of the infiltration of recipient-derived myeloid cells 
into the allograft during AR. This was indeed confirmed by immunohistochemistry 
for the S100 proteins.
We showed that during acute rejection intragraft expression of S100A9 and 
S100A8 was significantly higher in patients who retained their graft long-term than in 
patients who lost their graft over time (Figures 2 and 3). Graft survival of the patients 
in the S100A9high group was similar to that of patients who had received a kidney 
transplant within the same time period and did not experience an AR episode. The 
high correlation between S100A9 and S100A8 expression levels points toward co-
expression of the two genes in the graft. These observations confirm and extend 
the data from a previous patient cohort 11. Overall, the results suggest that intragraft 
S100A9 and S100A8 expression during AR within the first months after transplantation 
provides prognostic information for the patient with respect to graft survival.
We also investigated the expression of FoxP3, IL-10, and KIM-1. FoxP3 is expressed 
by regulatory T cells, which play an important role in suppressing immune responses 
and immunologic tolerance after organ transplantation 33;34. Multiple studies have 
shown that FoxP3 expression was significantly higher among renal allograft recipients 
with AR who had stable graft function than in patients who eventually showed graft 
loss 35;36. Similarly, expression of the anti-inflammatory cytokine IL-10 was found to 
be increased in renal allograft recipients with stable graft function compared with 













































relatively high S100A9 expression and favorable graft outcome showed significantly 
higher expression of the FoxP3:CD3e ratio and IL-10 (Figure 3), and at the same time 
lower expression of markers reflecting total T cell burden (CD3, CD4) in the graft. 
S100A9high expressers also expressed significantly lower levels of KIM-1, which is a 
transmembrane receptor on proximal tubules that is upregulated during acute and 
chronic kidney injury 38. Urinary KIM-1 expression is associated with renal function 
decline and graft failure 39. Our findings suggest that patients with relatively high 
S100A9 and S100A8 expression during acute rejection have improved graft survival 
due to increased local regulation of the immune response and less renal allograft 
damage. Compared to biopsies with no or minimal inflammatory infiltrate, S100A8 
and S100A9 expression was elevated in biopsies with subclinical rejection (Figure 
1). We propose that inflammatory infiltrate during acute rejection episodes, which 
contains relatively low numbers of S100-positive myeloid cells, are resolved less 
adequately and/or persist in the graft for prolonged time. Studies with sequential 
protocol biopsies during the first year after transplantation have shown that 
(untreated) subclinical inflammation and subclinical acute rejection resulted into 
increased interstitial fibrosis and tubular atrophy 40-42, which account for chronic 
allograft dysfunction and graft loss.
Immunohistochemical triple labeling experiments showed that S100A9 protein 
is expressed by CD68+ cells in the tubulointerstitial compartment (Figure 7), which 
was also previously suggested to be the case based on stainings for these markers on 
sequential tissue sections 26;43. Myeloid cells comprise a heterogeneous cell population 
with both pro- and anti-inflammatory subtypes 44-49. S100A9-positive cells in the 
grafts to a large extent seem to represent a myeloid cell subset with distinct effects 
from those of CD163-positive cells. CD163 has previously been proposed as a marker 
of anti-inflammatory macrophages 50;51. However, our observation that patients with 
high CD163 expression in situ have a higher risk of losing their graft compared to 
patients with low expression (Figure 5) rather point toward CD163 as a marker of 
activated macrophages 52;53. Further data from cultured macrophages supported our 
in vivo finding that high S100A8/A9 expression associates with immunoregulation. 
S100A9 and S100A8 were mainly expressed by IL-10 polarized macrophages (Figure 
8), which are known for their immunoregulatory properties 28. Vice versa, we showed 
that overexpression of the S100A8 and S100A9 genes in the monocytic cell line THP-1 





































Overall, this shows that there may be a positive feedback loop between IL-10 and 
maintenance of high S100 levels. These findings provide support that renal allograft 
survival is dependent on the presence of different macrophage subtypes within the 
graft.
The biologic effects of S100A9 and S100A8 in disease are dual and concern both 
pro- and anti-inflammatory activities 54;55. The S100 proteins can act as ligands for 
Toll-like receptor 4, driving progression of septic shock 56 and autoimmune disease 
57. On the other hand, the S100 proteins can mediate wound repair 58 and regulate 
accumulation of myeloid-derived suppressor cells that are capable of inhibiting T 
cell responses 59;60. S100A8 and S100A9 proteins may potentiate activation of the 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 29;61;62. The NADPH 
oxidase is a multi-unit enzyme complex expressed by phagocytic cells like monocytes 
and macrophages, which generates reactive oxygen species (ROS) upon activation. 
ROS acts physiologically as a signaling molecule, which at low amounts can result in 
immune regulation 63;64. Kraaij and colleagues have shown that macrophage-derived 
ROS can suppress T cell responses via the induction of regulatory T cells 64. An 
essential factor in the formation and activation of NADPH oxidase is arachidonic acid 
65. S100A9 and S100A8 bind and transfer arachidonic acid to the membrane-bound 
NADPH oxidase 61. Overexpression of S100A8/A9 in epithelial cells and B lymphocytes 
results in increased activation of NAPDH oxidase and ROS generation 29;62. Based on 
previous studies and current findings, we hypothesize that increased S100A9 and 
S100A8 expression during AR leads to increased ROS production by myeloid cells and 
induction of regulatory immune mechanisms.
Our study shows that determination of S100A8 and A9 positive macrophages in 
renal allograft tissue is clinically relevant and may be useful for assessing the risk 
of adverse graft outcome. However, its usefulness is slightly limited by the invasive 
nature of the biopsy procedure. A potential alternative to intragraft assessment may 
be to measure the expression of S100A8 and S100A9 in serum or urine from the 
patients 17. Similar to our findings in the graft, the level of S100 expression in the 
serum may help predict if a patient has high or low risk of adverse graft outcome.
In conclusion, we show that patients with relative high S100A9 and S100A8 
expression during acute rejection have improved graft survival. We found that 
S100A9 and S100A8 are expressed by a subset of myeloid cells. The clinical effect 
may be explained by local effects of S100A8 and S100A9 on regulation of the immune 
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Figure S1: Virtual panel reactive antibodies (PRA) and renal allograft survival. Graft survival 
(censored for death with functioning graft) analyzed in non-immunized renal allograft 
recipients (virtual PRA of 0-5%; straight line) and immunized renal allograft recipients (virtual 
PRA of 6-100%; striped line). Non-immunized patients showed significantly better graft survival 
compared to immunized patients (log-rank = 9.410; P=0.002).
Table S1: Primer sequences








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S4: Association between graft outcome and demographic and clinical data of patients 
with acute renal allograft rejection
Variable 6 year outcome 12 years outcome
 P value P value
Patient age 0.17 0.53
Donor age 0.31 0.10
Year of transplantation 0.69 0.65
Donor type 0.21 0.33
HLA-AB matching 0.44 0.75
HLA-DR matching 0.37 0.55
Virtual PRA 0.002 0.0003
Cold ischemia time 0.40 0.52
Induction therapy 0.96 0.92
Maintenance therapy 0.13 0.06
Delayed graft function 0.08 0.23
C4d staining 0.69 0.99
Interstitial inflammation 0.46 0.42
Tubulitis 0.18 0.32
Intimal arteritis 0.93 0.99
Interstitial fibrosis 0.14 0.17
Tubular atrophy 0.09 0.15































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Summary and general discussion
Kidney transplantation is the preferred renal replacement therapy for patients 
suffering from end-stage renal disease. Unlike other renal replacement therapies, such 
as hemodialysis and peritoneal dialysis, renal transplantation results in the complete 
replacement of the native renal functions 1. Kidney transplantation provides superior 
long-term patient survival compared to dialysis and improves the patient’s quality 
of life 2;3. Despite the success of renal transplantation, the number of transplants 
performed each year is hampered by shortage of donors 1;4. This limitation stresses 
the need to improve long-term graft survival and prevent adverse graft outcome.
The occurrence of acute rejection is one of the most important risk factors for 
adverse graft outcome, as it is associated with reduced graft survival 5-9 and the 
development of chronic transplant dysfunction 10-13. Once the diagnosis acute rejection 
has been made, it remains difficult to predict the risk of graft loss and the response to 
anti-rejection treatment using clinical parameters and histopathologic assessment. 
Availability of biomarkers could provide complementary parameters for assessing 
the risk of adverse graft outcome. Although various markers for graft outcome have 
been proposed 14-23, the heterogeneity in transcriptional regulation observed among 
acute rejection biopsies makes interpretation of the findings difficult. The aim of the 
work described in this thesis was to identify biomarkers during acute rejection, which 
may predict the response to high-dose steroid therapy and renal allograft survival.
Optimization of molecular techniques used for measurement of biomarkers
Molecular techniques are vital for the identification and validation of biomarkers for 
graft outcome. Molecular methods, such as quantitative real-time polymerase chain 
reaction (qPCR) 24-28 and microarray analysis 28-30, offer a rapid, sensitive, and specific 
tool to detect differences between patient groups. The reliability of molecular 
techniques can be affected by the quality and quantity of RNA that is isolated from 
the patient samples 31-33. After kidney transplantation, the most valuable source of 
patient material is biopsy samples. Histopathological evaluation of biopsy samples 
can provide information on the location, severity, and characteristics of inflammatory 
infiltrates present in the renal allograft, which is important for diagnosis of the cause 
of graft dysfunction. In addition, renal biopsies form an important source of patient 
material for RNA extraction and subsequent gene expression analyses. Biopsy cores 





































long. The limited availability of biopsy material and the high sensitivity of molecular 
techniques stress the importance to optimize the yields and quality of RNA obtained 
from the patient samples, and to minimize the extent of RNA degradation. In chapter 
2, we investigated the impact of sample storage on RNA degradation, and compared 
the efficiency of various procedures for obtaining RNA and cDNA.
In order to conserve the renal biopsy samples for the actual biomarker discovery, 
peripheral blood cells were used as a model system for the optimization of the 
molecular techniques. Peripheral blood mononuclear cells (PBMC) and peripheral 
blood lymphocyte (PBL) blasts obtained from healthy individuals form a readily 
available source of RNA for research, and contain a full repertoire of immune cells 
known to infiltrate the graft during an acute rejection episode 14;34;35. The use of PBMC 
and PBL blasts for the optimization experiments also minimized the fluctuations 
in cells composition between test conditions. We and others have observed a 
considerable heterogeneity in the extent and composition of the interstitial cellular 
infiltrate among acute rejection biopsies (see Chapters 3 and 4) 35-37. These differences 
in cell composition could hamper the reliability of the optimization. In addition to the 
potential implications for biomarker discovery after transplantation, our finding may 
also be of interest for other research fields. Peripheral blood cells are frequently used 
for immunological research.
Impact of sample storage on RNA integrity
An essential requisite for the identification of biomarkers is the storage of patient 
material. Even though the storage of patient samples is often required for obtaining 
a meaningful sample cohort, it may also have an impact on RNA integrity. Therefore, 
we determined the impact of sample storage on RNA degradation. We found that 
RNA integrity is maintained during conventional procedures of storing peripheral 
blood cells at -180°C and thawing them thereafter, when compared to RNA extracted 
from freshly isolated cells. Incorporation of benzonase, a recombinant nuclease used 
for prevention of cell clumping 38, in the thawing procedure has no adverse effect on 
the preservation of high-quality RNA. In addition, thawed cells can be stored again in 
RNA-preserving reagents for RNA extraction on a later day. Our findings confirm that 
freezing of patient samples is a good approach to conserve RNA integrity. A limitation 
of our study is that we did not investigate the storage duration. Most frozen samples 













































RNA extraction and cDNA synthesis
Other important aspects affecting the reliability of gene expression profiling are 
the molecular techniques used for RNA extraction and subsequent cDNA synthesis. 
Comparison of five RNA extraction protocols revealed that the yield and quality of 
the isolated RNA was similar for all procedures. When the qPCR signals per nanogram 
of total RNA and convenience are taken into account, the use of NucleoSpin and 
mirVana extraction kits is preferable. However, these RNA extraction kits were not 
yet available at the start of the retrospective cohort studies described in this thesis. 
RNA extraction from the renal allograft biopsies was performed with the RNeasy 
spin columns, which resulted in high yields and high-quality RNA. Comparison of 
protocols for synthesizing cDNA from RNA revealed that the SuperScript III protocol 
provides the highest yields of cDNA. Robust cDNA synthesis increases the sensitivity 
of gene expression measurements.
Impact of RNA degradation on gene expression analysis
Assessment of RNA quality is a critical step for reliable quantification of gene 
expression levels. The integrity of RNA samples is an important element for the overall 
success of RNA-based analyses. We have shown that the RNA quality index (RQI), 
also known as RNA integrity number (RIN), provides a robust and reliable indicator 
of RNA integrity, which corresponds with earlier observations 33;39. To establish the 
effects of RNA degradation, we investigated the impact of RNA integrity on gene 
expression analysis. Our study revealed a negative impact of RNA degradation on 
mRNA expression levels 31-33. When normalized to endogenous reference genes, 
the expression of target mRNA transcripts can reliable be measured in moderately 
degraded RNA samples (RIN of 4 or higher). This finding corresponds with an earlier 
study, in which a RIN of 5 or higher was regarded as suitable for downstream qPCR 
application 31. The use of partly degraded RNA samples may result in suboptimal qPCR 
conditions and reduced sensitivity, which may hamper the measurement of mRNA 
levels from genes that are expressed to low extent, including various cytokines and 
chemokines. Therefore, we recommend the use of high-quality RNA for molecular 
experiments.
Furthermore, we investigated the stability of microRNA transcripts. The studies 
revealed that microRNA expression levels remain relatively stable in degraded RNA. 





































a RIN as low as 2). These observations hold promise for reliable quantification of 
microRNA expression in patient material that is prone to RNA degradation, such 
as urine samples. MicroRNA expression analyses could provide new insights into 
molecular mechanisms, and may lead to novel molecular markers of graft outcome 
after kidney transplantation.
Response to high-dose corticosteroid therapy for treatment of acute rejection
One of the main parameters determining graft outcome after renal transplantation 
is the sensitivity of the patient to high-dose corticosteroid therapy upon an acute 
rejection episode 40-42. Approximately 25 to 30% of first rejection episodes cannot be 
reversed with corticosteroid therapy alone 17;42-45. In such cases of steroid resistance, 
the patient requires more rigorous therapy with anti-lymphocyte antibodies to 
reverse the acute rejection episode. The incomplete restoration of graft function in 
steroid resistant rejection may lead to progression of chronic damage to the graft and 
has a detrimental effect on graft outcome 40-42;45;46.
The therapeutic effects of synthetic glucocorticoids (GC) for the treatment of 
acute renal allograft rejection, such as prednisone and methylprednisolone, are 
mainly attributed to their anti-inflammatory and immunosuppressive effects. They 
protect the allograft by inhibiting T-cell proliferation and cytokine gene transcription. 
The broad spectrum of immunomodulatory effects of GC are exerted through a 
complex system of molecular mechanisms.
Complexity of corticosteroid signaling
The actions of GC are mediated by the intracellular glucocorticoid receptor (GR), a 
ligand-dependent transcription factor of the nuclear receptor superfamily, which 
is ubiquitously expressed in most human cells 47;48. The genomic structure of the 
GR consists of 9 exons (Figure 1) 49-51. Alternative splicing in exon 9 generates two 
C-terminal receptor isoforms, termed GRα and GRβ 49. The predominantly expressed 
GRα is activated by GC binding and mediates most of the known immunomodulatory 
effects, whereas the GRβ isoform expresses a different C-terminal region which 
inhibits GC binding 52-54. The expression of GRβ is induced by cytokines 55. GRβ can 
exert a dominant negative effect upon GRα-induced transcription. However, the 
functional importance of the GRβ isoform has not yet been determined. The GR 













































which directs target gene activation and the interaction with other transcription 
factors; a central DNA-binding domain (DBD), responsible for binding with 
glucocorticoid response elements (GRE) in the promoter region of target genes; and 
a ligand-binding domain (LBD), which contains specific GC and heat shock protein 
(Hsp) binding sites 56-59.
Figure 1. Genomic and protein structure of the human glucocorticoid receptor. The GR gene 
consists of 9 exons and is located in chromosome 5. Exon 1 is untranslated region, exon 2 
codes for the N-terminal domain (NTD), exons 3 and 4 code for the DNA-binding domain 
(DBD), and exons 5 to 9 code for the ligand-binding domain (LBD). The GR gene contains two 
terminal exons 9 (exons 9α and 9β) alternatively spliced to produce the classic GRα and non-
ligand binding GRβ.
After administration, GC diffuse across the cell membrane and bind to the 
cytoplasmic GR. In its ligand-free state, the cytoplasmic GRα is associated with an 
inhibitory complex, in which two Hsp90 molecules and one molecule each of Hsp70 
and FKBP52 are included (Figure 2) 47;51;60. This association stabilizes the hormone-
responsive form of the receptor and inhibits nuclear localization. Upon ligand-
induced activation, the GR dissociates from the molecular chaperone proteins and 
undergoes conformational changes 60-62. This results in a rapid translocation of the 
GC-GR complex to the nucleus, where it regulates the transcription of target genes 
through direct or indirect signaling pathways (see Figure 2).
GR dimers bind via two zinc finger motifs in the DBD to GRE in the promoter region 
of target genes 63-65. To initiate transcription, the GR uses transcriptional activation 
domains, located in the NTD and LBD. The GR interacts with the promoter region 
and recruits transcriptional co-activators and basal transcription machinery to the 





































activator-1 (SRC-1), CREB-binding protein (CBP), and GR-interacting protein 1 (GRP-1), 
which induce histone acetylation and subsequent transcription of anti-inflammatory 
genes (trans-activation) 62;66. Less commonly, the GC-GR complex interacts with 
negative GRE (nGRE), which results in the repression of pro-inflammatory genes 
containing GR-binding sites (cis-repression) 60;61.
The major action of corticosteroids is the indirect suppression (trans-repression) 
of pro-inflammatory genes that are activated during acute rejection 48;50;62;67. The GC-
GR complex interferes with activating transcription factors, such as nuclear factor-
κB (NF-κB), activator protein-1 (AP-1), and cyclic AMP-responsive element-binding 
(CREB), and their transcriptional co-activator molecules. In addition, GR increase the 
transcription of IκB and MAP kinase phosphatase (MKP)-1, which inhibit NF-κB and 
mitogen-activated protein (MAP) kinase, respectively 47;48. Furthermore, activated GR 
recruit histone deacetylase (HDAC)-2 to the activated inflammatory gene complex, 
resulting in deacetylation of nuclear histones and inhibition of gene transcription 
48;50;62. The signaling pathways of the GC-GR complex inhibit the transcription of 
pro-inflammatory molecules, such as cytokines, chemokines, adhesion molecules, 
inflammatory enzymes, and receptors. Alterations in the molecular mechanisms of 
GR signaling may lead to steroid resistance.
Molecular biomarkers of steroid resistance
Prediction of steroid resistance at the time of biopsy could reduce unnecessary 
exposure to high-dose corticosteroids, and prevents irreversible nephron loss during 














































Figure 2. Complexity of corticosteroid signaling pathways. AP-1, activator protein-1; CREB, 
cyclic AMP-responsive element-binding; FKBP, FK506-binding protein; GR, glucocorticoid 
receptor; GRE, glucocorticoid response elements; HDAC-2, histone deacetylase-2; Hsp, heat 
shock protein; IκB, inhibitor of κB; MAP kinase, mitogen-activated protein kinase; MKP-1, 






































To identify cellular and molecular markers associated with steroid resistance during 
acute rejection, we performed retrospective studies in a large cohort of renal 
transplant patients with a first acute rejection episode. In chapter 3, we evaluated a 
broad panel of immunological markers at the RNA level within the renal allografts. The 
selected panel of immune-related genes, which included markers previously reported 
in association with steroid response 14-23;68-70, reflected the full immune repertoire that 
may be present in the grafts. The panel contained cytokines, chemokines, and surface 
and activation markers of various cell types including T cells, macrophages, and B 
cells. We showed that differences in intragraft expression profiles reflect variability 
in the response to anti-rejection treatment with high-dose steroids. We found that 
the combination of T cell activation markers CD25:CD3e ratio and LAG-3 offers an 
improved prognostic value for assessing steroid response, compared to conventional 
clinical parameters and histopathologic assessment. These two signal transduction 
molecules are involved in the regulation of T cells: CD25, the α-subunit of the IL-2 
receptor (IL-2R), is an important regulator of T cell survival and proliferation 71;72, 
while the activation-induced lymphocyte activation gene-3 (LAG-3) is involved in 
the negative regulation of homeostasis and T cell function 73;74. High expression of 
cytotoxic T cells has been associated with resistance to steroid treatment of acute 
renal allograft rejection 16. In addition, T cell characteristics, through disparities in IL-2 
responses, have been correlated with steroid resistance 68-70.
These findings indicate that steroid resistance may reside in specific activated 
T cell populations. However, the prognostic value of the T cell activation markers 
was hampered by the molecular heterogeneity among the biopsy samples with 
acute rejection. This observation may be a reflection of the complexity of the 
mechanisms involved in response to steroid therapy. In contrast, it might also be 
that the differences in T cell characteristics observed between patients with steroid-
refractory and steroid responsive acute rejection are the result of other upstream 
alterations in steroid signaling.
To gain further insight into the mechanisms underlying steroid resistance, and to 
identify novel molecular markers associated with steroid-refractory acute rejection, 
we performed genome wide expression profiling. Data presented in chapter 4 show 
that relatively high intragraft expression of metallothioneins (MT) during acute 













































family were expressed to a significantly higher extent in steroid resistant rejection. 
MT expression was mainly detected in activated macrophages and tubular epithelial 
cells within the kidney. These findings are in line with earlier findings in lung allograft 
recipients 75. Increased percentages of MT-positive macrophages were found in 
transbronchial biopsy samples of lung allograft recipients with steroid-refractory 
acute rejection. MT are cysteine-rich proteins involved in the homeostasis of 
biologically essential metals, of which the regulation of zinc ions is the most important 
63;76-79. By functioning as a zinc-donor or zinc-acceptor, MT can control cellular zinc 
distribution 63;76. Increased intragraft MT expression may lead to removal of zinc ions 
that are normally used in GC signaling (see Figure 3). The binding of activated GR 
to GREs relies on two zinc finger motifs located in the DBD 63-65. Increased MT levels 
may lead to removal of zinc ions complexed in the zinc finger motifs 80;81, preventing 
GR binding to GREs and inhibiting the immunomodulatory effects of trans-activation 
and cis-repression (Figure 3). Another GC signaling pathway that may be affected 
by MT is the zinc-dependent recruitment of HDAC-2 by the GC-GR complex 48;50;62. 
Increased expression of MT may lead to inhibition of the anti-inflammatory effects 
of this process (Figure 3).
Figure 3. Effects of zinc-regulating molecules upon corticosteroid signaling. GR, glucocorticoid 
receptor; GRE, glucocorticoid response elements; HDAC-2, histone deacetylase-2; nGRE, 





































Multivariate analysis of the genome wide expression profiles revealed the 
combination of MT-1 with CYP4A11, TIMP1 and F2R as the best predictive model for 
steroid-refractory acute rejection. This multivariate MT model offers a significantly 
improved prognostic value for assessing responsiveness to steroid therapy compared 
to conventional parameters, and has a slightly higher predictive value than the 
multivariate T cell activation model found in chapter 3. Combination of the two 
models resulted in a superior predictive model with MT-1, TIMP1, F2R, CD25:CD3e 
ratio, and LAG-3 as independent covariates, showing that the models reinforce each 
other’s prognostic value. This finding indicates that there is no association between 
the observed differences in T cell characteristics and the intragraft regulation of zinc 
ions.
Besides MT and T cell activation markers, the combined multivariate model 
contains two other novel markers for steroid resistance: tissue inhibitor of 
metalloproteinase-1 (TIMP1) and coagulation factor II receptor (F2R). TIMP1 has 
been identified as an endogenous inhibitor of matrix metalloproteinases (MMP) 82. 
TIMP1 inhibits MMP activity through coordination of the zinc ions of the MMP active 
site by the conserved cysteine residues in its N- and C-terminal domains 83;84. Similar 
to MT, TIMP1 may diminish the zinc-requiring anti-inflammatory effects of the GR 
through regulation of the intracellular zinc concentrations (Figure 3). In addition, 
more recent studies have implicated TIMP-1 in the regulation of cell growth and 
apoptosis 84, which may influence the effects of GC signaling. F2R is a regulator of 
numerous intracellular signaling pathways, which include NF-κB and MAP kinase 
pathways 85-87. Differences in F2R may influence the pro- and anti-inflammatory 
effects of GC. Further research will be needed to unravel the mechanism through 
which MT-1, TIMP1 and F2R affect the response to steroid therapy.
Finally, we investigated the role of glucocorticoid signaling and drug metabolism as 
predisposing factors towards responsiveness for high-dose steroid therapy during 
acute renal allograft rejection. Genetic polymorphisms in genes involved in these 
processes may explain the differences in response to steroid treatment. Data 
presented in chapter 5 show for the first time that resistance to steroid treatment 
during acute renal allograft rejection may be associated with differences in the drug 
metabolizing enzyme CYP3A5. An adequate response to high-dose steroid therapy 













































and with higher intragraft expression levels of CYP3A5. Carriers of the CYP3A5*1 
variant have been shown to produce high mRNA and protein levels of CYP3A5, while 
individuals homozygous for CYP3A5*3 are low expressors of CYP3A5 88-90. In line 
with earlier findings, we observed genotype-dependent CYP3A5 expression levels 
in biopsies samples obtained during acute renal allograft rejection. This expression 
was mainly detected in inflammatory cells and tubular epithelial cells. A potential 
explanation for this observed correlation may be that CYP3A5*1 expression within 
the graft results in improved metabolism of methylprednisolone into a more effective 
metabolite. This in turn may increase the immunosuppressive effect of the steroid 
therapy (see Figure 4). Alternatively, it may be that toxic side effects of high steroid 
concentration within the allograft are prevented by the higher metabolic capacity of 
the CYP3A5*1 variant, while the anti-inflammatory effects of therapy are preserved. 
Further research will be needed to gain insight into the mechanism for the correlation 
between CYP3A5 and the response to steroid treatment.
Figure 4. Effect of donor CYP3A5*1 gene variant upon corticosteroid signaling. GC, 
glucocorticoids; GR, glucocorticoid receptor.
Polymorphisms in other important drug metabolism-related genes, namely the efflux 
transporter P-glycoprotein (ABCB1) and the drug metabolism regulating pregnane 
X receptor (NR1I2), showed no correlation with response to steroid therapy, 
although polymorphisms in these genes have been associated with differences in 





































with nephrotic syndrome 97. Another important finding is that steroid-refractory 
acute rejection is not correlated with polymorphisms in GC signaling genes. Earlier 
studies have shown that genetic polymorphisms in NR3C1, the gene encoding the 
GR, may alter a patient’s sensitivity to GC 98-102. However, data presented in this thesis 
demonstrate that neither the genotype distribution of NR3C1 nor the intragraft 
expression levels of GR are correlated with the response to methylprednisolone 
during acute rejection. Combined, these findings provide data that gene variations in 
drug metabolism-related genes, but not in the glucocorticoid receptor, predispose to 
responsiveness to steroid therapy.
Clinical implications
The aim of the work described in this thesis was to identify cellular and molecular 
mediators that determine the response to high-dose steroid treatment during acute 
renal allograft rejection. The data from these studies demonstrate that resistance to 
steroid therapy is a complex and multifactorial condition, in which both immunological 
and non-immunological factors can be involved.
Investigations of immune-related biomarkers revealed that both T cells and 
macrophages play an important role in the response to steroid therapy. Renal allograft 
recipients with a steroid-refractory acute rejection episode express higher levels of T 
cells with characteristic activation markers compared to patients who are responsive 
to the treatment of acute rejection. Furthermore, macrophages derived from the 
transplant recipient were found to be an important aspect of the immune-infiltrate 
during acute rejection. The level of MT-expressing macrophages was correlated with 
steroid response. These findings support earlier observations correlating steroid 
resistance with the expression level and characteristics of T cells 16;68-70, and with 
the infiltration of macrophages into the renal allograft 20-23. Earlier studies have also 
described that B cells may play a role in steroid response 14;15. We investigated the 
predictive value of B cell specific transcripts, but found no correlation between the 
expression of B cell related genes and the response to steroid therapy. This is in line 
with earlier attempts to verify the impact of B cells infiltration on treatment response 
during acute renal allograft rejection 103-106. Combined, these findings indicate that 
steroid resistance resides in specific cell populations and is not a feature of all 
lymphocytes. This may guide the therapeutic approaches for treatment of steroid-













































A novel finding of our studies was that zinc regulation may play an important role 
in the response to steroid therapy during acute renal allograft rejection. Expression 
profiling revealed a correlation between steroid responsiveness and the expression 
levels of seven MT-1 family members and TIMP1. Both MT and TIMP1 are cysteine 
rich molecules involved in the regulation of intracellular zinc concentrations 76-79;83;84. 
Increased expression of these molecules may lower the availability of zinc ions 
required during steroid signaling. This may cause inactivation of the DNA binding 
capacity of the GC-GR complex and inhibition of HDAC-2 recruitment, which in turn 
reduces the immunomodulatory effects of the high-dose corticosteroid therapy. 
Renal allograft recipients who express high intragraft levels of MT and TIMP1 
during acute rejection might benefit from extra zinc intake for optimal GC signaling. 
A second, non-immunological factor that may affect GC signaling is the induction 
of metabolic changes in the administered methylprednisolone. Gene variations in 
the drug metabolism gene CYP3A5 expressed in the renal allograft may alter the 
metabolic capacity of CYP3A5, and improve the responsiveness to steroid therapy 
during acute rejection.
Thus, in summary, expression analyses revealed multiple markers which are 
associated with steroid resistant acute rejection. No single biomarker on itself 
predicts the response to steroid treatment with both high sensitivity and high 
specificity. The presence of multiple mechanisms underlying steroid resistance 
probably accounts for the restricted predictive power of single markers. Molecular 
heterogeneity among biopsy samples may also explain the difficulties in validating 
the prognostic value of previously proposed biomarkers for steroid resistance. In 
addition, it demonstrates the importance of using internal and external validation 
techniques to verify the robustness of potential biomarkers.
We also demonstrate that a multivariate prediction model, containing biomarkers 
related to different aspects of GC signaling, offers a superior prognostic value for 
assessing steroid response compared to conventional clinical parameters and 
histopathologic assessment, and to single biomarkers. Combined analysis of the 
intragraft MT-1, TIMP1, F2R, CD25:CD3e ratio, and LAG-3 expression levels can predict 
the responsiveness to high-dose corticosteroid therapy with high sensitivity and high 
specificity. This multivariate approach can identify patients who will not respond to 
steroid treatment and may benefit from immediate anti-thymocyte globulin (ATG) 





































reduce unnecessary exposure of renal allograft recipients to high-dose corticosteroid 
therapy. More importantly, it may help avoid the development and progression of 
irreversible nephron loss during the period that steroid resistant acute rejection 
is undertreated with steroids alone. In addition, our multivariate model provides 
insight into the causative mechanisms in steroid-refractory acute rejection episodes, 
which may guide the development of novel therapeutic approaches. However, our 
multivariate model did not reach one hundred percent specificity and sensitivity for 
the prediction of steroid-refractory acute rejection. This suggests that additional, yet 
unidentified factors influence the response to high-dose steroid treatment of acute 
renal allograft rejection.
Prediction of renal allograft survival: expression of S100 molecules
Using the current diagnostic procedures, it has proven difficult to differentiate 
between renal allograft recipients with a high or low risk for adverse graft outcome. 
Incorporation of molecular markers, determined in transplant biopsy specimens, 
could help to assess the risk of developing AR, and whether such AR episode 
subsequently leads to graft loss over time. Two potential biomarkers for graft 
outcome are members of the S100 family of calcium-binding proteins. S100A8 
and S100A9 are predominantly expressed in myeloid cells, such as neutrophils and 
early stages of monocyte/macrophage differentiation, but are absent in resident 
macrophages and lymphocytes 107-110. S100A8 and S100A9 have been implicated as 
biomarkers for a variety of acute inflammatory disorders, including complications in 
organ transplantation 107;111-113.
In chapter 6, we evaluated the usefulness of intragraft S100A8 and S100A9 
expression levels as prognostic markers for graft outcome. It has been shown that 
increased serum levels of S100A8 and S100A9 may predict the occurrence of acute 
rejection 113;114. In line with these observations, we found increased expression levels 
of S100A8 and S100A9 in biopsy samples with histologically proven acute rejection 
compared with biopsy specimens without signs of acute rejection. As these molecules 
are mainly expressed in myeloid cells, the observed increase in expression likely 
reflects the infiltration of myeloid cells into the graft. This was indeed confirmed 
by analysis of S100A8 and S100A9 protein expression in renal biopsies. Our findings 
indicate that tissue expressed S100A8 and S100A9 are biomarkers of the development 













































Incorporation of biomarkers could help in assessing if an acute rejection episode 
subsequently leads to graft loss over time. We showed that patients with relative 
high S100A8 and S100A9 expression during acute rejection have improved graft 
survival. These observations confirm the data from a previous patient cohort 103. The 
graft survival of patients with high S100 expression was similar to the graft survival of 
transplant recipients who had not experienced an acute rejection episode. Various 
studies have shown that the occurrence of acute rejection within the first few months 
is associated with an increased risk for graft loss. Our findings suggest that intragraft 
expression levels of S100A8 and S100A9 during acute renal allograft rejection may 
provide prognostic information for the patient with respect to graft survival.
The biologic effects of S100A8 and S100A9 in inflammatory disorders are dual 
and involve both pro- and anti-inflammatory actions 115-121. To gain insight into the 
mechanism by which these molecules exert their biologic effects during acute renal 
allograft rejection, we investigated the association of S100 expression with the 
expression of pro- and anti-inflammatory factors. Patients with relatively high S100 
expression and favorable graft outcome showed increased expression of immune 
regulatory markers, and at the same time low expression of markers reflecting kidney 
injury and total T cell burden in the graft, which is in line with earlier observations 
19;122-124. Furthermore, characterization of the S100 positive cell population revealed 
that S100A8 and S100A9 are expressed by a subset of CD68 positive myeloid cells in 
the tubulointerstitial compartment of the kidney. Although CD68 is widely regarded 
as a selective monocyte/macrophage marker 125-128, it can also be expressed by other 
myeloid cell types, such as granulocytes and dendritic cells 129;130. The S100 positive 
cells seem to represent a myeloid cell subset with distinct effects from those of CD163 
positive myeloid cells. CD163 has previously been proposed as a marker of anti-
inflammatory macrophages 131;132. However, our observations point toward CD163 
as a marker of activated macrophages 133;134. We propose that renal allograft survival 
is related to the presence of different myeloid cell subsets within the graft during 
acute rejection, and that high expression of S100 positive cells leads to increased 
local regulation of the immune response and a reduction in renal allograft damage.
Clinical implications
Our study shows that determination of S100A8 and S100A9 expression in renal 





































graft outcome. Screening of intragraft expression levels of S100 molecules may 
provide a complementary approach for diagnosing acute renal allograft rejection, 
and to determine whether such acute rejection episode subsequently leads to graft 
loss over time.
The extent of S100 expression during acute rejection correlates with the patient’s 
risk of renal allograft loss over time. This is of interest in terms of the immunological 
mechanisms involved in the acute rejection episode. We demonstrate that high 
intragraft expression of S100 positive myeloid cells leads to increased local immune 
regulation, accompanied by a decrease in total T cell burden in the graft. This shift 
towards regulation reduces the intensity of the acute inflammatory response directed 
against the renal allograft, which in turn is reflected by a reduction in allograft damage 
and favorable long-term graft outcome. Based on these findings, we hypothesize 
that inflammatory infiltrate during acute rejection episodes, which contain relatively 
low numbers of S100 positive myeloid cells, are resolved less adequately and/or 
persist in the graft for prolonged time. Further studies will be needed to unravel 
the mechanism through which S100A8 and S100A9 positive myeloid cells induce the 
observed immunomodulatory effects.
Thus, in summary, the identification of S100A8 and S100A9 as predictive markers 
for adverse graft outcome could lead to improved monitoring and intervention 
strategies after renal transplantation, and may contribute to improved long-term 
renal allograft outcome.
Strengths and considerations of study design
Although various cellular and molecular markers have been proposed as prognostic 
biomarkers for renal allograft outcome 14-23, heterogeneity in transcriptional 
regulation observed among acute rejection biopsies makes interpretation of the 
findings difficult. The prognostic value of earlier proposed biomarkers could not be 
verified in later studies 103-106. Important aspects that may influence the reproducibility 
of biomarker identification are differences in patient cohort characteristics (such 
as type of immune suppression, and the time between transplantation and the 
rejection episode), clinical endpoint definition, sample processing, and the molecular 
techniques used for expression analysis. This stresses the importance of the study 
design for the reliable and sensitive identification of biomarkers for renal allograft 













































strict inclusion criteria, clinical endpoint definitions, and quality controls for sample 
processing and expression assays.
Due to that the main focus of our research was on the response to 
corticosteroid therapy, we only included patients who received pulse therapy with 
methylprednisolone as anti-rejection treatment. Furthermore, to prevent effects of 
anti-rejection treatment upon the composition of the renal allograft, only patients 
from whom renal biopsies had been obtained prior to the start of anti-rejection 
treatment were included. In addition, we excluded patients who received ATG as 
induction therapy because of the long-lasting alterations in lymphocyte subset 
composition induced by ATG therapy 135.
Another factor that affects the interpretation of biomarker discovery findings is 
the definition of clinical endpoints. The definition of steroid resistance varies widely 
between studies, and frequently cases of steroid-refractory rejection are poorly 
defined 14-23. To improve the reproducibility of our findings, we used a stringent clinical 
endpoint definition. Steroid resistant acute rejection was defined as lack of clinical 
response to steroid pulse therapy with methylprednisolone, and a requirement for 
ATG treatment within 14 days after the start of the steroid therapy. Response to 
steroid therapy was monitored by serum creatinine concentration measurements 
and was defined as decrease in creatinine level to within 120% of the pre-rejection 
baseline value. This definition of steroid resistance is similar to the clinical endpoint 
definition used in earlier studies 21;106;136;137. To ensure a reliable distinction between 
steroid-resistant and steroid-responsive cases, we set a minimal time period of five 
days before assessing the response to steroids 43.
As previously indicated, the reliability of biomarker discovery can be affected by 
the quality of the molecular techniques used for sample processing and expression 
analysis. In our retrospective cohort studies, we performed stringent controls to 
ensure the quality of our measurements. Biopsy samples with very low RNA yield 
or severe RNA degradation were excluded from the study. To ensure high sensitivity 
of qPCR measurements, all primer sets were tested for optimal performance before 
use, and melting curve analysis was used for assessment of the characteristics of each 
PCR amplicon. Suboptimal qPCR results were excluded from the study. For reliable 






































Possible immune mechanisms of S100A8 and S100A9
The identification of S100A8 and S100A9 as prognostic biomarkers for adverse 
graft outcome could lead to improved long-term renal allograft survival. However, 
the immune mechanisms through which the S100 molecules induce this effect 
have not yet been uncovered. S100A8 and S100A9 may potentiate activation of 
the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase of phagocytic 
cells like monocytes and macrophages 138-140. Activation of NADPH oxidase leads to 
generation of reactive oxygen species (ROS), which act as signaling molecules and 
may induce immune suppression via the induction of regulatory T cells 141;142. An 
essential factor in the formation and activation of NADPH oxidase is arachidonic 
acid 143. S100A8 and S100A9 bind and transfer arachidonic acid to the membrane-
bound NADPH oxidase 138. Increased expression of S100A8 and S100A9 during acute 
renal allograft rejection could lead to increased ROS production by myeloid cells 
and induction of regulatory immune mechanisms 139;140. This local effect of S100 
molecules on regulation of immune responses may limit renal allograft damage 
and prevent graft loss. Further studies will be needed to elucidate the mechanisms 
through which S100A8 and S100A9 modulate the immune response during acute 
renal allograft rejection.
Non-invasive methods for monitoring of graft outcome
Although evaluation of renal biopsies remains the gold standard for the diagnosis of 
graft outcome, its usefulness is slightly limited by the invasive nature of the biopsy 
procedure. Due to the associated risk of procedural complications, biopsy material 
for diagnosis of acute rejection and performance of molecular analysis is generally 
only taken on clinical indication 144;145. A potential alternative to intragraft assessment 
may be the use of more non-invasive sources of material such as peripheral blood 
and urine. Identification of molecular markers in blood and urine may provide 
means to monitor graft function in time, which could lead to earlier detection of 
graft dysfunction and timely intervention of the immune process. However, it is not 
completely clear whether expression levels of molecular markers in blood or urine 
are as reliable as measurements of molecular markers in renal biopsies.
In addition to monitoring of the expression levels of molecular biomarkers, 













































recipient is responsive to steroid therapy. In vitro tests with PBMC exposed to GC 
have been used to correlate gene expression profiles with clinical disorders, including 
steroid responsiveness 67;146-148. However, the experimental design of these in vitro 
tests varied between studies, and the findings could not always be reproduced. 
Following this strategy, we used in vitro cultures of PBMC to investigate differences 
in response to methylprednisolone exposure. Comparison of molecular transcript 
levels allowed the distinction between responders and non-responders to steroid 
therapy. Further studies will be needed to confirm if in vitro cultures of patient PBMC 
represent a useful indicator of the patient’s response to steroid treatment in vivo.
Validation of the prognostic value of our biomarkers
An essential requirement in biomarker discovery is validation and verification of 
the predictive value of proposed biomarkers. The diagnostic and/or prognostic 
value of biomarkers is generally better in the original patient cohort used for 
biomarker discovery compared to other patient cohorts. Validation techniques are 
used to ensure accurate and appropriate data collection and verify the usefulness 
of proposed biomarkers. We incorporated a variety of validation techniques in 
our retrospective studies to validate the prognostic value of potential biomarkers, 
including cross-validation and the use of a discovery and validation cohort. Although 
these techniques confirm the prognostic value of our univariate and multivariate 
prediction models to a large extend, additional validation studies in unrelated patient 
cohorts will be needed to verify our findings. In addition, the prognostic value of the 
biomarkers should be confirmed in a prospective study before they can be introduced 
into the clinic.
Analysis of microRNA expression
Another target for the identification of potentially informative biomarkers is the 
expression of microRNA transcripts. MicroRNAs are a class of small, non-coding RNA 
molecules that negatively regulate mRNA expression by degradation or translational 
repression 149;150. Since the initial discovery in the early 1990s, over 1,000 microRNA 
transcripts have been identified. It is estimated that expression of more than one third 
of all genes is regulated by at least one microRNA 151;152. In recent years, microRNAs 
have gained interest for their involvement in hematopoiesis and immune cell function 





































expression, microRNAs are emerging as potential biomarkers. Analysis of microRNA 
expression profiles in renal biopsies may lead to the identification of novel prognostic 
biomarkers for the outcome of acute renal allograft rejection.
Conclusion
The results presented in this thesis demonstrate the potential of molecular and 
cellular biomarkers for the diagnosis and prediction of the outcome of acute renal 
allograft rejection. We demonstrated that resistance to steroid therapy is a complex 
and multifactorial condition, in which both immunological and non-immunological 
factors can be involved. The response to high-dose corticosteroid therapy for the 
treatment of acute renal allograft rejection correlates with the expression level 
and characteristics of T cells and macrophages infiltrating into the renal allograft. 
These findings indicate that steroid resistance resides in specific cell populations 
and is not a feature of all lymphocytes. Zinc regulation and drug metabolism may 
play a role in the response to steroid therapy during acute renal allograft rejection. 
Increased expression of zinc-regulating molecules may diminish the zinc-requiring 
anti-inflammatory effects of corticosteroid therapy. Therefore, kidney transplant 
recipients may benefit from additional zinc intake to optimize GC signaling. Genetic 
variations in drug metabolism genes may predispose to the responsiveness to 
steroid therapy during acute rejection. Furthermore, we demonstrated that no 
single biomarker on itself predicts the response to steroid treatment with both high 
sensitivity and high specificity. A multivariate prediction model, containing biomarkers 
related to different aspects of GC signaling, offers the best prognostic value for 
assessing steroid response. Combined analysis of the intragraft MT-1, TIMP1, F2R, 
CD25:CD3e ratio, and LAG-3 expression levels predicts the responsiveness to high-
dose corticosteroid therapy with high specificity and high sensitivity. The prognostic 
value of this multivariate model is superior compared to that of conventional clinical 
parameters and histopathologic assessment, and to single biomarkers. Use of our 
multivariate biomarker model could reduce unnecessary exposure of renal allograft 
recipients to high-dose corticosteroid therapy, and prevent irreversible nephron loss 
during the period that steroid resistant acute rejection is undertreated with steroids 
alone. Finally, we investigated cellular and molecular mediators that may be used to 
predict graft survival. We demonstrated that determination of S100A8 and S100A9 













































the risk of adverse graft outcome. Intragraft S100 expression levels can be used as 
an indicator for the development of acute rejection and for determining risk of renal 
allograft loss over time. High S100A8 and S100A9 expression during acute renal 
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Doel van het proefschrift
Het doel van het in dit proefschrift beschreven onderzoek was om tijdens acute 
donornier afstoting biomarkers te identificeren die de respons op steroïden 
behandeling en niertransplantaatoverleving kunnen voorspellen.
Patiënten met chronische nierinsufficiëntie ervaren een progressief verlies van de 
nierfunctie over een periode van maanden of jaren. Deze chronische achteruitgang 
van de nierfunctie kan leiden tot eindstadium nierfalen, een aandoening waarbij de 
nieren niet meer in staat zijn om voldoende bloed te filteren en het lichaam vloeistoffen 
en schadelijke afvalstoffen behoudt. Deze volledige of bijna volledige uitval van 
nierfunctie is permanent en vereist gewoonlijk nierfunctievervangende therapie. 
De geprefereerde therapie voor patiënten die lijden aan eindstadium nierfalen is 
niertransplantatie. In tegenstelling tot andere nierfunctievervangende therapieën, 
zoals hemodialyse en peritoneaaldialyse, resulteert niertransplantatie in volledige 
vervanging van de autochtone nierfuncties. Daarnaast levert niertransplantatie 
superieure patiëntoverleving en een toename in levenskwaliteit. Ondanks het succes 
van niertransplantatie belemmert een tekort aan donoren het aantal transplantaties 
dat jaarlijks kan worden uitgevoerd. Deze beperking benadrukt de noodzaak om 
de lange termijn overlevingskans van het transplantaat te verbeteren en nadelige 
transplantatie uitkomsten te voorkomen.
Het optreden van acute afstotingsreacties gericht tegen de donornier is een van de 
belangrijkste risicofactoren voor adversieve transplantatie uitkomsten. Acute rejectie 
episodes zijn geassocieerd met een verminderde kans op transplantaatoverleving en 
de ontwikkeling van chronische transplantaat dysfunctie. Na de diagnose van een 
acute rejectie episode blijft het echter lastig om aan de hand van klinische parameters 
en histopathologische bepalingen het risico op nadelige transplantatie uitkomsten 
te voorspellen. De beschikbaarheid van biomarkers kan aanvullende parameters 
bieden voor de beoordeling van het risico op transplantaatverlies en de respons 
op anti-rejectie behandeling. Hoewel er verscheidene markers voor transplantatie 
uitkomst zijn voorgesteld, maakt de heterogeniteit in transcriptionele regulatie die in 





































Optimalisatie van moleculaire technieken gebruikt voor het meten van biomarkers
Moleculaire technieken zijn vitaal voor het identificeren van biomarkers voor 
transplantatie uitkomst. Moleculaire onderzoeksmethoden, zoals kwantitatieve 
polymerase-kettingreactie (qPCR) en microarray analyse, bieden de mogelijkheid 
om snelle, sensitieve, en specifieke bepalingen te doen voor het detecteren van 
verschillen in genexpressie tussen patiëntengroepen. De betrouwbaarheid van 
moleculaire technieken kan beïnvloed worden door de kwaliteit en kwantiteit 
van ribonucleïnezuur (RNA), dat is geïsoleerd van patiëntmonsters. Biopten van 
de donornier zijn de meest waardevolle patiëntmonsters na niertransplantatie. 
Histopathologische evaluatie van biopten kan informatie verschaffen over de 
locatie, ernst en karakteristieken van ontstekingsinfiltraten in de donornier. Deze 
informatie is belangrijk voor diagnose van de oorzaak van transplantaat dysfunctie. 
Daarnaast vormen nierbiopten een belangrijke bron van patiëntmateriaal voor RNA-
extractie en daaropvolgende genexpressie analyses. De tijdens nierbiopsie verkregen 
weefselkernen zijn echter relatief klein; gemiddeld 1 millimeter in diameter en 
maximaal 1 centimeter lang. De gelimiteerde beschikbaarheid van biopsiemateriaal 
en de hoge sensitiviteit van moleculaire technieken benadrukken het belang om 
de opbrengst en kwaliteit van RNA te optimaliseren en om degradatie van RNA te 
minimaliseren.
Hoofdstuk 2 behandelt allereerst het onderzoek naar het effect van de opslag van 
patiëntmateriaal op RNA degradatie, vervolgens de vergelijking van de efficiëntie van 
verschillende procedures voor het verkrijgen van RNA en cDNA en daarna de impact 
van RNA degradatie op genexpressie analyse. Om de nierbiopten te behouden voor 
de uiteindelijke biomarkerontwikkeling, hebben we perifere bloed mononucleaire 
cellen (PBMC) gebruikt als modelsysteem voor het optimaliseren van de moleculaire 
technieken.
Impact van materiaalopslag op RNA integriteit
Ondanks dat opslag van patiëntmateriaal vaak noodzakelijk is voor het verkrijgen 
van een betekenisvol patiëntencohort, kan de opslag mogelijk ook nadelige effecten 
hebben op de integriteit van het RNA in het materiaal. Onze bevindingen tonen aan 
dat de RNA integriteit gewaarborgd blijft tijdens conventionele procedures voor het 
opslaan van perifere bloedcellen, waarbij de cellen worden bevroren tot -180ºC en 













































opnieuw worden opgeslagen in RNA-preserverende reagentia voor RNA-extractie op 
een later tijdstip. Onze bevindingen bevestigen dat het invriezen van patiëntmateriaal 
een goede methode is voor het conserveren van RNA integriteit.
RNA-extractie en cDNA-synthese
Naast de opslag van patiëntmateriaal kunnen ook de moleculaire procedures, gebruikt 
voor RNA-extractie en de hierop volgende cDNA-synthese, de betrouwbaarheid van 
genexpressie analyses beïnvloeden. Vergelijking van vijf RNA-extractie protocollen 
toont aan dat alle procedures een vergelijkbare opbrengst en RNA kwaliteit opleveren, 
waarbij de extractie protocollen zich alleen onderscheiden via lichte verschillen 
in qPCR sensitiviteit en gebruiksgemak. Vergelijk van cDNA-synthese protocollen 
onthult dat het SuperScript III protocol de hoogste cDNA opbrengst biedt. Robuuste 
cDNA-synthese verhoogt de sensitiviteit van genexpressie metingen.
Impact van RNA degradatie op genexpressie analyse
Evaluatie van RNA kwaliteit is een cruciale stap voor betrouwbare kwantificatie van 
genexpressieniveaus. De integriteit van RNA-monsters is een belangrijk element 
voor het algehele succes van op RNA gebaseerde analyses. Ons onderzoek naar de 
impact van RNA integriteit op genexpressie analyse toont aan dat RNA degradatie 
een negatief effect heeft op mRNA expressieniveaus. Gebruik van referentiegenen 
voor de normalisatie van genexpressie data maakt het mogelijk om betrouwbare 
mRNA niveaus te meten in RNA-monsters met matige degradatie. Echter, het gebruik 
van deels afgebroken RNA kan resulteren in suboptimale qPCR conditie en leiden tot 
verlaagde sensitiviteit.
Naast de impact van RNA degradatie op de stabiliteit van mRNA expressie 
metingen hebben we de stabiliteit van microRNA transcripten onderzocht. Uit onze 
studies blijkt dat microRNA expressieniveaus relatief stabiel blijven in gedegradeerd 
RNA. Kwantificatie van microRNA transcripten kan betrouwbaar worden uitgevoerd 
in ernstig aangetaste RNA-monsters. Deze observaties tonen de potentie voor het 
meten van microRNA expressieniveaus in patiëntmonsters met een verhoogde kans 





































Response op hoge dosis corticosteroïden therapie voor de behandeling van acute 
rejectie
Een van de belangrijkste parameters die transplantaatoverleving na niertransplantatie 
bepaalt, is de gevoeligheid van de patiënt voor steroïden therapie tijdens acute 
donornier afstoting. Ongeveer 25 tot 30% van de eerste afstoting episodes 
kan niet worden onderdrukt met enkel corticosteroïden behandeling. In deze 
gevallen van steroïden resistentie heeft de patiënt een sterkere behandeling met 
antithymocytenglobuline (ATG) nodig voor het onderdrukken van de acute rejectie 
episode. Het onvolledig herstel van de donornierfunctie in steroïden resistente 
rejectie kan leiden tot progressie van chronische transplantaatschade en heeft een 
nadelig effect op transplantatie uitkomst.
Het therapeutische effect van synthetische glucocorticoiden (GC) voor de 
behandeling van acute donornier afstoting, zoals prednison en methylprednisolon, 
wordt vooral toegeschreven aan hun anti-inflammatoire en immunosuppressieve 
effecten. Het brede spectrum aan immuun modulerende effecten van GC komt voort 
uit een complex systeem van moleculaire mechanismen.
Complexiteit van corticosteroïden signalering
De effecten van GC worden aangestuurd door de intracellulaire glucocorticoid 
receptor (GR), welke door bijna alle menselijke cellen tot expressie wordt gebracht. 
Door alternatieve gensplitsing kunnen twee isovormen van de GR ontstaan, 
genaamd GRα and GRβ. De overwegend geëxpresseerde GRα wordt geactiveerd 
door GC binding en zorgt voor de meeste immunomodulatoire effecten, terwijl de 
GRβ isovorm mogelijk leidt tot inhibitie van GC binding. Het functionele belang van 
de GRβ isovorm is echter nog niet vastgesteld.
In ligand-vrije vorm is de cytoplasmatische GRα gebonden aan een inhiberend 
eiwitcomplex (zie figuur 1). Deze associatie stabiliseert de hormoonresponsieve 
vorm van de receptor en inhibeert lokalisatie naar de celkern. GC diffuseren door 
het celmembraan en binden aan de GR. Na deze ligand-geïnduceerde activatie 
dissocieert de GR van het inhiberende eiwitcomplex en ondergaat conformationele 
veranderingen. Dit resulteert in een snelle translocatie van het GC-GR complex 
naar de celkern, waar het gentranscriptie reguleert via zowel directe als indirecte 
signaleringsroutes (zie figuur 1). GR-dimeren binden via zogeheten “zinc-finger” 













































glucocorticoid response elementen (GRE) in de promotorregio’s van specifieke 
immuungenen. Deze interactie rekruteert transcriptionele co-activatoren en 
transcriptie-eiwitten naar de startlocatie voor gentranscriptie. De co-activatoren 
induceren histone acetylatie in het DNA en daarop volgend de transcriptie van anti-
inflammatoire genen. Minder vaak gaat het GC-GR complex interacties aan met 
negatieve GRE (nGRE), welke resulteren in de onderdrukking van pro-inflammatoire 
genen.
Het belangrijkste effect van corticosteroïden is de indirecte suppressie van pro-
inflammatoire genen, die geactiveerd worden tijdens acute transplantaat afstoting 
(zie figuur 1). De GC-GR complexen interfereren met activerende transcriptiefactoren, 
zoals nuclear factor-κB (NF-κB), activator protein-1 (AP-1), en cyclic AMP-responsive 
element-binding (CREB), en hun transcriptionele co-activatie moleculen. Daarnaast 
zorgt GR voor verhoogde transcriptie van IκB en MAP kinase phosphatase (MKP)-
1, welke respectievelijk leiden tot inhibitie van NF-κB en mitogen-activated 
protein (MAP) kinase. Verder leidt activatie van de GR tot rekrutering van histone 
deacetylase (HDAC)-2 naar geactiveerde inflammatoire genen, wat resulteert 
in deacetylatie van nucleaire histonen en de inhibitie van gentranscriptie. Deze 
indirecte signaleringsroutes van het GC-GR complex onderdrukken de transcriptie 
van pro-inflammatoire moleculen, zoals cytokines, chemokines, adhesie moleculen, 
inflammatoire enzymen en receptoren. Veranderingen in de moleculaire 





































Figuur 1. Complexiteit van corticosteroïden signaleringsroutes.
Moleculaire biomarkers voor steroïden resistentie
Voorspelling van steroïden resistentie kan onnodige blootstelling aan hoge dosissen 
corticosteroïden verminderen en onomkeerbare schade aan nefronen in de 
donornier, die optreedt tijdens de periode waarin de acute afstoting onderbehandeld 














































Voor het identificeren van cellulaire en moleculaire markers, die geassocieerd zijn 
met steroïden resistentie tijdens acute donornier afstoting, hebben we retrospectieve 
studies uitgevoerd in een groot cohort van niertransplantatie patiënten met 
een eerste acute rejectie episode. In hoofdstuk 3 evalueren we de genexpressie 
van een breed panel van immunologische markers in niertransplantaten. Het 
geselecteerde panel van immuun-gerelateerde genen, welke markers bevat die in 
eerdere studies zijn geassocieerd met gevoeligheid voor steroïden, reflecteert het 
volledige immuunrepertoire dat in het transplantaat aanwezig kan zijn. Het panel 
bevat cytokines, chemokines, en oppervlakte- en activatie-markers van verscheidene 
celtypen, zoals T-cellen, macrofagen en B-cellen. Onze studie toont aan dat 
verschillen in expressie profielen gemeten in niertransplantaten een reflectie geeft 
van de variabiliteit in de response op anti-rejectie behandeling met steroïden. We 
hebben gevonden dat de combinatie van T-cel activatie markers CD25:CD3e ratio en 
lymfociet activatie gen-3 (LAG-3) een verbeterde prognostische waarde biedt voor 
het bepalen van respons op steroïden in vergelijking met conventionele klinische 
parameters en histopathologische bepalingen. Deze twee signaaltransductie 
moleculen zijn betrokken bij de regulatie van T-cellen: CD25, de α-subunit van de 
IL-2 receptor (IL-2R), is een belangrijke regulator van T-cel overleving en proliferatie, 
terwijl het activatie-geïnduceerde LAG-3 betrokken is bij de negatieve regulatie van 
homeostase en T-cel functie. Hoge expressie van cytotoxische T-cellen is in eerdere 
studies gekoppeld aan resistentie tegen steroïden behandeling van acute donornier 
afstoting. Daarnaast zijn de karakteristieken van de T-cel, door verschillen in reacties 
op IL-2, gecorreleerd met steroïden resistentie.
Deze bevindingen wijzen erop dat de oorzaak van steroïden resistentie zich 
mogelijk in specifieke geactiveerde T-celpopulaties kan bevinden. De prognostische 
waarde van de T-cel activatie markers word echter verstoord door heterogeniteit 
in transcriptionele regulatie in de biopten met acute donornier afstoting. Deze 
observatie is mogelijk een reflectie van de complexiteit in de mechanismen 
betrokken bij de response op steroïden therapie. Daarentegen kan het ook zijn dat 
de verschillen in T-cel eigenschappen, die zijn waargenomen tussen patiënten met 
steroïden resistente en steroïden responsieve acute afstoting, het resultaat zijn van 





































Om verder inzicht te krijgen in de onderliggende mechanismen van steroïden 
resistentie, en om nieuwe moleculaire markers geassocieerd met steroïden 
resistente acute afstoting te identificeren, hebben we genoomwijde expressie 
profilering uitgevoerd. In hoofdstuk 4 laten we zien dat relatief hoge expressie 
van metallothioneins (MT) in de donornier tijdens acute afstoting geassocieerd is 
met steroïden resistentie. Zeven leden van de MT-1 gen familie worden significant 
hoger tot expressie gebracht tijdens steroïden resistente donornier afstoting. MT 
expressie word voornamelijk gedetecteerd in geactiveerde macrofagen en tubulaire 
epitheelcellen in de nier. Deze bevindingen zijn in lijn met eerdere bevindingen 
in longtransplantatie patiënten, waar verhoogde percentages van MT-positieve 
macrofagen werden gevonden in transbronchiale biopsie weefselmonsters van 
patiënten met steroïden resistente acute donorlong afstoting. MT zijn cysteïne-rijke 
eiwitten die betrokken zijn bij de homeostase van biologisch essentiële metalen, 
waarvan de regulatie van zinkionen de belangrijkste is. Door te functioneren als 
een zinkdonor of zinkontvanger kunnen MT de cellulaire zinkdistributie reguleren. 
Verhoogde MT expressie in de donornier kan resulteren in het verwijderen van 
zinkionen, die normaal worden gebruikt in GC-signalering. Het kan leiden tot 
verwijdering van zinkionen uit de zinc-finger motieven, waardoor de binding van 
GR aan GREs voorkomen wordt en de immunomodulerende effecten geïnhibeerd 
worden. Een andere GC-signaleringsroute die beïnvloed kan worden door MT is de 
zink-afhankelijke recrutering van HDAC-2 door het GC-GR complex. Verhoogde MT 
expressie kan mogelijk leiden tot inhibitie van de anti-inflammatoire effecten van dit 
proces.
Multivariate analyse van de expressie profielen heeft onthuld dat de combinatie 
van MT-1 met CYP4A11, TIMP1 en F2R het best voorspellende model vormt voor 
steroïden resistente acute donornier afstoting. Dit multivariate MT model biedt een 
aanzienlijk verbeterde prognostische waarde voor de beoordeling van responsiviteit 
op steroïden therapie in vergelijking met conventionele parameters en biedt een 
iets hogere voorspellende waarde dan het multivariate T-cel activatie model dat 
in hoofdstuk 3 is gevonden. Combinatie van de twee modellen resulteert in een 
superieur voorspellend model met MT-1, TIMP1, F2R, CD25:CD3e ratio en LAG-3 
als onafhankelijke covariaten. Hieruit blijkt dat de modellen elkaars prognostische 
waarde versterken en er geen verband is tussen de waargenomen verschillen in T-cel 













































Naast MT-1 en de T-cel activatie markers bevat het gecombineerde multivariate 
model twee andere nieuwe markers voor steroïden resistentie: tissue inhibitor 
of metalloproteinase-1 (TIMP1) en coagulatie factor II receptor (F2R). TIMP1 is 
een cysteïne-rijk eiwit, dat matrix metalloproteinases remt via de coördinatie van 
zinkionen. Vergelijkbaar met MT kan TIMP1 mogelijk de zink-afhankelijke anti-
inflammatoire effecten van het GC-GR complex verminderen door de intracellulaire 
zinkconcentraties te reguleren. Daarnaast hebben recente studies TIMP1 geïmpliceerd 
in de regulatie van celgroei en apoptose, wat de effecten van GC-signalering kan 
beïnvloeden. F2R is een regulator van talrijke intracellulaire signaleringsroutes, 
waaronder de NF-κB en MAP kinase routes. Verschillen in F2R expressie kunnen 
mogelijk de pro- en anti-inflammatoire effecten van GC beïnvloeden. Verder 
onderzoek is nodig om de specifieke mechanismen te ontrafelen waarmee MT-1, 
TIMP1 en F2R invloed hebben op de respons op corticosteroïden therapie.
Verder is ons onderzoek gericht op de rol van DNA variaties in genen betrokken bij 
glucocorticoïden signalering en medicijn metabolisme als predisponerende factoren 
voor steroïden responsiviteit. Enkel-nucleotide polymorfie in deze genen kan leiden 
tot verschillen in respons op steroïden behandeling. In hoofdstuk 5 laten we zien dat 
steroïden responsiviteit tijdens acute donornier afstoting alleen afhankelijk is van 
genetische variatie in CYP3A5, een enzym dat betrokken is bij het metabolisme van 
ongeveer 50% van alle medicijnen. Een adequate reactie op steroïden behandeling 
is geassocieerd met expressie van de CYP3A5*1 genvariant in het donorweefsel. 
Dragers van de CYP3A5*1 variant hebben hogere expressie van het CYP3A5 enzym in 
vergelijking met individuen die homozygoot zijn voor de veel voorkomende CYP3A5*3 
genvariant. Deze expressie wordt voornamelijk gedetecteerd in ontstekingscellen 
en tubulaire epitheelcellen in de donornier. Een mogelijke verklaring voor deze 
waargenomen correlatie kan zijn dat CYP3A5*1 expressie in het transplantaat leidt 
tot verbeterde omzetting van methylprednisolon in een effectievere metaboliet, 
wat het immunosuppressieve effect van de steroïden behandeling kan verhogen. 
Een andere mogelijkheid is dat de hogere metabolische CYP3A5*1 variant toxische 
bijwerkingen van hoge steroïden concentraties in het transplantaat voorkomt, terwijl 
de anti-inflammatoire effecten van de therapie bewaard blijven. Verder onderzoek is 
nodig om inzicht te krijgen in het mechanisme voor de correlatie tussen CYP3A5 en 





































Klinische implicaties van biomarkers voor response op steroiden therapie
Onze studies tonen aan dat steroïden resistentie een complexe en multifactoriële 
aandoening is, waarbij zowel immunologische en niet-immunologische factoren 
betrokken kunnen zijn. Onderzoek naar immuun-gerelateerde biomarkers 
demonstreert dat zowel T-cellen en macrofagen een belangrijke rol spelen bij de 
respons op steroïden therapie. Niertransplantatie patiënten met een steroïden 
resistente acute rejectie episode hebben hogere expressieniveaus van T-cellen met 
karakteristieke activatie markers vergeleken met patiënten die goed reageren op 
steroïden behandeling. Daarnaast blijken macrofagen, afkomstig van de transplantaat 
ontvanger, een belangrijk component te zijn van het immuun-infiltraat tijdens 
acute afstoting. Hierbij correleert het niveau van MT-expresserende macrofagen 
in het infiltraat met de respons op steroïden behandeling. Verder is er, ondanks 
aanwijzingen in eerdere studies, geen correlatie gevonden tussen B-cel infiltratie en 
de respons op steroïden. Gecombineerd toont deze data aan dat steroïden resistentie 
gevestigd is in specifieke celpopulaties en geen kenmerk is van alle lymfocyten. Deze 
bevindingen kunnen sturing geven aan de toekomstige therapeutische benaderingen 
voor de behandeling van steroïden resistente acute donornier afstoting.
Een nieuwe bevinding van ons onderzoek is dat regulatie van zinkionen een 
belangrijke rol speelt in de reactie op steroïden behandeling. De response op 
steroïden therapie tijdens acute donornier afstoting correleert met de expressie 
van MT-1 familieleden en TIMP1, die via hun cysteïne rijke molecuulstructuur 
betrokken zijn bij de regulatie van intracellulaire zinkconcentraties. Verhoogde 
expressie van deze moleculen kan de beschikbaarheid van zinkionen, vereist 
tijdens steroïden signalering, verlagen. Dit kan leiden tot inactivatie van de DNA-
bindingscapaciteit van het GC-GR complex en remming van HDAC-2 werving, wat 
vervolgens de immunomodulerende effecten van de steroïden therapie vermindert. 
Niertransplantaat ontvangers, die tijdens acute afstoting hoge niveaus van MT en 
TIMP1 tot expressie brengen in de donornier, kunnen mogelijk profiteren van extra 
zink inname voor een optimale GC-signalering. Een tweede niet-immunologische 
factor, die GC-signalering kan beïnvloeden, is de inductie van metabole veranderingen 
in de toegediende methylprednisolon. Expressie van genetische variaties in het 
metabolisme gen CYP3A5 in de donornier kan de metabole capaciteit van CYP3A5 














































Samengevat, onze studies hebben meerdere markers onthuld, die geassocieerd 
zijn met steroïden resistente acute donornier afstoting. De aanwezigheid van 
meerdere mechanismen die ten grondslag liggen aan steroïden resistentie is 
waarschijnlijk bepalend voor de beperkte voorspellende kracht van op zichzelf staande 
markers. Daarnaast kan de geobserveerde moleculaire heterogeniteit onder biopsie 
weefselmonsters ook verklaren waarom het moeilijk is gebleken om de prognostische 
waarde van eerder voorgestelde biomarkers te bevestigen. Wij demonstreren dat een 
multivariaat voorspellingsmodel, waarin biomarkers zijn opgenomen die betrekking 
hebben tot verschillende aspecten van GC-signalering, een superieure prognostische 
waarde biedt voor de beoordeling van steroïden respons ten opzichte van zowel 
conventionele parameters als losstaande biomarkers. Deze multivariate benadering 
kan worden gebruikt om patiënten te identificeren, die niet reageren op behandeling 
met steroïden en die kunnen profiteren van directe behandeling met ATG. Echter, 
de specificiteit en sensitiviteit van ons multivariate model liggen onder de honderd 
procent voor het voorspellen van steroïden resistente acute afstoting. Dit suggereert 
dat aanvullende, nog te identificeren factoren invloed hebben op de respons op hoge 
dosis steroïden behandeling van acute donornier afstoting.
Voorspelling van niertransplantaatoverleving: expressie van S100 moleculen
Gebruikmakend van de huidige diagnostische procedures is het lastig om onderscheid 
te maken tussen patiënten met een hoog of laag risico op nadelige transplantatie 
uitkomsten. Incorporatie van biomarkers kan bijdragen tot de voorspelling van 1) het 
risico op ontwikkeling van acute afstoting en 2) of een dergelijke acute rejectie episode 
na verloop van tijd leidt tot transplantaatverlies. Twee potentiële biomarkers voor 
transplantatie uitkomst zijn S100A8 en S100A9. Deze leden van de S100 familie van 
calciumbindende eiwitten worden voornamelijk tot expressie gebracht in myeloïde 
cellen en zijn in eerdere studies geïmpliceerd als mogelijke biomarkers voor een 
verscheidenheid aan acute inflammatoire aandoeningen, waaronder complicaties bij 
orgaantransplantatie.
Hoofdstuk 6 behandelt ons onderzoek naar de potentie van in de donornier 
gemeten expressieniveaus van S100A8 en S100A9 als prognostische markers voor 
ongewenste uitkomsten na niertransplantatie. Eerdere studies hebben laten zien 
dat verhoogde serumspiegels van S100A8 en S100A9 mogelijk het optreden van 





































onze studie aan dat donornierbiopten met histologisch bewezen acute afstoting 
verhoogde expressie van S100A8 en S100A9 hebben ten opzichte van biopten zonder 
tekenen van acute afstoting. Onze bevindingen tonen dat de expressieniveaus van 
S100A8 en S100A9 in de donornier biomarkers zijn voor de ontwikkeling van acute 
niertransplantaat afstoting.
Verdere analyse van S100 expressie binnen de patiëntenpopulatie met histologisch 
bewezen acute afstoting demonstreert dat relatief hoge S100A8 en S100A9 expressie 
tijdens acute afstoting correleert met betere transplantaatoverleving over de tijd. 
Deze waarnemingen bevestigen data afkomstig van een eerder patiëntencohort. De 
transplantaatoverleving van patiënten met hoge S100 expressie is vergelijkbaar met 
de transplantaatoverleving van ontvangers die geen acute rejectie episode hebben 
ervaren. Diverse studies hebben aangetoond dat het optreden van acute afstoting 
tijdens de eerste paar maanden na transplantatie is geassocieerd met een verhoogd 
risico op transplantaatverlies. Onze bevindingen suggereren dat de expressieniveaus 
van S100A8 en S100A9 gemeten in de donornier tijdens acute afstoting prognostische 
informatie geeft over lange termijn transplantaatoverleving.
Om inzicht te krijgen in het mechanisme, waarmee deze moleculen hun biologische 
effecten uitoefenen tijdens acute donornier afstoting, hebben we de associatie van 
S100 expressie met de expressie van pro- en anti-inflammatoire factoren onderzocht. 
Patiënten met relatief hoge S100 expressie en gunstige transplantatie uitkomst tonen 
verhoogde expressie van immuunregulerende markers en tegelijkertijd lage expressie 
van markers die nierschade en inflitratie van T-cellen in de donornier reflecteren. 
Deze bevindingen zijn in lijn met observaties in eerdere studies. Karakterisering van 
de S100 positieve celpopulatie onthult dat S100A8 en S100A9 tot expressie worden 
gebracht door een subset van CD68 positieve myeloïde cellen in de nier. Hoewel CD68 
algemeen wordt beschouwd als een selectieve monocyten/macrofagen marker, kan 
het ook worden geëxpresseerd door andere myeloïde celtypes, zoals granulocyten 
en dendritische cellen. De S100 positieve cellen lijken een subgroep van myeloïde 
cellen te vertegenwoordigen, die andere immuunregulerende effecten heeft op 
de immuunrespons dan eerder beschreven CD163 positieve anti-inflammatoire 
macrofagen. Op basis van deze bevindingen stellen wij dat de overlevingskans van de 
donornier afhangt van de aanwezige myeloïde cel subgroepen in het transplantaat 
tijdens acute afstoting en dat hoge expressie van S100 positieve cellen leidt tot lokale 













































Klinische implicaties van S100 moleculen als biomarkers voor transplantaat-
overleving
Onze studie toont aan dat het bepalen van S100A8 en S100A9 expressie in 
donornierweefsel klinisch relevant is en gebruikt kan worden voor het inschatten 
van het risico op een nadelige transplantatie uitkomst. Screening van de S100 
expressieniveaus in de donornier kan een complementaire aanpak bieden voor het 
diagnosticeren van acute donornier afstoting en om te bepalen of een dergelijke acute 
rejectie episode na verloop van tijd tot transplantaatverlies leidt. De omvang van 
S100 expressie tijdens acute afstoting biedt daarnaast inzage in de immunologische 
mechanismen, die betrokken zijn bij de acute rejectie episode. We tonen aan dat 
hoge expressie van S100 positieve myeloïde cellen in de donornier leidt tot een 
verhoging in lokale immuunregulatie en een daling van het totale T-cel infiltraat in 
het transplantaat. Deze verschuiving naar regulering vermindert de intensiteit van de 
acute ontstekingsreactie gericht tegen de donornier, die op zijn beurt gereflecteerd 
wordt door een vermindering van donornierschade en gunstige langdurige 
transplantatie uitkomst. Onze hypothese is dat ontstekingsinfiltraten tijdens acute 
afstoting, die relatief lage aantallen S100 positieve myeloïde cellen bevatten, minder 
adequaat opgelost worden en/of voor langere tijd in het transplantaat stand houden.
Dus, samengevat, de identificatie van S100A8 en S100A9 als voorspellende 
markers voor ongunstige transplantatie uitkomst kan leiden tot betere controle- 
en interventiestrategieën na niertransplantatie en bijdragen tot een betere lange 
termijn donornier uitkomst.
Toekomstperspectieven: mogelijke immuunmechanismen van S100A8 en S100A9
De immuunmechanismen achter de effecten van S100 moleculen op transplantatie 
uitkomst zijn nog onbekend. S100A8 en S100A9 versterken mogelijk de activering 
van de nicotinamide adenine dinucleotide fosfaat (NADPH) oxidase in fagocyterende 
cellen zoals monocyten en macrofagen. Activatie van NADPH oxidase leidt tot 
vorming van reactieve zuurstofradicalen, signaalmoleculen die immuunsuppressie 
kunnen induceren via de inductie van regulatoire T-cellen. Essentieel bij de vorming 
en activering van NADPH oxidase is arachidonzuur. S100A8 en S100A9 binden 
arachidonzuur en brengen het over naar het membraangebonden NADPH oxidase 
complex. Verhoogde expressie van S100A8 en S100A9 tijdens acute donornier afstoting 





































door myeloïde cellen en de inductie van regulatoire immuunmechanismen. Deze 
lokale immuunregulerende effecten van S100 moleculen kunnen donornierschade 
beperken en verlies van het transplantaat voorkomen. Verdere studies zijn nodig 
om op te helderen via welke mechanismen S100A8 en S100A9 de immuunrespons 
moduleren tijdens acute donornier afstoting.
Conclusie
De in dit proefschrift gepresenteerde resultaten demonstreren het potentieel 
van moleculaire en cellulaire biomarkers voor de diagnose en voorspelling van de 
uitkomst van acute donornier afstoting. We demonstreren dat resistentie tegen 
steroïden therapie een complexe en multifactoriële aandoening is, waarbij zowel 
immunologische en niet-immunologische factoren betrokken kunnen zijn. De 
respons op steroïden therapie voor de behandeling van acute niertransplantaat 
afstoting correleert met het expressieniveau en de karakteristieken van T-cellen en 
macrofagen infiltraten in de donornier. Deze bevindingen geven aan dat steroïden 
resistentie zich in specifieke celpopulaties bevindt en geen kenmerk is van alle 
lymfocyten. Daarnaast kunnen zinkregulatie en het metabolisme van geneesmiddelen 
een rol spelen in de respons op steroïden therapie tijdens acute donornier 
afstoting. Verhoogde expressie van zinkregulerende moleculen kunnen de zink-
afhankelijke anti-inflammatoire effecten van corticosteroïden verminderen, terwijl 
genetische variaties in metabolisme genen predisponeren voor responsiviteit voor 
steroïden therapie tijdens acute afstoting. Verder demonstreren onze bevindingen 
dat een multivariaat voorspellingsmodel, met biomarkers die gerelateerd zijn aan 
verschillende aspecten van GC-signalering, de beste prognostische waarde biedt 
voor de beoordeling van response op steroïden therapie. Deze prognostische waarde 
was beter dan die van conventionele klinische parameters en histopathologische 
beoordeling. Ten slotte demonstreren we dat beoordeling van S100A8 en S100A9 
expressie in donornierweefsel gebruikt kan worden als een indicatie voor het 
optreden van acute afstoting en voor het beoordelen of een acute afstotingsepisode 
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AUC area under the curve
BP biological process
Bx biopsy




CREB cyclic AMP-responsive element-binding
CTD chronic transplant dysfunction




DGF delayed graft function
DIG digoxigenin
DMSO dimethylsulfoxide
EGF epidermal growth factor
F2R factor II receptor
FBS fetal bovine serum





GLCCI1 glucocorticoid-induced transcript 1 gene







































GRα glucocorticoid receptor α
GRβ glucocorticoid receptor β
GREs glucocorticoid response elements
GRP-1 GR-interacting protein 1
HAECs human aorta endothelial cells
HDAC histone deacetylase
HLA human leukocyte antigen
Hsp heat shock protein
HUVECs human umbilical vascular endothelial cells
IFTA interstitial fibrosis and tubular atrophy
IκB inhibitor of κB
IL interleukin
IL-2R IL-2 receptor
IMDM Iscove’s modified Dulbecco’s medium
KIM-1 kidney injury molecule 1
LAG-3 lymphocyte activation gene-3
LBD ligand-binding domain
LNA locked nucleic acids
LPS Lipopolysaccharides
MΦ macrophages
MΦ (stim) stimulated macrophages
MAP mitogen-activated protein
M-CSF Macrophage colony-stimulating factor
MF molecular function
MKP MAP kinase phosphatase
MMP matrix metalloproteinases
MP methylprednisolone
MPK-1 mitogen-activated protein kinase phosphatase-1
MT metallothioneins
NADPH nicotinamide adenine dinucleotide phosphate
nGRE negative GRE
NF-κB nuclear factor-κB













































NK cells natural killer cells
NP Non-progression
NR1I2 nuclear receptor 1I2; pregnane X receptor




PBL peripheral blood lymphocyte 
PBMC peripheral blood mononuclear cells




PRA panel reactive antibodies
Pre-Tx pretransplant
prot. Bx protocol biopsy
PTC peritubular capillaries
PTECs proximal tubular epithelial cells
PV predictive value
PXR pregnane X receptor
qPCR quantitative PCR
RIN RNA integrity number
ROC receiver operating characteristics
ROS reactive oxygen species
RQI RNA quality index
rRNA ribosomal RNA
RT Room temperature
SAR subclinical acute rejection
SEM standard error of the mean
SNP Single nucleotide polymorphism
SRC-1 steroid receptor co-activator-1
TCMR T-cell mediated rejection
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